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ABSTRACT
DEVELOPMENT OF A VASCULARIZED, INDUCED PLURIPOTENT STEM CELLDERIVED LIVER-TISSUE MIMIC FOR THERAPEUTIC APPLICATIONS
Venkat Madhav Ramakrishnan
November 23, 2015

This dissertation describes the incorporation of several technologies (stem cells,
gene therapy, tissue engineering and regenerative medicine) into a single project that
aims to produce a liver-tissue mimic for therapeutic applications. The liver is arguably
one of the most complex organs in the body. In addition to its remarkable capacity to
regenerate, it performs a host of vital functions. As a result, its impairment has
widespread systemic consequences. The work described herein focused on the liver in the
context of cardiovascular disease and used the heritable disorder Familial
Hypercholesterolemia (FH) as a clinical disease model. As (a) the only definitive cure for
FH is currently liver transplant and (b) the availability of quality liver organs for
transplant is critically low, these studies seek to develop a liver-tissue mimic comprised
of two parts: functional hepatocyte-like cells (derived from induced pluripotent stem
cells, or iPSC) and vascular support (provided by adipose-derived stromal vascular
fraction (SVF)).
The dissertation is divided into six sections. Chapter I provides an introductory
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overview and lists the aims and hypotheses for the dissertation. Chapter II provides a
four-part background discussing cholesterol metabolism, the liver organ, stem cells, and
the vasculature. Chapter III describes our efforts to generate a proof-of-concept livertissue mimic, using HepG2 as a hepatocyte model cell source and SVF cells as the
vascular support system. As vascular support is critical for parenchymal survival and
function, Chapter IV examines the mechanisms of spontaneous SVF vascular selfassembly. Chapter V discusses development of a patient-specific, therapeutic cell system.
FH-patient dermal fibroblasts were programmed into iPSC using modRNA technology,
and eventually subjected the iPSC to directed differentiation into hepatocyte-like cells1.
Yet, as the iPSC were derived from an FH patient, the cells required functional
restoration of their LDL-R in order to impart any therapeutic benefit. To accomplish this,
a novel episomal LDL-R plasmid containing (a) upstream regulatory control sequences
that confer physiological feedback control of LDL-R expression and (b) Epstein-Barr
sequences for episomal retention and replication was used. To mitigate any potential
concerns associated with viral vectors, the iPSC were derived and corrected using nonviral modalities. These cells were combined with an SVF derived vascular support
system to assess iPSC-HLC survival characteristics in vivo. Chapter VI provides a
comprehensive discussion regarding our experimental efforts.
These experiments demonstrate the development of a vascularized, iPSCderived hepatocyte liver-tissue mimic that could potentially be used for therapeutic
applications, such as for the treatment of FH. Efforts to create this tissue engineered liver
construct were guided by three aims: (1) Assess the role of adipose SVF in providing
vascular support to implanted parenchymal cells, (2) Evaluate and define the
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mechanism(s) of SVF vascular self-assembly, and (3) Restore the functionality of
monogenic-deficient FH cells. These studies provide several proofs-of-principle towards
the development of effective cell-based treatments, not only for FH, but also for other
diseases classically requiring whole-organ transplantation.

vii

TABLE OF CONTENTS
PAGE
ACKNOWLEDGEMENTS
ABSTRACT
LIST OF TABLES
LIST OF FIGURES

iv
v
x
xi

CHAPTER I: DISSERTATION INTRODUCTION & SPECIFIC AIMS

1

CHAPTER II: BACKGROUND / LITERATURE REVIEW
PART I: Cholesterol and Disease

6

PART II: The Liver and Hepatic Substitutes

28

PART III: Stem Cells

39

PART IV: The Vasculature

53

CHAPTER III: Generation of a Functional Liver-Tissue Mimic Using Adipose
Stromal Vascular Fraction Cell-Derived Vasculatures
OVERVIEW

63

INTRODUCTION

64

MATERIALS & METHODS

65

RESULTS

69

DISCUSSION

79

CHAPTER IV: Wnt5a Modulates the Assembly of Human Stromal Vascular
Fraction-Derived Microvasculatures
OVERVIEW

84

viii

INTRODUCTION

85

MATERIALS & METHODS

87

RESULTS

97

DISCUSSION

116

CHAPTER

V:

Restoration

of

Physiologically

Responsive

Low-Density

Lipoprotein Receptor-Mediated Endocytosis in Genetically-Deficient Induced
Pluripotent Stem Cells
OVERVIEW

121

INTRODUCTION

122

MATERIALS & METHODS

123

RESULTS

137

DISCUSSION

157

CHAPTER VI: SUMMARY AND CONCLUSIONS

164

REFERENCES

173

CURRICULUM VITA

232

ix

LIST OF TABLES
TABLE

PAGE

Table 1: Chapter II: Common Angiogenic Inhibitors

89

Table 2: Chapter II: RT-PCR primer listing

91

Table 3: Chapter II: Antibody / Stain / Lectin listing

93

Table 4: Chapter III: Electroporation parameters

128

Table 5: Chapter III: RT-PCR primer listing

134

Table 6: Chapter III: Antibody / Stain listing

136

x

LIST OF FIGURES
FIGURE

PAGE

Figure 1: Mechanism of cholesterol synthesis from Acetyl-CoA

8

Figure 2: LDL-R Feedback Loop

20

Figure 3: Episomal LDL-R plasmid

26

Figure 4: Liver microscopic anatomy

32

Figure 5: Liver sinusoids

32

Figure 6: Fresh vs. cultured SVF in vivo

70

Figure 7: Fresh vs. cultured SVF & angiogenic participation

72

Figure 8: FACS analysis on fresh vs. cultured SVF

74

Figure 9: hSVF in vivo & with HepG2 spheroids

75

Figure 10: SVF within a liver-tissue mimic facilitates LDL uptake

78

Figure 11: hSVF angiogenic inhibition

90

Figure 12: EC network tracing and area determination

96

Figure 13: Culture reduces hSVF vascular potential

98

Figure 14: Wnt5a mediates hSVF vascular assembly

100

Figure 15: Wnt & Wnt5a receptor PCR screening

102

Figure 16: Wnt5a & FZD4 are highly expressed in hSVF cultures

103-104

Figure 17: rhWnt5a mediates hSVF EC assembly during IWP2 inhibition 106-107
Figure 18: IWP-treated hSVF EC networks are not affected by rhWnt3a

xi

109-110

Figure 19: Anti-Wnt5a blocks hSVF EC length and segments

112

Figure 20: Wnt5a drives EC microvascular assembly in vivo

113-114

Figure 21: FH fibroblast LDL-R functional assessment

138

Figure 22: FH-iPSC derivation and pluripotency

140

Figure 23: FH-iPSC karyotyping

142

Figure 24: FH-HLC derivation

144

Figure 25: Stage-specific gene expression during FH-HLC derivation

146

Figure 26: FH-HLC functional assessment

147

Figure 27: pEHZ-LDLR-LDLR functionality in CHO-a7

149

Figure 28: Functionality of FH-HLC±LDLR

153-154

Figure 29: Quantitation of plasmid functionality in FH-MC±LDLR

156

Figure 30: Concept of Wnt5a and hSVF self-assembly

171

xii

CHAPTER I
DISSERTATION INTRODUCTION & SPECIFIC AIMS

Multiple genetic diseases of the liver, including fulminant hepatic failure, nonalcoholic fatty liver disease (NAFLD), alpha-1 antitrypsin (A1AT) deficiency, and
familial hypercholesterolemia (FH), are only functionally cured by orthotopic liver
transplant. Yet, existing deficiencies in transplant teleology (the requirement for
immunosuppression, the risk of rejection, and consequent loss of quality of life) have
launched efforts to regenerate cells and tissues to mitigate such dysfunction.
Induced pluripotent stem cells (iPSC) are a novel, theoretically limitless source of
cells that could potentially address these issues and others, as they can differentiate down
any cell lineage and be derived autologously, eliminating any need for the
immunosuppression associated with transplant. However, iPSC from genetically impaired
patients would differentiate into syngeneic replacement cells that are fully compatible
with the host, but just as dysfunctional as targeted diseased tissue. Therefore a critical
need in advancing iPSC as a cell-based therapeutic is an appropriate strategy for
correcting the clinical deficiency. Though genetic origin of disease often has multiple
sources, monogenic disorders could theoretically be corrected by the introduction of a
single functional gene product. One example of monogenic disease is Familial
Hypercholesterolemia (FH), characterized by dysfunction of the LDL-cholesterol
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receptor (LDLR). FH has been extensively studied and represents a suitable model for
investigating the functional correction of genetically dysfunctional iPSC, which can then
be used to generate a liver tissue mimic.
Efforts to restore the functionality of primary and derived hepatocytes have
resulted in varying degrees of success. LDLR-containing corrective plasmids have been
delivered to hepatocytes via adeno-associated2 and retroviral vectors3. In numerous
instances, the high transduction efficiencies afforded by viral vectors yielded significant
reductions in plasma LDL cholesterol (LDL-C). However, concerns about transgene
activation, insertional mutagenesis4, and oncogenesis5 (all of which can result in patient
morbidity and/or mortality) hamper broad clinical use of such viral vectors for gene
therapy. Non-viral transfection modalities represent a practical alternative, but these
typically suffer from transient expression and do not provide long-term resolution. Our
approach to address these issues is utilization of a novel corrective plasmid that was
designed to be episomal and non-integrating, stably transfected, and physiologically
sensitive6. The latter feature is especially relevant, as corrective LDLR plasmids lacking
physiologic sensitivity could force cells to internalize LDL-C without regulation or
inhibition, leading to toxic cholesterol saturation and eventual cell dysfunction7.
The generation of a supportive vasculature is also important, as it would serve as
a vital conduit for parenchymal nutrient delivery and metabolic byproduct expulsion. The
literature provides evidence of implanted parenchymal cell death in the absence of a
vascular supply. Investigations have also demonstrated a need for co-cultured support
cells that enhance parenchymal viability8. Such findings suggest that a stable, functional
microvasculature is required for parenchymal cell survival and function. We have already
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demonstrated that adipose-derived stromal vascular fraction (SVF) is an easily accessible,
heterogeneous mixture of cells capable of providing stromal and vascular support to
implanted parenchymal hepatocytes9. In our hands, SVF cells formed a functional
microcirculation that spontaneously assembled, interfaced with these hepatocytes, and
anastomosed with surrounding host vasculature. Hepatocytes were able to internalize
peripherally injected circulating LDL-C, providing further evidence for the formation of a
functional, SVF-derived vasculature at the host-parenchyma interface. The nuclei of cells
cultured without SVF exhibited characteristics of apoptosis, whereas those cultured with
SVF appeared intact and ostensibly healthy. This combination of hepatocytes with SVF
cells formed the basis for a functional liver-tissue mimic.
In conclusion, we aim to use a monogenic disease model for exploring the nonviral, functional restoration of genetically dysfunctional iPSC. Corrected iPSC will be
used to engineer and generate hepatocyte-like cells that will be assessed for restored
functionality as well as for evidence of maturation in the presence of an SVF cell coculture. The reciprocal effect of the parenchyma on the newly developed, surrounding
microvasculature will also be assessed. The development of a functional tissue mimic
lays the groundwork for further exploration into the architecture, size, and scalability of
engineered organoids specific to various dysfunctional phenotypes. This translational
project will contribute to the development of cell-based therapies and other autologous,
transplantable organs.
Globally, I hypothesize that functionally corrected autologous FH-iPSCderived parenchymal cells, combined with stromal and vascular support, will form
following implantation a functional tissue mimic that offers sustainable therapeutic
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value in end-organ dysfunction. This hypothesis will be examined via the following
specific aims:

Aim 1: Assess the role of Stromal Vascular Fraction (SVF) cells in providing
vascular support to implanted hepatocytes.
Aim 1 Hypothesis: An SVF-derived vasculature enables the engraftment and
function of implanted hepatocytes.
Aim 1 Rationale: The hypothesis for this aim is predicated on SVF’s documented
ability to rapidly self-assemble into vessels. We further postulated that SVF could
likely form self-assembled vasculatures in the presence of hepatocytes.
Aim 2: Define mechanisms of human SVF vascular assembly.
Aim 2 Hypothesis: Wnt5a mediates hSVF vascular assembly.
Aim 2 Rationale: Our preliminary data indicates that the pan Wnt-release inhibitor
IWP2 inhibits endothelial cell (EC) networking in SVF, implicating all Wnt
isoforms in EC network formation. The literature has suggested that Wnt5a is
implicated in processes such as perivascular recruitment, vascular sprouting,
vascular pruning, and tight-junction maintenance, all of which are intimately
associated with EC.
Aim 3: Restore the functionality of monogenic-deficient FH parenchymal cells.
Aim 3 Hypothesis: A non-viral, non-integrating episomal plasmid containing a
wild-type LDL receptor (LDL-R) cassette will restore LDL-R functionality to FHiPSC-derived hepatocytes.
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Aim 3 Rationale: The technology and function of an episomal LDL-R-containing
plasmid has already been demonstrated in the literature. Additionally, iPSC have
been shown to generate autologous hepatocyte-like cells (HLC) in addition to a
variety of other parenchymal cell types. Further, iPSC can be easily cultured and
are amenable to genetic manipulation.
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CHAPTER II
BACKGROUND & LITERATURE REVIEW

PART I: CHOLESTEROL & DISEASE

Cholesterol Production
The liver is the primary organ responsible for cholesterol regulation in the body10.
Cholesterol is an important constituent of cell membranes and several cellular
byproducts, including steroids, hormones, and bile11. Systemic cholesterol homeostasis is
tightly regulated, between inputs (such as cholesterol obtained through cell synthesis or
through the diet) and outputs (such as the byproducts described above). Therefore, a
long-term increase in plasma cholesterol is a result of deregulated homeostasis leading to
accelerated development of cardiovascular disease (e.g. atherosclerosis, cardiac
infarction) and death12.
Before discussion of the implications of cholesterol in disease, it is important to
outline the mechanisms of cholesterol synthesis and metabolism (Figure 1). The process
of cholesterol synthesis begins with Acetyl CoA, a central intermediate in lipid
metabolism13. The breakdown of glucose or amino acids yields Acetyl CoA, whose
downstream products include fatty acids and ketone bodies, triglycerides, phospholipids,
eicosanoids, and cholesterols, as well as carbon dioxide, water, and ATP (energy) in
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cellular respiration. Specifically, with respect to cholesterol, Acetyl CoA is converted to
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) and then Mevalonate, whose generation is
mediated by the enzyme HMG-CoA reductase (HMGCR). HMGCR serves as the ratelimiting step of cholesterol synthesis and a target for several pharmacological therapies
(discussed below). Additionally, the ultimate conversion of Acetyl CoA to Mevalonate
constitutes the first stage of cholesterol synthesis. The second stage converts Mevalonate
into several 5-carbon building blocks, while the third stage generates lipid intermediates
of biological importance. For instance, one of these intermediates, Farnesyl phosphate, is
a branch point intermediate in ubiquinone and dolichol synthesis. Ubiquinone is an
important electron carrier in the electron transport chain, and dolichol is an important
endoplasmic reticulum anchor involved in N-linked glycosylation. Thus, these
intermediates play vital roles in cell metabolic and homeostatic processes. The fourth and
final stage of cholesterol synthesis involves the cyclization of the intermediate Squalene
into a 4-ringed structure with a steroid nucleus, hydrocarbon side chain, and single
alcohol group. This forms the basic structure of cholesterol.
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Figure 1. General, conceptualized mechanism of cholesterol synthesis from Acetyl-CoA.
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Cholesterol Transport
The transport of cholesterol around the body is also another important
consideration. For instance, cholesterol is not water-soluble and, therefore, requires a
vehicle for transportation12. To this end, it is packaged as a cholesterol ester (CE) within
one of several lipoproteins, all of which act as cholesterol and triacylglycerol (TAG)
transporters from cholesterol-producing cells to peripheral recipients. Enzymes known as
acyl CoA-cholesterol acyl transferases (ACAT) or phosphatidylcholine cholesterol acyl
transferases (PCAT) take long fatty acid chains and append them to cholesterol
molecules, generating CEs. While ACAT acts intracellularly and PCAT acts
extracellularly, these are two different enzymes that act at two different sites but
ultimately perform the same function – yielding the same CE product. While the bulk of
cholesterol within a lipoprotein is stored as CE, the phospholipid monolayer of the
lipoprotein itself contains varying proportions of unesterified cholesterol, depending on
the identity of the lipoprotein12.
There are four main classes of lipoproteins, all of which are complexed with
specific carrier proteins known as apolipoproteins12. Chylomicrons (typically complexed
with APOB48, APOC2, APOC3, and/or APOE) are synthesized in the intestine and are
responsible for the transport of dietary cholesterol and triglycerides from the intestines to
the liver and other tissues. In this case, since lipids originate from the diet, this pathway is
considered to be an exogenous lipid transport pathway. Chylomicrons typically have the
highest TAG composition (85% of their weight), but also transport CE (3% wt) and free
cholesterol (1% wt). After the removal of APOC2 and its TAG stores, chylomicrons
become significantly smaller and are termed chylomicron remnants, which go back to the
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liver for degradation14. Very low-density lipoproteins (VLDL; can be complexed with
APO-B100, APOC1, APOC2, APOC3, and APOE) are made in the liver. VLDL serves
to transport newly synthesized TAG and cholesterol to the extrahepatic tissues for storage
as fat. Since these lipids originate from the liver, the VLDL-mediated pathway is
considered to be the endogenous pathway for lipid transport. These lipoproteins hold
considerably more CE than chylomicrons (at 12% wt) as well as unmodified cholesterol
(7% wt) but significantly less TAG (50% wt). Low-density lipoproteins (LDL) are
ultimately generated from VLDL by the removal of TAG during VLDL metabolism.
LDL contains the highest density of CE (37% wt) and free cholesterol (8% wt), but the
second lowest concentration of TAG (10% wt). Lastly, high-density lipoproteins (HDL;
complexed with APOC1 and APOC2, but also associated with APOA1, APOA2,
APOA4, APOC3, APOD, and APOE) are synthesized in the liver and intestine. In
addition to harboring intermediate amounts of CE and free cholesterol (15% wt and 2%
wt, respectively), HDL actually has a significantly higher density of proteins (55% wt)
and phospholipids (24% wt). HDL plays a significant role in a process known as reverse
cholesterol transport (RCT), since it primarily collects cholesterol from peripheral
locations and transports it back to the liver for processing. It also contains the enzyme
LCAT, converting the cholesterol from chylomicrons and VLDL remnants into CE12. All
of these lipoproteins play intermediary, interactive roles in a larger cascade.
HDL and LDL are the two most clinically relevant lipoproteins. LDL cholesterol
is often termed “bad cholesterol”, while HDL cholesterol is often termed “good
cholesterol”15. Though this is somewhat simplistic, there is some truth to these
viewpoints. First, to physically compare the two molecules, LDL has a diameter of 22nm
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and a mass of 3000kDa. It can hold a significant amount of CE, and is associated with a
single 500kDa Apolipoprotein B molecule16. HDL, on the other hand, is a much smaller
molecule, having a diameter between 5-12nm17,18 and most commonly associating with a
28kDa Apolipoprotein A molecule19. The lipid-protein bonds in LDL are arranged as
beta-sheets, making the two components inseparable. These same bonds in HDL form
alpha-helical structures, which can freely dissociate and change structure. As cholesterol
is one of many energy sources, it requires less energy (i.e., it is easier) for the body to
utilize the cholesterol stored in HDL molecules versus LDL molecules. Secondly, higher
HDL levels can confer a protective effect on the heart, lowering the risk for heart attack
and stroke. This is partly because HDL is thought to have scavenger-like properties that
enable it to clear the LDL cholesterol. Liver sinusoidal cells have an abundance of HDL
receptors that then facilitate HDL clearance20. This said, peripheral tissues largely derive
their cholesterol from LDL. Therefore, while excessive LDL can be harmful (discussed
below), a moderate amount is beneficial, if not required.

LDL Cholesterol Metabolism and Regulation
LDL cholesterol and the LDL-R participate in an intricate form of metabolic
regulation. In 1977, Brown, Goldstein, and colleagues were the first to describe LDL
metabolism as a process involving receptor-mediated endocytosis (RME)21. In this
process, LDL cholesterol binds to the LDL receptor (LDL-R), a protein that spans the
plasma membrane and contains a cysteine-rich Apolipoprotein B binding site. Once
endocytosed, LDL cholesterol is contained within an endosome. The endosome merges
with a cell lysosome; the CEs within LDL are hydrolyzed, releasing pure cholesterol. The
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cell then utilizes this cholesterol to supplement its plasma membrane or for steroid and
hormone production16. As for the LDL-R, it can either be recycled back to the cell
surface, or broken down and reconstituted by the endoplasmic reticulum (ER). From the
ER, the new LDL-R is routed to the cell membrane via the Golgi complex12.
While LDL and the LDL-R possess a fairly simple relationship in terms of
binding and internalization, the more complicated and fascinating aspect is the precise
control that is exerted on LDL-R expression and endogenous cholesterol production. The
German scientist Rudolph Schoenheimer and colleagues were the first to describe the
existence of an overall cholesterol feedback loop22. Schoenheimer placed mice in glass
flasks and fed them a sustained cholesterol-infused or control diet over a period of one
month. After sacrificing and dissolving the mice in an ether-sodium hydroxide-alcohol
steam bath, he measured the total cholesterol content of each flask. Interestingly, mice
given a cholesterol-free diet yielded flasks with a higher cholesterol content than those
from mice given cholesterol-laden diets. The experiment indicated that animals can
generate cholesterol, and stop making cholesterol when it is present in the diet.
In 1975, Brown and Goldstein described LDL-R regulation in human fibroblasts,
noting that the receptor was under feedback regulation and influenced by exogenous
cholesterol levels in the culture media23. In 1986, Brown and Goldstein discovered a
feedback suppression mechanism within cells that kept the amount of membrane
cholesterol at a constant level. This was, in large part, due to mediation of the cells’
endogenous production of cholesterol by HMGCR24, which made enough cholesterol to
maintain membrane fluidity. The 1990s and 2000s brought on a greater understanding of
the ‘cholesterol sensing mechanisms’ that drive LDL-R expression and HMGCR activity.
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Yokoyama was the first to describe the existence of the sterol response element binding
protein (SREBP)25, a transcription factor that resides on the endoplasmic reticulum. Once
translated, SREBP binds the protein Scap26-28, the protein that detects membrane sterol
levels29 through direct binding of cholesterol30. A deficiency in membrane cholesterol
levels induces the SREBP-Scap complex to bind a complex of vesicular proteins known
as COPII31. COPII facilitates the internalization of SREBP and Scap into the Golgi
apparatus, where proteases cleave the SREB proteins into transcriptionally active
segments27,28,32. These segments then enter the nucleus to initiate LDL-R and
HMGCR33,34 gene transcription, ultimately forcing the cell to produce more endogenous
cholesterol and scavenge circulating LDL cholesterol with greater efficiency through
increased receptor expression. An excess of membrane cholesterol (with cholesterol
levels comprising greater than 5% of total lipids) results in (a) cholesterol binding
directly to Scap30, (b) an alteration in the configurations of Scap35 and COPII31, and (c)
the binding of Scap to a COPII binding inhibitor known as Insig36.

Implication of Cholesterol in Heart Disease
The pathophysiology of atherosclerosis has been demonstrated to be intimately
dependent on circulating cholesterol levels. While we take it for granted today that higher
LDL levels yield atherosclerotic plaques, this direct relationship was unknown to us as
recently as a century ago. Here, we examine several key studies that ultimately
characterized this interaction.
One of the earliest contributors to our understanding of cholesterol in heart
disease was Russian scientist Alexander Ignatowski, who, in 1907, published a study in
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which he fed full-fat milk, eggs, and meat to rabbits in an effort to understand their
effects on atherosclerotic development37. Five years later, Nicolai Anichkov conducted a
similar experiment, substituting the milk, eggs, and meat with boluses of cholesterol38. In
both cases, Ignatowski and Anichkov observed the development of aortic atherosclerosis
and confirmed a relationship between dietary cholesterol and atherogenesis.
In 1953, Ancel Keys, a Mayo Clinic scientist who eventually popularized the
relationship between diet and health, began a pioneering study on the epidemiology of
myocardial infarction across seven different countries. He demonstrated that those with
higher fat intakes exhibited higher levels of serum cholesterol. Because western diets
were known to contain more fat than eastern diets, Keys assessed the role of diet in
coronary events for Japanese males situated in Japan, Hawaii, and California. Here, he
noticed that males in California had a higher fat intake and increased number of coronary
events compared to those living in Hawaii and Japan39.
In that same decade, John Gofman, a prominent physician and researcher at the
University of California, Berkeley, was the first to identify the presence of VLDL, LDL,
and HDL in serum by centrifugation40. He and E. Virginia Dobbin, a dietician at a local
hospital, then demonstrated the link between increased dietary fat intake and the resulting
increases in serum LDL cholesterol41. Gofman was also the first to study LDL and HDL
levels in heart attack patients compared to healthy controls. He demonstrated that heart
attack patients had significantly increased LDL and significantly decreased HDL levels
compared to their healthy counterparts.
Several other studies have also focused on the role of HDL in cardiovascular
dysfunction19. Most notably, the Framingham Heart Study (one of the longest,
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continuously running studies) elucidated in 1988 that high levels of HDL cholesterol
reduced the risk of death from heart disease42. While HDL can potentially mitigate LDL
oxidation (discussed below)43-45, HDL levels below normal can also independently
indicate cardiovascular dysfunction even in the presence of low LDL cholesterol levels46.
Conversely, a recent study demonstrated that mutations in which HDL was increased did
not necessarily confer a cardio-protective effect, suggesting that HDL levels alone may
be unable to overcome particular genetically mediated modes of cardiovascular
dysfunction47. Still, though much of today’s therapies focus on therapeutically lowering
LDL levels, the use of HDL to target heart disease is under increasing investigation48.
In sum, these key studies dictate a critical interplay between HDL and LDL
cholesterol levels and their implications in heart disease. Diet plays a critical role in the
prevalence of particular cholesterol subtypes. Diets high in fat lead to a greater incidence
of LDL-driven coronary events, while HDL plays a more regulatory role and can even
have therapeutic benefit in sufficient concentrations. However, since LDL cholesterol is
the key driver of atherosclerosis and heart disease, we will next look at the mechanism of
its involvement.

Pathophysiology of Atherosclerosis
Today, we have a direct mechanism for LDL’s involvement in forming
atherosclerotic plaques. While all blood vessels are lined with endothelial cells,
atherosclerosis is a condition that uniquely affects only the arterial endothelium. The
development of a fatty streak (the origins of atherosclerotic plaques) can be broken down
into roughly seven distinct steps: (1) lipoprotein transport, (2) lipoprotein retention, (3)
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lipoprotein modification, (4) monocyte adherence, (5) monocyte chemotaxis, (6)
monocyte differentiation, and (7) the formation of foam cells49.
The earliest atherosclerotic lesions, termed ‘fatty streaks’, are formed at arterial
sites that experience significant turbulent blood flow and sustained hemodynamic stress,
both of which can damage the lining endothelium. While normal arterial endothelial cells
resist the binding of circulating monocytes and other immune cells, a dysfunctional
endothelium at these sites serves as a recruiter for such cells by up-regulating the
adhesion molecules required for their binding50. Furthermore, endothelial dysfunction
impairs tight junctions, enhancing permeability and facilitating the entry of LDL into the
sub-intimal space51. The oxidation of LDL further seeds the lipoprotein beneath the
endothelium as well as modify the lysine residues on Apolipoprotein B. Further oxidation
leads to an exacerbation of monocyte chemotaxis; more monocyte-macrophages are
recruited to the LDL-filled sub-endothelial space and bind the modified Apolipoprotein B
using scavenger receptors. Once LDL is internalized, the monocytes take on a foamy
appearance and are thusly termed foam cells49. Foam cells then secrete a variety of
cytokines that promote inflammation, causing resident smooth muscle cells to proliferate
and secrete collagen. This results in an enlargement of the fatty streak to a full-fledged
plaque, which can severely narrow or completely occlude a vessel, or can rupture and
embolize16.

Familial Hypercholesterolemia and LDL-R Dysfunction
Though some have elevated LDL cholesterol levels because of poor diets, a
significant number have genetic deficiencies that predispose them to high levels of
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circulating LDL and, ultimately, accelerated cardiovascular disease development. One
such group of patients is those suffering from Familial Hypercholesterolemia (FH), a
disease characterized by pathologically high levels of plasma LDL cholesterol due to
dysfunctional LDL-R. Though Brown and Goldstein were the ones who described the
existence of the LDL-R in the mid-1970s52-54 and discovered its regulation in the 1980s24,
Müller was among the first to clinically describe FH in 1938, as an “inborn error of
metabolism” that was inherited in an autosomal dominant manner55. Further, he
demonstrated that the unusually high plasma LDL cholesterol levels in FH resulted in a
consequent 20-fold increased incidence of heart attacks.
It wasn’t until many decades later that Khachadurian described the bimodal
inheritance of FH in homozygous (have two defective LDL-R alleles, one inherited from
each parent) or heterozygous variants (having only one defective LDL-R allele)56.
Untreated, homozygotes (seen in ~1 in 106) exhibit severely elevated cholesterol levels as
high as 600-1000 mg/dl, while heterozygotes exhibit more moderate elevations of 300600 mg/dl. Though the standard assumption is that 1:500 have the heterozygous variant,
it is as frequent as 1:200 to 1:100 in Scandinavian populations, suggesting that the
disease is in fact under-diagnosed57. This buildup of cholesterol can have broad systemic
effects. In addition to non-lethal symptoms, such as the formation of xanthomas and
xanthelasmas (visible collections of cholesterol in the joints and eyes, respectively),
patients also exhibit accelerated cardiovascular disease. To this end, untreated
homozygotes can die of heart failure as early as their teens, while untreated heterozygotes
can die in their 30s or 40s58,59
As stated before, these clinical manifestations are largely due to inherited defects
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in the LDL-R. To date, over 1200 mutations affecting the LDL-R have been identified60.
These mutations affect LDL-R functionality in at least one of six ways: (1) LDL-R is not
made, (2) LDL-R is not transported to the surface, (3) the binding domain of LDL-R is
altered, preventing LDL from binding to LDL-R, (4) LDL can bind, but LDL-R cannot
be internalized, and (5) LDL-R are not recycled and are rapidly degraded in the
lysosome61.
However, there are other, much less prevalent, non-LDL-R-mediated modalities
that lead to the same clinical presentation as that seen with LDL-R dysfunction-induced
FH. For instance, mutations in Apolipoprotein B prevent LDL cholesterol from binding
to LDL-R, affecting about 10% of individuals with FH62. In another example, in 2009,
Horton and colleagues described the role of proprotein convertase subtilisin/kexin type 9
(PCSK9), an enzyme secreted by the liver and other organs63. A gain-of-function
mutation in PCSK9 allows PCSK9 to bind the LDL-R and prevent receptor cycling after
the receptor and ligand have been internalized. In doing so, the number of surface LDL-R
decrease and result in an increase in plasma LDL levels similar to those seen with FH.
Conversely, a loss-of-function PCSK9 mutation, described by Cohen in 2006, can lead to
significant reductions in both LDL levels and heart attacks compared to the general
population64. To this end, pharmaceutical companies have sought to reproduce this effect
with drugs that act as PCSK9 inhibitors.

Current FH Therapies
There are several pharmacologic agents that are used to treat FH, though none of
these therapies offers a definitive cure. The most prominent example are statins, which

18

are considered to be a mainstay of FH therapy and act by blocking the activity of
HMGCR and, consequently, cells’ endogenous cholesterol production. A better
understanding of this comes from reconsideration of the LDL-R and endogenous
cholesterol production via a feedback loop (described in the ‘LDL Cholesterol
Metabolism and Regulation’ section above; also see Figure 2). When statins block
HMGCR activity, they block endogenous cholesterol production. With the cells unable to
produce their own cholesterol, they are forced to scavenge LDL cholesterol to meet their
membrane cholesterol requirements. Consequently, their expression of the LDL-R is upregulated, allowing the cells to internalize more LDL through receptor-mediated
endocytosis65. This, in turn, lowers peripheral, circulating LDL cholesterol levels and
imparts a therapeutic effect.
Statins have had a profound impact on cardiovascular therapy and are amongst the
most widely prescribed class of drugs on the market today66. This, in large part, has to do
with the overwhelming evidence showing the dramatic effect of statins on lowering the
plasma LDL levels in dogs67, humans68, and human FH heterozygote patients69 (in whom
“a single functional [LDL-R gene] is present and susceptible to activation by cholesterol
deprivation”16).
However, statins have some significant drawbacks. Implicit in the description
above is the fact that statins require a functional LDL-R in order to elicit any benefit.
Thus, homozygous FH patients lack functional LDL-R and, therefore, are minimally
benefitted by statins alone70 and, at a minimum, require the administration of other
supplemental agents. Statins also harbor side effects such as myalgias and can increase
the potential for liver damage, digestive problems, and propagation of Type-2 diabetes,
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Figure 2. General schematic of the LDL-R feedback loop. (A) In a normal, functional
system, the binding of LDL to the LDL-R has an inhibitory effect on the activity of HMGCoA Reductase (HMGCR) within the cell. If the cell obtains enough cholesterol through
the LDL-R, endogenous cholesterol production ceases and expression of the LDL-R on
the cell surface is down-regulated. (B) In FH, the LDL-R is dysfunctional. This
dysfunction impairs the negative feedback on HMGCR, leading to increased production
of endogenous cholesterol regardless of circulating LDL levels. Statins act to block
HMGCR and increase LDL-R, but statins only exert a therapeutic effect if LDL-R is
functional. Many FH patients have completely dysfunctional LDL-R and are therefore
refractory to treatment with statins.
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skin rashes, and neurological side effects.
In many instances, statins are coupled with other drugs to amplify their
therapeutic effect2. For example, niacin, one of the oldest drugs used for managing
circulating lipid levels, has been shown to independently lower LDL cholesterol by up to
20% while raising HDL levels by as much as 31%71. In another example, PCSK9
inhibitors act to mimic the loss-of-function mutations seen with PCSK9, rendering it
unable to prevent LDL-R cycling and consequently making more LDL-R available at the
cell surface for binding to LDL cholesterol. In conjunction with statins, PCSK9 inhibitors
significantly reduce circulating LDL levels72. Third, bile acid sequestrants such as
cholestyramine or cholesevelam bind bile in the intestines and prevent their reabsorption
via the enterohepatic circulation. Thus, excess bile is removed in the feces. With a
shortage of bile in the body, the liver converts excess cholesterol into bile and
consequently reduces the amount of cholesterol in the body71. As a final example,
Ezetimibe is an agent that acts at the intestinal brush border to inhibit cholesterol
absorption via lacteals73. Though it has significantly reduced LDL cholesterol levels in
some trials, other trials have indicated that it can actually increase LDL cholesterol and
independently contribute to atherogenesis, negating any potential therapeutic benefit74.
Pharmacologic therapies such as these are not completely effective in the face of
severe disease. Patients must resort to more invasive options. For instance, homozygous
FH patients may require lipoprotein apheresis, a dialysis-like process that physically
extricates LDL cholesterol from the blood. However, this approach has several
drawbacks. Patients with extremely elevated cholesterol levels may be required to
undergo apheresis with increasing frequency. This presents with several challenges,
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namely that (a) the reduction in circulating cholesterol is not permanent (cholesterol
rebound), (b) like dialysis, the patient is at risk for infections at the vascular access site,
and (c) with the requirement for increased visits, quality of life is reduced while cost of
care is increased75.
Because liver hepatocytes have the highest density of LDL-R in the body76, liver
transplant provides the only known cure for FH. In one study, the pediatric recipients of
normal LDL-R via liver transplant achieved a clinical resolution of their symptoms and in
the case of one patient, even a reversal of their atheromatous lesions77-79. However,
transplant is not without its own challenges. Hampered by a low availability of quality
organs to start with, transplant is also mitigated by non-ideal donor-host compatibility,
necessitating lifelong immunosuppression and resulting in an increased susceptibility and
adverse response to common infections. Furthermore, transplants are expensive, often
costing several hundreds of thousands of dollars. Above all, the procedure itself carries
significant risk and can lead to death.

Restoring LDL-R Functionality in FH
To date, the only definitive cure for FH is liver transplant. However, quality
hepatocytes (and liver organs) are in short supply and transplantation has several practical
issues. Thus, there are several genetic strategies for mitigating the LDL-R defect present
in FH. Broadly put, these efforts rely on either transplanting healthy hepatocytes into
patients80-83, delivering the corrected LDLR gene directly to hepatocytes (discussion with
Wade-Martins as well as 84,85), correcting LDLR in cells ex vivo before their eventual (re)implantation3,86,87, or genetically correcting pluripotent cells for eventual implant88 or
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differentiation1,89.
However, before discussing specific approaches to treating FH, we should first
consider the characteristics of these approaches in isolation. Regenerative medicine has
significantly advanced due to the advent of gene therapies and transgene delivery90. One
major driver of gene therapy has been the use of viral vectors, which in general, can
infect a wide variety of cell types in an efficient manner via a predictable mechanism.
However, viruses have also been associated with significant safety risks91. In one case, it
has even resulted in death92. To understand these dynamics, we will discuss details
regarding the four main classes of viral vectors – retroviruses (and lentiviruses),
adenoviruses, and adeno-associated viruses.
Retroviruses traditionally replicate their single stranded RNA and convert this
into double stranded DNA, which can then integrate into the host genome and utilize host
machinery for viral propagation. From this point, viral particles can bud from infected
cells and go on to infect other cells. Because retroviruses are naturally highly efficient at
performing this process, they are often generated to be replication-deficient for scientific
applications to curtail the likelihood of an adverse outcome93. Despite this, these viruses
still harbor significant limitations. First, they are traditionally not ideal for situations in
which transient gene expression is desired, though a more recent effort has highlighted
the effectiveness of removing integrase in potentially yielding a transient outcome94. In
scenarios where a long-term, stable outcome is desired, transgene integration facilitated
by viral reverse transcriptase is still required, though adversities have arisen from
insertional mutagenesis95. Secondly, many retroviruses have difficulty in infecting nondividing cells96-98, though lentiviruses (a class of retroviruses) such as HIV-1 can infect
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resting cells99 with varying efficiencies100. To this end, in treating FH, Grossman and
colleagues used retroviral vectors to transduce a functional LDL-R into five FH
patients101, though only one patient exhibited a significant reduction of LDL levels. This
highlights another limitation – efficient retroviral transduction into the liver to
sufficiently restore LDL clearance is still challenging102. A fourth limitation is that some
retroviruses are quite large (upwards of 150nm in diameter in some cases)103. In the
context of the liver, this is important as its vasculature is sinusoidal and fenestrated, and
these fenestrations facilitate the transendothelial passage of various biomolecules into
parenchymal hepatocytes104,105. Additionally, other resident liver cells, such as Kuppfer
Cells and the endothelial cells comprising sinusoids (LSEC) can also actively take up
various vectors106-108. All of these factors serve as barriers that reduce the efficiency of
gene therapies to treat genetically dysfunctional hepatocytes.
Adenoviruses have been another option for therapeutic applications. They are
desirable as they can carry a relatively large gene payload – for instance, up to 30kb of
36kb of wild-type adenoviral DNA can be replaced by foreign DNA109,110. Though they
can be used for transient gene expression, their involvement in inducing host
inflammatory responses is not desirable111. Though second- and third-generation
adenoviruses can offer prolonged transgene expression and reduced immunogenicity112115

, more attention has been turned to adeno-associated viral vectors.
Adeno-associated viruses (AAV) are desirable as they are not associated with

pathogenicity, exhibited relatively low immunogenicity, and can offer stable, episomal
transgene expression116. However, their ability to accommodate only small gene packages
(~5kb) due to their small size (~22nm)117 means not only are they more ideally suited for
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traversing liver fenestrations, but also that larger genes must delivered in a piecemeal
fashion by multiple AAV vectors and re-assembled in vivo by homologous
recombination118-120. Because all of these pieces have to be delivered to the same cell for
the transgene to be functional, this obviously poses an impediment to high efficiency and
may require the use of higher viral concentrations. Additionally, several species have preexisting antibodies to AAV, further limiting their efficiency121,122. While AAVs recently
received European approval for the treatment of familial hyperchylomicronemia (a
deficiency of lipoprotein lipase)123, AAV delivery to the liver has been shown to elicit
liver-tissue damage, likely through a T-cell mediated mechanism124-126.
With respect to viral delivery of LDL-R transgenes, though reductions in LDL-C
have been reported for relatively short time periods post transfection127,128, viral vector
LDLR delivery does not yield full amelioration of the FH LDLR deficiency. This is
likely because of long-term reductions in transgene expression as well as a diminished
degree of vector delivery to target cells3,129. Additionally, strong promoters that appear to
benefit LDL-C regulation in the short term often drive LDLR transgenes. For instance,
some have reported no cytotoxicity with constitutive LDLR expression127. However, this
is controversial since uncontrolled LDLR expression has also been shown to cause
lipoprotein cytotoxicity130,131.
Hibbitt and colleagues developed a non-viral plasmid (pEHZ-LDLR-LDLR)
containing Epstein-Barr virus OriP and EBNA1 for episomal retention and stable
replication with a Hygromycin-B antibiotic selection cassette6 (Figure 3). To control the
LDLR transgene expression, the plasmid contains 10kb of upstream genomic DNA
including three sterol response elements for physiological feedback control. In
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Figure 3. A schematic of the episomal LDL-R-containing plasmid (generated by Hibbitt
and colleagues) shows several key features: 1) A wild-type LDL-R gene is preceded by
10kb of upstream regulatory control sequences, which house the sterol response elements
that confer physiological sensitivity to the plasmid. 2) The plasmid confers Hygromycin-B
resistance. 3) Epstein-Barr Viral Nuclear Association factor-1 (EBNA-1) facilitates
nuclear localization and maintenance, and is supported by OriP. Note: plasmid is not
drawn to scale; locations of various cassettes in this schematic do not reflect their actual
position, size, or relation to one another in the plasmid.
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functionality assessments, the plasmid conferred physiologically responsive receptormediated LDL internalization to the Ldlrnull CHO-a7 cell line1,6,132 and retained an in vivo
episomal localization in hepatocytes for 270 days after transfection. These data
demonstrate the potential of the pEHZ-LDLR-LDLR system as a gene therapy for treating
FH.
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PART II: THE LIVER AND HEPATIC SUBSTITUTES

As this dissertation project seeks to recapitulate particular aspects of hepatocyte
function in the context of a liver-tissue mimic, we should briefly consider the liver
anatomy, its cellular organization, major functions, blood supply, and other related
functions. However, to best orient ourselves, we will begin with an overview of liver
development.

Hepatobiliary Embryological Development
Our discussion of the liver in the context of cardiovascular dysfunction is
particularly fortuitous, as these two systems are intimately related – even in development.
There is a considerable degree of interplay between liver and heart growth; in fact, the
liver’s embryological function is primarily cardiovascular in nature, serving to shunt
blood from maternal circulation and umbilical cord directly to the fetal heart and
circulation.
To better understand this interplay, consider the interactions between two germ
layer derivatives – the primitive ventral endoderm (which gives rise to the liver) and
cardiac mesoderm (which gives rise to the heart). The cardiac mesoderm is required for
liver formation. In the 1960s and 70s, the French scientist Le Douarin studied the
interactions between endoderm and mesoderm in developing, chimeric avian embryos.
She demonstrated that a piece of primitive gut was unable to develop into a liver by itself,
and that hepatogenesis was only achievable in the presence of cardiac mesoderm133.
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Furthermore, a juxtacrine interaction between the two developing tissues was required, as
the placement of a barrier abrogated the formation of glycogen-storing hepatocytes134.
During hepatogenesis, the ventral endoderm tissue expresses a large degree of
FGF receptor 4 (FGFR-4)135 and FGF receptor 1 (FGFR-1)136, while the cardiac
mesoderm only expresses FGFR-1136. Of these, FGFR-1 is required for endodermal
development137. In 1999, Jung demonstrated that FGF-1 and FGF-2 can act as signals that
promote liver development138. Additionally, FGF-8 promotes outgrowth of the liver bud,
though it is not necessary for the induction of hepatogenesis. Interestingly, FGF has a
local effect because of its high affinity for the extracellular matrix139. This is of particular
importance to portions of the ventral endoderm that do not closely oppose the cardiac
mesoderm; a lack of local, cardiac mesoderm-derived FGF causes ventral endoderm to
develop into pancreatic tissue instead140. Therefore, while the ventral endoderm can
develop into pancreatic tissue by default, the presence of FGF inhibits pancreatic
development and promotes hepatogenesis. Furthermore, this FGF is cardiac mesodermderived141. As a second example, the dorsal endoderm can readily differentiate into
hepatoblasts in the absence of surrounding tissues. However, in the presence of the dorsal
mesoderm, the dorsal endoderm does not undergo hepatogenesis, and instead undergoes
gut development. These examples indicate that there are positive and negative
differentiation factors that finely modulate hepatic development based on movement and
signaling140.
Hepatogenesis can be described as a two-step process140. We have already
discussed the first step, during which cells of the ventral endoderm differentiate down the
hepatic lineage. The second step is comprised of the differentiation of hepatoblasts into
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hepatocytes, which depends on additional stimulation by the Septum Transversum (ST)
mesenchyme. Mesenchymal interaction may also be necessary for hepatogenesis142. The
ST is an intermediary cellular layer between the endoderm and cardiac mesoderm that
later develops into the epicardium and diaphragm143. The ST is also a rich source of
BMP4. Multiple studies have demonstrated that the ST, and its abundance of BMP4, are
vital to hepatogenesis. Cultures of ventral endoderm sans ST mesenchyme failed to yield
a liver. Likewise, BMP4null mice also failed to develop a liver. Lastly, when both the
ventral endoderm, cardiac mesoderm, and ST mesenchyme were all present, the addition
of Noggin (a BMP4 antagonist) blocked hepatogenesis and resulted in no albumin
expression142, even though previous studies demonstrated that FGF alone could drive
hepatogenesis138,140.
Within this complex milieu of hepatocyte development, hepatic cords begin
coalescing around immature endothelial cells known as angioblasts. These cords begin to
grow and organize at the expense of the ST, which eventually also forms the liver
capsule143. The influence of VEGF/Flk1 signaling drives the angioblasts to take on a
sinusoidal phenotype; these sinusoids then act as gestation templates for the threedimensional growth of hepatic cords into liver cell plates. At the same time, Notch
signaling promotes the differentiation of hepatoblasts into cholangiocytes, the cells of the
biliary tree144.
In sum, liver development is an incredibly complex process, defining a
collaboration between the developing cardiovascular and GI systems. This process is
significant to this dissertation project, as the pluripotent stem cells used in our
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experiments undergo similar sequences of differentiation into hepatocytes with several of
the same growth factors mentioned above.

Liver: Gross and Microscopic Anatomy
The human liver is an encapsulated organ that is divided into four key areas, or
lobes – the left, right, caudate, and quadrate lobes145. These lobes are subdivided into nine
segments, all of which are numbered after the nine terminal subdivisions of the portal
vein. Approximately 75% of the liver blood supply is derived from the portal vein
(receiving derivatives of the mesenteric veins and arcades), while the hepatic artery (an
aortic descendant) provides the remaining 25%. Thus, (1) venous blood from the portal
vein is rich in nutrients and (2) blood from the hepatic artery is rich is oxygen. This dual
blood supply constitutes the portal circulation145.
Microscopically, the liver largely comprised of parenchymal hepatocytes, which
are arranged as a series of hexagonal lobules (Figure 4). Each lobule is divided into
sixths, with each sixth constituting a liver acinus, the functional unit of the liver (Figure
4)145. At the vertices of each lobule are trios of vascular and biliary structures collectively
referred to as portal triads, each of which contains a hepatic artery, portal vein, and bile
duct. A central vein lies at the center of each liver lobule. Given this organization, blood
and nutrients travel from the periphery of a hexagonal lobule past all of the hepatocytes
within an acinus towards the central vein (Figures 4 and 5). Each lobule is subdivided
into three different zones of oxygen and nutrient exposure (Figure 4). Hepatocytes
situated within Zone I (periportal zone) are closest to the portal triad and receive the most
nutrients, but are also subjected to the highest degree of drug- or toxin-induced damage.
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Figure 4. Schematic of a hepatic lobule, with portal triads (or tracts, shown with an
arrow), a hepatic acinus (bounded by dashed lines) and zones of oxygenation and
nutrient distribution. PV = portal vein, BD = bile duct, HA = hepatic artery, CV =
central vein.

Figure 5. Schematic of fenestrated liver sinusoids lined with endothelial cells (*). Arrows
indicate the flow of bile or blood. Also shown is the Space of Disse in-between
hepatocytes and the sinusoids.
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Zone II is the area in-between Zones I and III. Zone III (perivenous zone) surrounds the
central vein and contains hepatocytes that have minimal oxygen supply but are most
resistant to damaging drugs and toxins. From here, the central vein empties into hepatic
veins, which drain into the inferior vena cava and returns to the heart.
The liver plays chief roles in cholesterol metabolism (previously discussed),
osmotic balance, and the bulk transport of proteins145. For all of these processes, the liver
requires a unique sinusoidal, fenestrated, discontinuous vasculature (Figure 5). The
presence of a discontinuous basement membrane as well as gaps and fenestrations, in the
endothelial lining allow large proteins and macromolecules to leave hepatocytes to enter
the circulation, and vice versa. To this end, liver sinusoidal endothelial cells (LSEC) are a
subset of endothelial cells and are replete with unique identifiers (such as the Mannose
receptor, L-SIGN, LYVE-1, VAP-1, and Stabilin-1 and -2)146. Sinusoidal vessels link
peripheral portal veins with central veins.
Hepatocytes within liver lobules and acini are arranged into sheets of cells that are
separated from this sinusoidal vasculature by perisinusoidal voids termed the Spaces of
Disse145 (Figure 5). Macrophages of the liver, known as Kuppfer cells, have been shown
to reside in the Spaces of Disse as well as the sinusoidal lumen147. Kuppfer cells target
and sequester bloodborne pathogens before sinusoidal blood reaches the surrounding
hepatocytes. Hepatocytes, in turn, extend microvilli into this Space to facilitate nutrient
absorption. In various pathologies (discussed in detail below), the basement membrane
can become continuous and thickened (a process known as capillarization)148,149, while
the Spaces of Disse are obliterated. Both of these morphological changes detrimentally
affect the hepatocytes’ ability to obtain nutrients and filter toxins and other metabolites
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from the blood and vice versa.
Hepatic stellate cells (also known as Ito cells) also reside in the Spaces of
Disse145. The majority of their existence is spent in a quiescent state; their role in this
state is still under investigation. Some studies suggest that hepatic stellate cells are liver
progenitor cells that mediate liver regeneration and normal cell turnover150-152. In
instances when the liver is damaged, stellate cells are activated and lay down significant
amounts of collagen – similar to the functions of many fibroblasts and perivascular cells
– leading to the development of scar tissue and fibrosis.

Liver Dysfunction: Other Examples
A discussion of the liver would not be complete without briefly acknowledging
some other modes of liver dysfunction other than FH. For example, liver failure is a
broad classification of organ failure that can lead to systemic dysfunction145. As
discussed above, because the liver plays a crucial role in cholesterol metabolism, a
dysfunctional liver can lead to cardiovascular disease. The liver also acts as a major
vascular reservoir and conduit, termed the portal system. In chronic liver failure (taking
place over months to years), the microscopic organization of sinusoids and fenestrations
undergoes capillarization. Outwardly, portal hypertension ensues, resulting in the
development of varices at portacaval anastomoses (connections between liver and
systemic circulation) due to the increased pressure. Esophageal varices (swollen, tender
blood vessels in the lower esophagus), hemorrhoids (swollen vessels of the rectum), and
caput medusae (dilated vessels around the belly button) are consequently exhibited.
Additionally, liver hepatocytes are consequently starved of nutrients and oxygen,
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propagating organ failure. However, as the liver filters systemic metabolites and toxins, a
failing liver is unable to carry out these functions. Toxins accumulate in the bloodstream
and can cause neurological symptoms (such as asterixis (flapping tremors) and mental
disorientation and confusion (termed hepatic encephalopathy)) and multi-organ failure145.
To contrast, acute liver failure (also known as fulminant liver failure) is sudden,
with hyper-acute failure taking place within 1 week, and acute failure occurring within
the span of a month. Acute failure accelerates many of the outward symptoms present in
chronic liver failure. Cerebral edema and problems with clotting and coagulation are
hallmark features of acute disease. Causes of acute failure include drug (e.g.,
acetaminophen) and alcohol overdose, adverse reactions to particular drugs (such as
tetracycline), and viral disease (hepatitis A or B, or Varicella in children leading to
Reyes’ syndrome)145.
In a broader regard, the liver is a major producer of proteins and enzymes.
Albumin is a major transport protein produced by the liver that resides in the blood
plasma. It also maintains osmotic balance. In liver failure, the production of albumin is
significantly reduced. Thus, fluid that would have normally been contained in albuminrich blood is no longer subjected to the same osmotic forces, and consequently collects in
the interstitium and perivascular spaces. For this reason, patients with liver failure often
present with ascites and edema. In another example, alpha-1 antitrypsin (A1AT) is an
enzyme produced by the liver that acts in the lungs. As a protease inhibitor, A1AT
protects the lungs from long-term exposure to neutrophil elastase, a local enzyme used
for pathogen defense and cell maintenance. A failing liver does not produce sufficient
amounts of A1AT, producing symptoms similar to A1AT deficiency, a heritable disorder.
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Here, a lack of A1AT in the lungs results in unmitigated neutrophil elastase. Elastase
persists for time periods much longer than normally allowed, leading to destruction of the
intricate lung architecture and resulting in lung disease145.
In short, these examples are not intended to specifically discuss the full range of
complex liver diseases. Rather, they are intended to demonstrate the key functionality of
the liver and the systemic consequences of liver failure. Again, this dissertation focuses
on the liver from a parenchymal and cardiovascular perspective. However, its key roles
with regards to other organ systems are indisputable.

Hepatocyte Cell Sourcing & Configurations
The liver is amongst the top organs sought for transplantation. Unfortunately, the
demand for high-quality, compatible livers (over 30,000 in the US die annually of liver
failure153) far outstrips its relatively meager supply. Over 16,000 US patients are
currently waiting for a liver154, and only about 65% of liver transplant recipients survive
after 5 years. Dialysis is an option that is available to kidney failure patients, but because
the liver is highly complex and regulates numerous metabolic functions, there are
currently few accessible stopgaps to prolong life in the face of liver failure. The major
therapeutic option for people with liver failure is transplant. Further complicating care is
the fact that the course of liver failure is very hard to predict155. These statistics
demonstrate the dire need for a personalized, long-lasting, and widely accessible
therapeutic system.
Four main biological approaches are being investigated for liver failure; these
include hepatocyte transplantation, extracorporeal devices such as the bioartificial liver
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(BAL), xenografts, and implantable constructs155. These approaches aim to expedite
recovery, promote regeneration, or serve as a bridge-to-transplant. However, there are
several considerations. First, hepatocyte transplantation depends on having a sufficient
quantity of functional hepatocytes to (a) transplant and (b) elicit a therapeutic outcome.
As livers are in short supply, hepatocytes (the liver parenchymal cell) are also in
relatively short supply. Though many have attempted to culture and expand primary
hepatocytes, these cells are difficult to culture as they depend on the liver
microenvironment to survive. As such, in culture, they dedifferentiate and lose their
polarity and function over time156,157. Others have tried to lengthen in vitro hepatocyte
life with enhanced medias158-160; however, these specialized formulations are
incompatible with patient exposure155. Several have developed cell lines (examples
include HepG2161 and C3A162, HepZ163, HH25164, and HepaRG165,166) that closely
approximate some primary hepatocyte functions, but these cell lines are either
immortalized or tumor-derived. Though several lines have been used in clinical trials, the
risk of oncogenic gene transfer is still of concern and hampers widespread clinical
application.
Second, non-biological approaches to correct hepatic metabolic deficiencies
(hemodialysis, hemoperfusion, and plasmapheresis) are less successful as they only
partially and transiently recapitulate the vital functions that whole, healthy livers
provide155. Extracorporeal devices such as BAL seek to mitigate these shortcomings by
adding a hepatocellular element to the device. However, these devices have unique
complications such as issues with the transport barrier, scale-up, cell exposure to shear
stress, non-uniform perfusion, and cellular stability in suspension.
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Third, xenografts are another source for hepatocytes. Porcine hepatocytes are the
most abundant alternative and have been used in pre-clinical and clinical trials167-170.
Hepatocytes from rabbits, dogs, and rodents have also been used, albeit on a more limited
scale. In numerous instances, porcine xenografts incorporated into BAL systems provided
measurable therapeutic relief169. These xenografts are capable of producing sufficient
amounts of albumin, though they express decreased CYP450 activity over time. Further,
xenografts are subject to human immunologic reactions and could lead to zoonotic
transmission171,172. Lastly, hepatocytes are responsive to species-specific signals that are
absent in xenograft173. All of these factors potentially limit their long-term clinical
utility.
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PART III: STEM AND REGENERATIVE CELLS

As one of the biggest challenges with liver transplant is inadequate supply, stem
cells provide a potential avenue for generating the significant cell numbers required for
producing enough therapeutic hepatocytes. This section provides a brief overview of stem
cells, from embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC)
development, to ethical boundaries, to discussing various efforts in producing stem cellderived hepatocyte-like cells.
To begin, we should first acknowledge the differences between totipotent,
pluripotent, multipotent, and unipotent cells. Cells that give rise to all embryonic and
extraembryonic tissues, they are deemed totipotent174. If the cells give rise to only
embryonic tissues (these cells are typically sourced from the inner cell mass of a
blastocyst (i.e., the second stage of development post-fertilization)), they are termed
pluripotent175. Adult stem cell populations that give rise to cell lines of related or single
lineages are referred to as being unipotent or multipotent, respectively. Lastly, a key
consideration with all of these cell designations is that once the cells have fully
differentiated down a particular lineage, they lose their ability to differentiate into other
tissue types (i.e., their differentiation potential)175.
Cloning, another topic common to both ESC and iPSC, was first established by
Briggs and King in the 1950s176,177 and later perfected by John Gurdon in 1960s and
70s178. In all of these studies, Briggs, King, and Gurdon made the seminal observation
that a frog’s cells contain the genetic material required to clone entire frogs175.
Additionally, it demonstrated that differentiated cells are maintained in such a state
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through a series of epigenetic changes, and that these changes could potentially be
reversed to force the cells into a de-differentiated state (through a process known as
reprogramming). However, simply cloning cells has highlighted problems with genome
integrity, ostensibly due to problems with reprogramming178-180. For these reasons, cloned
cells may be useful for establishing a proof-of-principle but not for more detailed
research endeavors.
Experimentation with pluripotent stem cells started in the 1950s, when cells were
taken from mouse germ cell tumors known as teratocarcinomas (or alternatively,
embryonic carcinomas181). These cells could be clonally expanded182 and were shown to
maintain pluripotence by differentiating into the three embryonic germ layers – the
ectoderm, mesoderm, and endoderm183. Thus, embryonic carcinoma cells could be used
to model aspects of mammalian development.
Embryonic carcinoma cells (ECC) played a pivotal role in ESC and iPSC
development in the late 1970s, when Miller and Ruddle demonstrated that the
combination of ECC with thymus cells yielded a cell line with ECC properties devoid of
all somatic features184,185. These studies were critical, as they demonstrated that (a)
pluripotent phenotypes exert a dominant influence on differentiated somatic cells, (b) the
ECCs contained some transferrable factor that induced pluripotence, and (c) if these
factors existed, they should be identifiable175.

Embryonic Stem Cells
The transition from ECC to ESC took place after the implantation of mouse
embryos outside the uterus resulted in the development of embryonic carcinomas186. This
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finding led to the postulation that embryos themselves might have stem cells. In 1981,
Evans and Kaufman187 and Martin188 successfully isolated mouse ESC (mESC) from
blastocysts and developed in vitro culture conditions. These mESC were able to generate
all three germ layers in vivo in spontaneously differentiated, tumor-like structures known
as teratomas. A few years later, between 1984 and 1988, the basis for human ESC
(hESC) development was formed when Andrews generated pluripotent stem cells (PSC)
from a human teratocarcinoma line189; later on, clones from this line were exposed to
retinoic acid to form neuron-like cells190. Pera and colleagues subsequently derived
human embryonic carcinoma cells that were able to form all three germ layers, but
exhibited chromosomal abnormalities and limitations in their ability to undergo
spontaneous differentiation191.
The mid 1990s marked key advances in hESC generation. In 1994, human
blastocysts were donated by patients for research purposes; the inner cell mass of these
blastocysts were able to be cultured for 2 passages, but exhibited normal karyotyping and
maintained a stem cell-like morphology (i.e., a bunched appearance with a high nuclearto-cytoplasm ratio)192. Isolation of ESC from the blastocysts of rhesus monkeys193 and
marmosets194 provided the first proof-of-concept for what could be expected with human
cells. These non-human primate ESC were pluripotent and resembled human embryonic
carcinoma cells in vitro. In 1998, Thomson made a significant leap when he and
colleagues were able to use donated human blastocysts to derive ESC195. Several nonclonal lines were established, all of which demonstrated pluripotence through teratoma
assays.
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In addition to practical issues with hESC maintenance of a normal karyotype, the
long-term maintenance of unique characteristics, and a generalized need for improved
differentiation protocols196, hESC are also shrouded in ethical controversies that hamper
their widespread use in clinical therapies. While hESC are sourced from embryos that
develop from eggs that have undergone in vitro fertilization195, these eggs are not
fertilized in vivo and do not become fully formed fetuses. However, isolation of hESC
require the early embryo to be destroyed, leading several to question the existence and
degree of a moral status197. These challenges prompted researchers to find other avenues
of generating pluripotent cells, and in particular, induced pluripotent stem cells.

Induced Pluripotent Stem Cells
The generation of induced pluripotent stem cells (iPSC) depends on three key
principles, namely (a) reprogramming, (b) the derivation and culture of pluripotent stem
cell lines, and (c) the observation that transcription factors determine cell fate175. With
respect to the last principle, several have made the observation that transcription factors
associated with a particular lineage could drive pluripotent cells towards that same
lineage198-200. Furthermore, these studies demonstrated that during lineage-specific
differentiation, erroneous factors goading the differentiating cells into inappropriate
lineages were automatically stifled. Progressing in a reverse direction, pluripotent stem
cells were shown to induce pluripotence in somatic cells after cell fusion, suggesting that
there are some transferrable factors that behave in a dominant fashion201,202. However, the
identity of these factors remained unknown for several years.
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In 2003, Tokuzawa, Yamanaka, and colleagues developed an elegant screening
mechanism for determining which transcription factors conferred pluripotence203. Using
24 transcription factors associated with pluripotent stem cells, they methodically removed
one transcription factor after another, ultimately discovering that a series of four factors
(Oct4, Sox2, Klf4, and cMyc) were required to produce colonies that resembled mouse
ESC204; these colonies were then termed induced pluripotent stem cells, or iPSC. A year
later, the same feat was achieved with human cells205. These discoveries were so
monumental that Yamanaka and Gurdon were jointly awarded the Nobel Prize in
Medicine in 2012. To date, iPSC have been derived from several species, such as
humans, pigs, rodents, and monkeys. In several these species, factors such as OCT4, by
itself or in combination with SOX2206 KLF4207,208, cMYC204,209, and/or LIN28 and
NANOG210, induced pluripotence in a variety of terminally differentiated, somatic
tissues, indicating that there are several fundamental features of transcript networks that
are evolutionarily conserved.

iPSC and Reprogramming
As mentioned earlier, the use of factors to convert a terminally differentiated
somatic cell into a pluripotent stem cell is termed reprogramming. As the ability to
produce iPSC are predicated on the use of the four reprogramming (or “Yamanaka”)
factors, the modality by which these factors are introduced is equally as important. In this
section, we will discuss several methodologies as well as their advantages and any
caveats.
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The first efforts in reprogramming utilized constitutively active retroviral vectors.
While retroviruses enabled an efficient delivery of the reprogramming transgenes, the
transgenes themselves stably integrated into the host genome. Additionally, they could be
inactivated by host methyltransferases211,212, leading to cell lines that were partially
reprogrammed. As the transgenes were integrated, they were also susceptible to
reactivation, propagating the formation of tumors in chimeric animal models213. To
increase the efficiency of transgene delivery, lentiviruses were utilized, though many
lentiviruses actually intensified other retroviral shortcomings and led to such robust
transgene expression that differentiation was completely impeded214,215.
Because inadvertent transgene expression can have undesirable consequences,
efforts to mitigate this were subsequently pursued. Inducible lentiviral vectors improved
on lentiviral performance by relying on indolent drugs to control transgene expression.
For example, when somatic cells were placed in medium containing doxycycline, the
reprogramming factors were expressed. Conversely, the removal of doxycycline from the
cell medium led to an abrogation of reprogramming transgene expression214,216.
A fourth reprogramming modality involves using inducible vectors in a two-step
process known as secondary reprogramming217-220. In the first step, inducible lentiviral
vectors are used on somatic cells as described above. Because the removal of the indolent
drug terminates reprogramming, primary iPSC clones can be identified and differentiated
into a terminal somatic cell type. As all primary iPSC are exposed to the same
differentiation regimen, the resulting somatic cells are, theoretically, genetically identical.
Introducing these iPSC-derived somatic cells to the same, indolent drug leads to a
reactivation of the reprogramming transgenes, forcing the newly generated somatic cell
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population to uniformly regress into a pluripotent state. This method of reprogramming is
advantageous because it facilitates reprogramming on a large scale. Secondly, it enhances
efficiency because a homogeneous population is being used (in the second step) to
generate an iPSC population (hence the term “secondary reprogramming”). Thirdly, this
reprogramming modality permits the comparison of genetically matched iPSC from
different somatic cell populations175. However, these approaches still result in integration,
which can permit transgene activation at any time as well as increase the likelihood for
insertional mutagenesis. These pose obstacles for widespread clinical use.
To counter these caveats, several non-integrating reprogramming approaches have
recently been developed. Simply put, these approaches fall into one of three classes: (1) a
complete obviation of integration, (2) transient integration, or (3) complete avoidance of
nucleic acids in the reprogramming vectors. We can similarly assess these three classes as
we did with the integrative modalities.
Non-integrating adenoviruses221, Sendai viruses222, polycistronic mini-circles223,
and self-replicating episomes224 have all been used to reprogram various human
fibroblast lines. Because the reprogramming transgenes are not integrated, these
modalities provide a unified proof-of-principle that transient transgene expression is
enough for producing iPSC. While all of these methods obviate integration, a significant
hit is taken with respect to reprogramming efficiency compared to traditional, integrative
methods175, though reprogramming efficiency is not that significant a concern given iPS
cells’ propensity to proliferate rapidly once formed.
Another method involves using recombinant vectors that initially integrate into
the host genome, but are later removed by the actions of Cre recombinase225. This
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approach, known as integration-dependent gene delivery, is particularly advantageous
when single mRNAs encoding multiple genes (i.e., polycistronic mRNA) are used226.
However, the nature of transgene extrication is such that small segments of genetic
material (i.e., “footprints”) are left behind. The long-term, downstream effects of such
footprints are unknown. Similar to integration-dependent gene delivery, Piggybac
transposons are mobile genetic elements that can efficiently transpose genetic material
between vectors and chromosome in a “cut and paste” fashion227. The enzyme Piggybac
transposase moves the reprogramming transgene from the donor vector for integration at
TTAA sites on the recipient chromosome. After transgene expression occurs for a desired
amount of time, an excision Piggybac transposase can be used to fully excise the
transgene without leaving behind any foreign genetic material228. While this improves on
some of the shortcomings associated with integration-dependent gene delivery,
sequencing of candidate integration sites is required. Additionally, the effects of
Piggybac transposase on the host genome have yet to be investigated.
The next approach is perhaps most analogous to the early experiments in which
pluripotent cells were cultured with somatic cells. This led to the hypothesis that there
must be some transferable, dominant factor(s) that confers pluripotence. In 2010, Cho
and colleagues delivered whole-cell extracts from ESC to somatic cells229. While
laboratory-directed genetic manipulation was obviated, the methodology was not
efficient.
A methodology for delivering synthetic modified RNA (modRNA) was recently,
successfully used for iPSC reprogramming230,231. The potential advantages of this
strategy are that (a) transfection is transient, with a modRNA half-life of 12 hours232 and
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(b) being mRNA based, modRNA avoids the possibility of genomic insertion, though it
requires repeated transfection with c-Myc which could be potentially problematic233. In
addition to these facets, modRNA is reported to yield one of the highest reprogramming
efficiencies, approaching 2% in normal fibroblasts234.

Challenges with iPSC
Like ESC, iPSC face several challenges as well, but many of these can be
overcome with alternative approaches to their generation and maintenance. However,
while ESC and iPSC are similar in their ability to self-renew indefinitely, express genes
associated with pluripotency, engage in spontaneous differentiation and teratoma
formation, and form live animals235, there is some debate as to whether or not iPSC are
truly functionally equivalent to ESC236. Several epigenetic control and gene expression
patterns are similar between the two cell types213,237-239, though iPSC exhibit a propensity
for tumor formation (Miura 2009), senesce prematurely240, exhibit differences in
mRNA241 and micro RNA242 expression patterns.
Another issue lies with iPSC supposed predilection for differentiating towards
particular lineages, namely those of their source cells; in this instance, the cells are
described as having epigenetic memory243. In 2010, Kim and colleagues sourced iPSC
from fibroblast and blood cells, and found that the iPSC exhibited the same DNA
methylation patterns as the cells from which they were derived244. Ji and colleagues
subjected 8 iPSC lines to methylation analysis and determined that the lineage outcome
was potentially orchestrated by changes in DNA methylation patterns245. To corroborate
these findings, that same year, Polo and colleagues looked at a full array of tissues and
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noted that iPSC possessed an altered differentiation capacity compared to ESC246.
However, recent findings suggest that these differences may be artifacts of the
environments in which the iPSC were generated247, and that different labs’ emphases may
in fact be leaving different signatures on the cells235.
When pondering the issue of iPSC-ESC equivalence in light of this information, it
is also important to consider that ESC can also be affected in similar ways. ESC have
been shown to exhibit lineage propensity248 as well as differential gene expression
patterns249. ESC and iPSC, despite their many similarities, are not absolutely equivalent
and are even different from isolation onwards235. Therefore, more stringent, standardized
methods for generating these cell types need to be developed, or we need to consider
other means of overcoming these realities.
Another consideration is that iPSC form teratomas more readily than ESC250.
While this may not be problematic in fully differentiated cultures, like hESC, the
efficiency of iPSC differentiation into terminal cell types has never reached 100%. In
fact, efficiencies can vary between 1% to 80% depending on the lineage to which the
iPSC are being directed251, though such variation could be attributed to the particular
differentiation protocol being utilized. That said, the presence of even once
undifferentiated iPSC in a culture that has 99.9% differentiation efficiency would,
theoretically, be enough to form a teratoma. The US Food and Drug Administration
considers iPS cells’ propensity for teratoma formation a barrier to clinical adoption.
Consequently, this enhances the requirement for highly robust, efficient differentiation
protocols as well as measures to remove undifferentiated cells from such cultures. For
example, one strategy involves the selective, chemical ablation of only pluripotent stem
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cells in differentiating cultures252,253. This approach spares fully differentiated cells and
facilitates the elimination of pluripotent cells that can give rise to teratomas, though the
long term genetic stability of iPSC-derived cells and tissues remains to be seen. In
another example, Wu and colleagues recently described the development of a caspase-9based safety switch in their mouse iPSC lines254. Since their caspase-9 mechanism relies
on dimerization to initiate cell suicide, all that is required is that cells be exposed to a
chemical dimerizer (in their case, AP1903).
Fifth, cMYC is an oft-present member of traditional reprogramming factor
cocktails. Ectopic cMYC is associated with tumorigenicity255. While the omission of
cMYC from pluripotent transcription factor cocktails do indeed yield iPSC208,233,
reprogramming efficiency reduces significantly256. Still, if the presence of cMYC is a
concern, reprogramming efficiency is less of a concern as iPSC proliferate rapidly once
generated; in principle, only one iPS cell is required to then generate larger volumes of
cells for downstream applications.
Lastly, another concern for the generation and potential clinical use of iPSC are
genomic integration of exogenous reprogramming factors and unwanted spontaneous
transcriptional activation post genomic integration, both of which are associated with
viral-vector technologies230,231,257. To avoid stable integration, DNA-based transgenes
have also been delivered by non-integrating plasmids258, mini-circles223, and Epstein-Barr
episomal vectors210. However, because the transgene is still DNA-based, spontaneous
insertion259,260

and oncogenesis232,258,261 are still considerations. With DNA-free

technologies, the risk of random genomic integration is obviated. This makes approaches
such as modRNA particularly attractive.
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In sum, iPSC have a theoretically limitless proliferation and differentiation
potential that makes them attractive for cell-based therapies because of difficulties in
culturing and correcting cellular dysfunction in primary cells (such as hepatocytes).
Current strategies for (a) deriving iPSC from somatic cell sources non-virally, (b)
enhancing differentiation efficiency, and (c) preventing tumorigenesis and teratoma
formation better position iPSC as a clinically relevant, therapeutic cell source.

Stem Cell Differentiation into Hepatocyte-Like Cells
The use of primary donor hepatocytes in a therapeutic capacity does not assure
successful treatment in the face of liver failure262. While one obvious challenge in this
regard is donor-recipient compatibility, a cirrhotic or diseased liver can provide a
suboptimal environment for primary hepatocytes to thrive, let alone function263. While
several workarounds include optimizing primary hepatocyte placement (for example, in
the lymph nodes264, pluripotent stem cells offer unique promise in treating liver
dysfunction. Despite the aforementioned challenges, pluripotent stem cells can be
differentiated to directed cell types. Additionally, since hepatocytes are notoriously
difficult to expand in culture, the ability of several types of PSC to rapidly proliferate in
culture means that they can be scaled prior to differentiation and use. To this end, several
efforts have utilized pluripotent stem cells to generate hepatocyte-like cells (HLC).
In 2009, Song was amongst the first to develop a multi-stage method for
differentiating iPSC into HLC. iPSC were first committed to an endodermal lineage
before being exposed to a sequence of factors that gradually matured the developing
hepatocyte in three subsequent stages265. The resulting HLC expressed characteristic
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hepatic markers alpha-fetoprotein (AFP; marker of immature hepatocytes) and albumin
(marker of mature hepatocytes) by day 7. By three weeks after the start of differentiation,
the HLC were able to participate in glycogen and urea synthesis and exhibited inducible
P450 activity. Others have used similar methods to generate HLC from iPSC – for
instance, Si-Tayeb and colleagues utilized a four-stage protocol to similar effect266, while
Ishikawa obviated the use of exogenous factors entirely and relied on iPSC propensity to
differentiate down a particular lineage, presumably based on epigenetic memory267.
However, Takebe and colleagues were the first to use iPSC-derived HLC to
develop a human organoid – more particularly, an iPSC-derived liver-tissue mimic268.
They first differentiated the iPSC in two stages, first committing the cells to an endoderm
lineage before specifying them down a hepatic lineage. The cells were then combined
with a stromal support system comprised of mesenchymal stem cells (MSC) and human
umbilical vein endothelial cells (HUVEC), as Zaret and colleagues demonstrated that
hepatogenesis is facilitated by adequate stromal and vascular support269. Upon placing the
newly formed iPSC liver buds (iPSC-LB) in vivo atop the mesenteric circulation, the
implant anastomosed with and was perfused by the surrounding mesentery. Furthermore,
the iPSC-LB were able to rescue drug-induced liver failure. These findings provided us
with a broad proof-of-principle that we sought to refine by using corrected, patientspecific iPSC in conjunction with a clinically relevant, adipose-derived vascular support
system.
With regards to iPSC-derived cells for the management of FH, work by Cayo and
Fattahi were amongst the first to address patient-specific iPSC generation. Cayo and
colleagues developed an FH-specific iPSC line using lentiviral-reprogramming vectors.
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Additionally, they were the first to demonstrate that FH-iPSC could be used to form HLC
(using the protocol developed by Si-Tayeb266) and that without correction of the LDLR,
these HLC were deficient in their ability to take up LDL cholesterol270. Fattahi followed
suit by used a retroviral reprogramming vector to generate iPSC from patient-specific
fibroblast population89 before differentiating the cells using a modified version of a
protocol developed by Basma and colleagues271. These cells were able to internalize
lipids, produce and store glycogen, metabolize Indocyanine green, and uptake circulating
LDL after correction via a lentiviral LDLR transgene vector that was constitutively
expressed.
Though all of the aforementioned modalities yield HLC, no single assay can
determine whether the resultant cells are analogous to primary hepatocytes. Rather, a
combination of tests (such as consideration of cellular morphology, gene and protein
expression profiles, and functional characterization) can help272. Additionally, while HLC
are certainly “hepatocyte-like” based on their physical appearance and phenotype, the
cells are often immature (as they express significant amounts of AFP) and possess
significantly reduced cytochrome P450 activity272 compared to primary hepatocytes.
Though these differences may be subtle, they pose some challenges for HLCs’ clinical
applicability and therapeutic value as a standalone system.
Our work in generating FH-iPSC-derived HLC seeks to combine several nonviral, non-integrating innovative technologies to develop a clinically relevant cell
therapy. However, the generation of a functional liver tissue mimic does indeed depend
on a stromal and vascular supply. Our next section discusses the vasculature and its
support system in greater detail.
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PART IV: THE VASCULATURE

Overview of Vascular Formation, Organization and Function
A major goal of the studies described in this dissertation is the development of a
functional microcirculation in a liver organ mimic using stromal vascular fraction cells
derived from adipose tissue. The presence of a vascular supply is critical to organ
survival and function.

The studies performed utilize in vitro and in vivo experimental

models that replicate aspects of blood vessel development observed in embryos as well as
adult organisms undergoing physiologic and or pathologic blood vessel development.
During embryonic development the blood vessels that invest all organs originate from a
primitive tubular structure. These blood islands form through the process of
vasculogenesis and are composed of primitive vessel-forming cells known as the
hemangioblasts. During subsequent embryogenesis, the blood islands exhibit cellular
proliferation, migration and de novo vessel formation from existing vessels, a process
known as angiogenesis.

Further maturation of vessels through arteriogenesis and

venulogenesis results in a hierarchy of structures collectively known as the
microcirculation.

Strategies to create a new microcirculation from cellular components

must incorporate the signals and cues that support embryonic and adult blood vessel
formation, as the presence of an operative microvasculature is critical to organ survival
and function.
The peripheral vascular system is broadly subdivided into five groups: arteries,
arterioles, capillaries, venules, and veins. Arteries and arterioles carry oxygenated blood
away from the lungs and heart and deliver it to the organs. Arteries are typically
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comprised of three layers, or “tunics”: (1) The tunica intima is the endothelial lining,
underneath which there is an internal elastic membrane (IEM). (2) The tunica media
comprises the next layer outside the IEM and is composed of smooth muscle, which
maintains vascular tonicity. Just around this layer is the external elastic membrane
(EEM). (3) The tunica adventitia is the outer layer, comprised of fibroblasts, connective
tissue, and perivascular nerves. Arterioles differ from this organization mainly in the
extent and orientation of their smooth muscle composition and overall diameter – both
are decreased; arterioles serve as bridges between arteries and capillary beds, and
arterioles act to regulate the blood flow of the microcirculation. Venules drain blood from
capillary beds into larger veins. Veins themselves are similar to arteries in terms of their
organization; however, they appear larger and are less rigid in their structure, namely due
to their considerably decreased amount of smooth muscle in the medial layers.
Additionally, since veins represent the low-pressure side of the circulation, they exhibit
valves as part of their intimal layer; these valves rely on surrounding skeletal muscle
contractions to propel blood against gravity back to the heart while minimizing backflow.
Capillaries are the intermediate vessels connecting arterioles with venules273.
They are one cell layer thick and are comprised primarily of endothelial cells.
Embryonically formed by vasculogenesis (de novo vascular formation)274-276, capillaries
have a diameter of approximately 5-10 µm and normally function in conjunction with
other capillaries as part of a capillary bed. Depending on an organ’s complexity and
metabolic requirements, the number and arrangement of beds varies accordingly. This
minute organization makes capillaries the ideal sites for gas, nutrient, and waste
exchange. Three types of capillaries exist: continuous, fenestrated, and sinusoidal.
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Continuous capillaries are comprised of endothelial cells that maintain tight junctions
throughout, as well as a continuous basement membrane. This arrangement provides no
room for larger molecules to freely traverse across the endothelial cells, and most
transport is restricted to vesicles. The tight endothelial arrangement and continuous
basement membrane are integral to the functionality of the blood-brain barrier, for
example. To contrast, fenestrated capillaries are different in that they maintain a
continuous basement membrane, but feature fenestrations (the Latin fenestra means
“window”). These fenestrations are approximately 60-80 nm wide and facilitate small
molecule and protein diffusion277. Lastly, the sinusoidal capillaries combine a fenestrated
endothelial lining with a discontinuous basement membrane. This membrane features
large openings (30 – 40 µm) and allow for the passage of red (~8 µm) and white (~25
µm) blood cells as well as large proteins like albumin (~65 kDa). As such, organs such as
the liver, spleen, and sites like the bone marrow and lymph nodes are replete with this
type of capillary system.

Endothelial Cells
All blood vessels have an endothelial lining. Thus, vascular endothelial cells (EC)
are a critical component of circulatory and systemic health. In addition to serving as a
barrier, endothelial cells play active roles in vascular remodeling, the trafficking of
hormones, recruitment and binding of neutrophils, fluid filtration (namely in the renal
glomerulus), control blood vessel tone (via signaling with surrounding smooth muscle
cells), and hemostasis. The cells are also able to adjust their numbers (by proliferating)
and orientation (through branching) to better meet tissue metabolic needs273.
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EC exert systemic and cellular influence through a variety of factors. For
example, vasoactivity is mediated by bradykinin278, which can act on EC to balance
tissue oxygen levels as well as overall vascular tone and diameter. Using
mechanoreceptors to detect changes in cardiac output and, consequently, shear stress, EC
can release nitric oxide (NO) via endothelial nitric oxide synthase (eNOS) to modulate
the degree to which tissues are perfused279. eNOS production is also potentiated by
vascular endothelial growth factor (VEGF), serotonin, bradykinin, and adenosine280. In
addition to promoting vasodilation, NO also modulates inflammation, oxidative
phosphorylation281, and thrombosis, all of which serve to maintain relative environmental
quiescence282,283. EC-produced NO can also affect proliferation efficiency at the
transcriptional level, blocking the translocation of NFκB and inhibiting the activity of
various cyclins284. In addition to NO, EC can also produce endothelin and other
prostanoids (potent vasoconstrictors)285 and prostacyclins (which also act as vasodilators
in a manner independent of NO activity)286. Thus, EC are equipped to finely modulate
vascular flow in the existing vasculature to affect perfusion and, ultimately, oxygen
delivery.
EC can also play a role in vascular remodeling through angiogenesis.
Angiogenesis is the process by which new blood vessels are formed from existing ones.
A whole host of factors are involved, but VEGF is amongst the most prominent and wellstudied of the angiogenic factors287. In vivo, the presence of low oxygen levels triggers
the expression of hypoxia inducing factor-1 (HIF-1), which acts to boost local VEGF
expression in EC. VEGF that is produced then has a paracrine effect on surrounding
endothelium, leading to (1) EC migration towards a VEGF gradient, (2) new EC
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producing proteases to be able to permeate existing extracellular matrices, (3) a
proliferation of EC, and (4) the formation of tube-like structures. Once these tubes are
perfused, local oxygen levels increase and the driver of HIF-1 signaling is removed in a
feedback-looped manner, stopping angiogenesis. In the formation of more complex
vessels, such as arterioles and venules, these vessel subtypes primarily depend on the
formation of EC tubes and surrounding basement membranes. Depending on
environmental requirements, different cell types (such as smooth muscle cells, adventitial
cells, and mural cells) are recruited as needed.
The reorganization of cultured endothelium into phenotypic cord-like structures
has also been demonstrated in two-dimensional in vitro systems. In 1980, Folkman and
Haudenschild reported that EC plated onto a collagen-coated dish formed tubes by 20
days and an extensive network 10 days later288. A few years later, Madri and Williams
used endothelial cells from rodent fat pads to demonstrate that connective tissues regulate
the endothelial phenotype with respect to micro-anatomical structures, such as tubes289.
In the presence of interstitial collagen for example, EC predominantly formed a
monolayer, whereas with basement membrane collagen, the EC formed tube-like
structures. Montesano and colleagues confirmed these findings, and showed that EC cord
formation was indeed a collagen matrix-dependent process290. While this phenomenon
occurs in the absence of other cell types, it yields capillary-like networks that carry no
blood. However, it also demonstrates that the absence of blood flow and pressure are not
required for basic EC network assembly and architecture9,287. The formation of EC cords
in vitro could very well provide novel experimental models for understanding analogous
processes in vivo.
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The Stromal Vascular Fraction
The generation of a stable, supportive vascular supply is critical to the
development of large volumes of engineered tissue for implant. In normal host tissue,
parenchymal cells often require intimate association with circulating factors, proteins,
and products via a patent, well-distributed vascular supply. The literature provides
evidence of in vivo implanted parenchymal cell death in the absence of a vasculature291295

. This is largely because oxygen can only diffuse over a very short distance of no more

than a few hundred microns. Additionally, depending on the site of implantation,
parenchymal cells may not be able to utilize existing host vasculatures296. To circumvent
these issues, it may be necessary to implant parenchymal cells with vascular support
cells.
The adipose-derived stromal vascular fraction (SVF) is a heterogeneous, cell
population with tremendous vascularization potential9,297-299. SVF has been shown to
spontaneously self-assemble into vessel-like networks of cells when placed in culture300.
In vivo studies have established that adipose SVF, following implantation, forms
functional, hierarchical vasculatures that anastomose with host vessels9,299 and perfuse
implanted parenchyma1,9. These findings suggest that SVF may have potential
therapeutic vascularization applications toward the accelerated formation of new
microvascular structures in ischemic tissues. To this end, SVF has already been shown to
promote revascularization in models of myocardial infarction301,302 and peripheral
ischemic disease299,303,304.
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The first isolations of SVF were conducted by Rodbell and colleagues, who used
the enzyme collagenase to digest fat into buoyant adipocytes and a sedimented SVF
pellet305-307. Though their efforts focused on only the isolated adipocytes, the first studies
evaluating the cellular composition of SVF was published in the 1970s, when Wagner
and Matthews used Rodbell’s fat digestion protocols to isolate and culture endothelial
cells from the rodent epididymal fat pads308. Additionally, they noted the presence of
perivascular cells as a multicellular, heterogeneous population that surrounded the
developing vasculature. Later that decade, Van and colleagues isolated and cultured SVF,
documenting an overall doubling time of 40 – 60 hours309. Though they originally
thought SVF to be fibroblastic with lipid-storage potential, adipose-derived vasculatures
were also initially thought to have mesothelial cells and not endothelial cells310, while
others have stated that adipose tissue-derived vessels have endothelial cells as their major
cell type311., though this study utilized omental fat instead of fat acquired from the
epididymal fat pads or uterine horn. SVF is now known to have fibroblasts, mesenchymal
stem cells, and endothelial cells, as well as smooth muscle cells, mural cells,
macrophages, blood cells, and a whole cadre of other stem cell phenotypes9,312,313. While
this mixed population more closely recapitulates the variety of cells seen in vivo, there is
a lack of consensus regarding the specific proportions of these constituents to one
another314, though Nunes and colleagues demonstrated the relative proportions of
endothelial cells (CD31+), monocyte/macrophages (CD14+), multipotent cells (CXCR4+ /
cMet+), and perivascular cells (PDGFR-B+) in fresh and cultured rat SVF cells9.
A fundamental consideration with SVF is that it is heterogeneous and forms
vasculatures that closely resemble those seen in vivo. For instance, host vessels in vivo
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are organized such that larger vessels give off smaller branches, which in turn give off
smaller branches, so on and so forth. The degree of branching (and consequently, surface
area) constitutes a hierarchy that is dictated by local tissue oxygen and nutrient
requirements. Hierarchy is a key feature of mature vascular systems315. As discussed
above, pure EC cultures have a demonstrated ability to form cords and networks in
vitro288,290. Additionally, Koh demonstrated that the EC in SVF are required for network
formation, and that depletion of EC abrogated vascular assembly299. However, pure ECderived networks are largely uniform in diameter, lacking a hierarchical organization, and
are therefore considered to be immature316,317. SVF is unique in that it not only has the
EC required for vascular network assembly, but also a full cadre of support cells as well.
These support cells are likely required for stabilization and maturation316,318-320.
Additionally, SVF may be better able to adapt to different therapeutic applications as it is
thought to bear a higher degree of plasticity than other vascular cell sources321, though
cell sourcing from white adipose tissue versus brown adipose tissue yields site-specific
differences322.
Another point to emphasize is that SVF itself may promote healing. Adipose stem
cells (also known as adipose-derived stromal cells; ASC) are considered to be a
mesenchymal stem cell (MSC) subpopulation of SVF323. In addition to the fact that ASC
appear to be immunoprivileged, these cells have been shown to migrate to sites of injury
and release paracrine secretions that reduce inflammation324. This trait has been seen with
both intraocular injections and tail vein injections, where the former stabilized the
progression streptozocin-induced diabetic retinopathy324 and the latter mitigated systemic
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inflammation, improved glucose tolerance, preserved pancreatic ß-cell mass, and
increased ß-cell proliferation in the face of streptozocin treatment325.
ASC have also been shown to directly play significant roles with the vasculature.
For instance, Cai and colleagues were amongst the first to demonstrate that ASC impact
capillary density and perfusion, and that these actions are mediated by hepatocyte growth
factor (HGF)326. When placed with human microvessel endothelial cells, ASC improved
endothelial network assembly and stability298. In trying to determine a mechanism for
these outcomes, initial analyses revealed that these cells were positive for a full cadre of
markers associated with stromal cells such as mesenchymal cells (CD10, CD13, CD90),
pericytes (CD140a/b), and smooth muscle cells (alpha actin, calponin, and caldesmon).
Immunohistochemical analysis of ASC-microvessel endothelial cell co-cultures showed
that after extensive culturing, the cells encase the vascular lumen in much the same way
as pericytes would. Again, determining the density of ASC per SVF isolation is difficult
since specific markers have not been identified, though others such as PDGF-B and
3G5298,313,327-329 and Pref1330 have been implicated. Additionally, since ASC exhibit
variable abundance – white adipose tissue is enriched with ASC, for example322,323 – the
sourcing of SVF and its subpopulations need to be taken into consideration.
To determine a mechanism of interaction between ASC and endothelial cells,
Merfeld-Clauss and colleagues performed a series of co-culture experiments, noting
increases in overall extracellular matrix production, ASC expression of alpha smooth
muscle actin, and endothelial expression of CD31331. Co-cultures yielded the highest
degree of endothelial network formation, followed by ASC-conditioned media with the
next highest density and ASC-fibroblast co-cultures with the lowest density. Not only do
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these findings suggest that ASC-endothelial cell interactions are contact dependent, but
also that these interactions progress in both directions (as ASC increased aSMA
expression as well). This is evidenced in later studies, implicating Activin A as an ASCendothelial cell contact-initiated means of (a) inducing ASC smooth muscle cell
differentiation300 and (b) impairing VEGF expression, reducing endothelial network
formation332. Thus, there is a complex interplay between ASC and endothelial cells. A
key takeaway is that ASC are a subpopulation of SVF, and SVF is also replete with
endothelial cells9. Thus, there is reason to suspect that these mechanisms and others are
already at play within this heterogeneous population.
A third, clinical and translational, consideration with SVF is that it is easily
isolatable. Adipose tissue can be easily acquired through minimally invasive means and
subjected to enzymatic digestion, usually with Collagenase. The resulting digest can then
be centrifuged and separated into three distinct layers: (1) adipocytes, which are buoyant,
(2) collagenase solution, tumescent fluid, washing buffers, and cell debris, and (3) the
SVF cell pellet at the bottom of the centrifuge tube. Though these steps can be performed
manually, there is a growing interest in automating them333,334 for rapid application at the
bedside or during an operation335. Further, such automation enhances the likelihood of a
desirable, repeatable outcome and may mitigate the effects of lab-to-lab variations.
In short, SVF contains a multitude of cell types that not only promote vascular
networking, but vascular support as well. Additionally, SVF’s relative ease of isolation
makes it a clinically relevant therapeutic cell source for vascularization applications.
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CHAPTER III
GENERATION OF A FUNCTIONAL LIVER-TISSUE MIMIC USING ADIPOSE
STROMAL VASCULAR FRACTION CELL-DERIVED VASCULATURES

OVERVIEW
A

major

challenge

with

therapeutic

cell

implantation

is

achieving

microcirculatory integration between the implanted cells and host vasculature. Adiposederived stromal vascular fraction (SVF) cells were used vascularize an implant comprised
of HepG2 human hepatocyte analogue cells. We hypothesized that the SVF cells would
form a functional microcirculation via vascular assembly and inosculation with the host
vasculature. Initially, we assessed the extent and character of neovasculatures formed by
freshly isolated and cultured SVF cells and found that freshly isolated cells have a higher
vascularization potential. Generation of a 3D implant containing fresh SVF and HepG2
cells formed a tissue in which HepG2 cells were entwined with a network of
microvessels. Implanted HepG2 cells sequestered labeled LDL delivered by systemic
intravascular injection only in SVF-vascularized implants demonstrating that SVF cellderived vasculatures can effectively integrate with host vessels and interface with
parenchymal cells to form a functional tissue mimic.
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INTRODUCTION
Tissue replacement is a strategy that can be used for the regeneration of different
organs in scenarios such as organ failure. Cell transplantation offers an alternative to treat
patients with organ failure, such as in liver diseases336,337. However, minimal engraftment
is achieved with this approach336,338,339. One of the major caveats in tissue replacement
therapies is to promote effective vascularization of the transplanted tissue in order to
prevent death and promote engraftment of transplanted cells. Several approaches have
been utilized in an attempt to promote vascularization of implanted tissues such as the
delivery of angiogenic growth factors to recruit host vessels or co-implantation of
endothelial and angiogenic signaling cells with target tissue cells (reviewed in

340,341

).

Although considerable progress has been achieved, significant obstacles still exist, such
as the short half-life of growth factors in the tissues resulting in regression of newly
formed vasculatures342,343 and potential sources of endothelial and angiogenic signaling
cells for human transplants. Adipose-derived stromal vascular fraction (SVF) cells are an
attractive cell population for transplantation studies since human adipose tissue is an
easily accessible and dispensable tissue source that can provide large numbers of cells
suitable for implantation with little donor morbidity and patient discomfort. In addition,
SVF cell preparations have been shown to be safely and effectively transplanted to either
an autologous or allogeneic host and can be manufactured in accordance with Good
Manufacturing/Tissue Practice guidelines314. SVF cells are obtained from the enzymatic
digestion of adipose tissue to single cells followed by discarding adipocytes. They are a
mix of heterogeneous cell populations composed of endothelial cells, fibroblasts,
perivascular cells, immune cells and undefined stem cell sub-populations314,319,344. The
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potential of SVF cells to promote vascularization and improve organ function when
delivered to sites of ischemia has been demonstrated in animal models of peripheral
ischemic disease299,303,304 and myocardial infarction301,302. Here, our goal was to harness
the vascularization potential of SVF cells in vivo to generate an effective vascular
interface between host and transplanted liver cells that results in a functional tissue
mimic. We show that (1) adipose-derived SVF cells have a potent intrinsic vascularizing
potential, (2) culturing freshly isolated SVF cells retains this vascularization potential
despite possible changes in cell populations, and (3) SVF cell-derived vasculatures form
a functional interface between host and implanted parenchymal cells.

MATERIALS & METHODS
Ethics statement. All animal experiments were performed in compliance with
institutional guidelines, as per US National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were approved by University of Louisville Institutional
Animal Care and Use Committee procedures and policies (IACUC #12059, 12060).
Rodent and human SVF isolation. Adipose-derived SVF cells were isolated
from the epididymal fat pads of male, retired breeder Sprague-Dawley rats (Charles
River) under anesthesia [ketamine (40–80 mg/kg) and xylazine (5–10 mg/kg)]. Green
fluorescent protein (GFP)-tagged SVF were obtained from Sprague-Dawley rats that
ubiquitously express GFP (Rat Research and Resource Center, University of Missouri,
Columbia, MO). Human SVF were isolated from adipose tissue obtained from
abdominoplasty (IRB Exempt, #09.0037). Harvested fat was washed in 0.1% BSA-PBS,
finely minced, and digested in 2 mg/ml type I collagenase solution (Worthington
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Biochemical Company, Freehold, NJ, USA) for 40 min at 37°C with vigorous shaking.
Adipocytes were removed by centrifugation, and the entire cell pellet was washed with
0.1% BSA-PBS. Cells were either immediately used (Fresh SVF, fSVF) or plated into
gelatin-coated plates (Cultured SVF, cSVF 5x104 cells/cm2) in fresh media (DMEM
supplemented with 2mM L-glutamine, 50 µg/ml ECGS and 10% FBS). Cultured SVF
were used at P0 after 5-7 days when cells reached confluence.
Flow cytometry analysis. cSVF were dissociated with non-enzymatic Cell
Dissociation Buffer (Sigma) after reaching confluence (P0) and fixed with 4%
paraformaldehyde for 10 min at room temperature. Cells were blocked with PBS
containing 5% fetal bovine serum (FBS) for 30 minutes on ice and incubated with the
following antibodies in blocking buffer on ice for 1 hour: anti-CD14 (1:100), anti-CD31APC (1:500)(BD Biosciences); anti-cKit (1:100, Abcam); anti-CXCR4 (1:100,
Ebiosciences); anti-c-Met (1:100), anti-PDGFRb (1:100, Santa Cruz Biotechnology)
overnight at 4°C. Secondary antibodies used were anti-mouse-Alexa Fluor 488 (1:400)
(Jackson ImmunoResearch) and anti-rabbit-Cy6 (1:500) (Jackson ImmunoResearch) for
30min at 4°C.
Microvessel isolation. Fat-derived microvessels (FMF) were isolated from rat
epididymal fat by limited collagenase digestion and selective screening as previously
described345,346. The collagenase used (type I; Worthington Biochemical Company,
Freehold, NJ, USA) was lot tested to yield high numbers of fragments with intact
morphologies. These vessel fragments have the potential to form a microcirculation
composed of different vessel types 4 weeks post implantation in vivo in 3-dimensional
collagen gels347.
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HepG2 cell culture. HepG2 cells were cultured in T-75 tissue culture flasks in
HepG2 growth media consisting of Dulbecco’s Modified Eagle’s Media high glucose,
10% fetal bovine serum, 1X penicillin/streptomycin, and 1X L-glutamine (Invitrogen
Camarillo, CA, USA). Media was changed every other day and cells were grown to
confluence at which time they were prepared for Cytodex-3 culture as described below.
Plasmids and Cell Transduction HepG2 were transduced with retrovirus to constitutively
express GFP (pBMN-I-GFP) or Ds-Red as previously described348.
Cytodex-3 cell culture. 50 mg of Cytodex-3 microcarrier beads (Sigma, St.
Louis, MO, USA) were hydrated with 5 mL phosphate buffered saline (PBS) -Ca2+/-Mg2+
(Hyclone) for four hours with occasional mixing to avoid aggregation349,350. PBS solution
was removed and washed out with freshly prepared 70% ethanol for a total of four
washes. The last 70% ethanol wash was carried overnight. The following day, ethanol
was removed and 10 mL of HepG2 growth media was added for a total of four washes.
The last wash was removed and HepG2 cells were passaged into a resuspension of 1 x
106 cells/mL. 6 x 106 cells were added to 4 mL of HepG2 media containing Cytodex-3
beads and were gently mixed. The bead-cell mixture was added to a 100 mm petri dish
(BD Falcon) and incubated for three days at 37°C and 5% CO2 for optimal microcarrier
coverage.
Preparation of 3-dimensional constructs and in vivo implantation. To form
the 3D constructs, fresh or cultured SVF (106 cells/mL) were suspended into 3mg/mL of
collagen type I (BD Biosciences, San Jose, CA, USA) and 0.2 mL of the suspension was
seeded into wells of 48-well culture plates. Constructs were implanted subcutaneously on
the flanks of Rag1 mice as previously described351. To assess the potential of fresh and
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cultured SVF to participate in the neovascularization process, fresh or cultured SVF from
GFP rats (106 cells/mL) were seeded into collagen gels concomitantly with isolated FMFs
(20,000⁄mL). FMF/SVF/collagen suspensions were pipetted into wells of a 48-well
culture plate (0.2 mL⁄well) to form a 3D construct that were either cultured in DMEM +
10% FBS or implanted subcutaneously on the flanks of Rag1 mice as previously
described352. Alternatively, SVF were seeded in the presence of HepG2 cells before
implantation.
Construct analysis. Microvascular constructs were harvested at either 4 or 6
weeks after implantation and fixed in 4% paraformaldehyde for 20 minutes. Samples
were permeabilized with 0.5% Triton X-100 and rinsed with PBS. After blocking for two
hours with 10% goat serum (Sigma), samples were incubated overnight with fluorescent
or biotin conjugated lectins. Following three 15-minute washes in divalent cation-free
(DCF)-PBS, samples were imaged en bloc with an Olympus MPE FV1000 Confocal
Microscope and analyzed with Amira 5.2 (Visage Imaging, Inc., San Diego, CA, USA).
SVF cells were identified by either constitutive expression of GFP (when obtained from
animals that ubiquitously and constitutively express GFP) or labeling with
TRITC/Fluorescein conjugated or Cy5-streptavidin GSI (rodent SVF) or UEAI (human
SVF) lectin (Vector labs, Burlingame, CA, USA). To evaluate vessel perfusion in the
implanted constructs, host mice were perfused intravenously with Dextran-TRITC
2,000,000 MW for 15 minutes before the constructs were harvested. Confocal
microscopy images with HepG2-GFP+ clusters were identified and examined for
presence of GS1-Cy5+ vasculature, DiI-LDL, or both, and recorded in Microsoft Excel.
Those images without HepG2-GFP+ clusters were not included. In addition, clusters void
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of both GS1-Cy5+ vasculature and DiI-LDL were recorded. The number of HepG2
clusters associated with each variable were counted and graphed using SigmaPlot. To
determine if DiI-LDL uptake is correlated with the presence of GS1-Cy5+ vasculature,
HepG2-GFP+ clusters positive for DiI-LDL were plotted against those clusters positive
for GS1-Cy5 vasculature. The Pearson correlation coefficient was then calculated for
statistical correlation between the two variables.

RESULTS
Cultured and fresh rodent SVF cells form vessels that are perfused. The
development of a functional organ-tissue mimic relies not only on parenchymal cells, but
also a vasculature that links this implant with the surrounding vasculature. The stromal
vascular fraction (SVF) is an adipose-derived, heterogeneous single cell suspension that
has been shown to inosculate with the host vasculature after implantation. SVF cells have
also demonstrated vessel-like properties in culture as well. Therefore, fresh and cultured
SVF (fSVF and cSVF, respectively) have therapeutic promise in vascularization
applications. In this aim, we hypothesized that we could use SVF to functionally
vascularize implanted hepatocytes, thereby forming a liver-tissue mimic. To start, using
SVF derived from rats constitutively expressing GFP, we were able to assess the nature
and degree of interaction between SVF-derived vessels, implanted parenchymal cells, and
the native host vasculature (Figure 6). In 3D collagen gel matrices, both fSVF and cSVF
spontaneously assembled into perfused, vascular networks. In both populations, GFP+
cells were seen contributing to hierarchical, organized vasculatures reminiscent of mature
vascular structures. Despite these similarities, there were also many differences. For
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Figure 6. Fresh and cultured SVF cells from GFP-transgenic rats were seeded in 3D
collagen matrices and implanted for 4 weeks. Prior to explantation, host animals were
perfused with dextran-TRITC. Here, we see that cultured cells are significantly impaired
in their perfusion (*p = 0.001) and have significantly increased diameters (*p = 0.02)
compared to fresh SVF isolates. Results shown as mean ± S.E.M.
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instance, cSVF appeared to form a lower density of vessels when compared to fSVF. In a
particular field of view, cSVF generated 59.2 ± 8 vessels, while fSVF generated
considerably more – 94.2 ± 22. Additionally, there was significantly lower perfusion in
cSVF-derived vessels as opposed to fSVF-derived vessels. To this end, 97.4 ± 0.8% of
fSVF-derived vessels were perfused, versus the 86.7 ± 1.9% seen with cSVF.
Furthermore, differences could be ascertained with the average vessel diameters of the
two populations, with cSVF yielding a larger diameter (14.6 ± 2.3 µm) vs. fSVF (11.7 ±
1.5 µm). In sum, these results broadly indicate that both cSVF and fSVF possess a
proclivity to produce vessels with a similar organization. However, the two populations
differ with respect to the magnitudes of various, quantifiable vascular parameters.

Cultured and fresh rodent SVF cells participate in angiogenesis in different
ways. We have shown that cSVF and fSVF can form perfused, hierarchical vessels in
vivo. However, the next question that we asked was whether or not SVF-derived vessels
could incorporate into an angiogenic bed. To test this, we relied on an angiogenic
microvessel implant model, again comparing fSVF and cSVF cells.
Both cell types took active roles in forming new vessels through angiogenesis
(Figure 7). To provide some context, early on, angiogenesis is defined by the formation
of immature vascular networks. Here, we observed SVF intimately associating with the
endothelial cells of this developing neovascular system. In implants assessed at later time
points, we observed vascular systems that were a hybrid of GFP+ and GFP- cells,
indicating that these vascular systems were chimeric in nature.

71

Figure 7. Fresh and cultured SVF cells differ in their ability to participate in
angiogenesis. GFP-laden 3D collagen constructs were implanted in non-GFP mice for
14 or 28d. The images and quantitation demonstrate that significantly fewer cultured
SVF cells incorporate into developing vessels (*p = 0.01) and that most cultured SVF
cells take perivascular positions. Results shown as mean ± S.E.M.
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What is most unique about these two populations is that fSVF yielded vessels in
which GFP+ cells were part of both the main vascular tube as well as perivascularly. To
contrast, cSVF cells predominantly occupied the perivascular space. Along the same
lines, fewer cSVF cells were incorporated into the neovascular network (13 ± 6.6%, vs.
24.6 ± 10.4% for fSVF).

Cultured rodent SVF has fewer endothelial and progenitor cells than fresh
rodent SVF. Given that we saw numerous quantifiable differences between cSVF and
fSVF, we next wanted to determine if there were differences in the cellular composition
of these populations that drove their respective phenotypes. Using flow cytometry, cSVF
were observed to contain roughly 50% less CD31+ (presumably endothelial) cells than
fSVF. Moreover, a similar trend was seen with respect to the number of cKit progenitor
cells (Figure 8). Despite these differences, the proportions of CD14+ monocytes and
macrophages, PDGF-Rß+ perivascular cells, and CXCR4 and cMet+ multipotent cells
remained approximately the same.

Thus, the number of endothelial and progenitor cells

in SVF may be diminished with culturing, while perivascular presence and functionality
appear to be unaffected.

Implanted parenchyma can be vascularized by human SVF cells. Thus far,
cultured and fresh SVF cells have been shown to possess a unique vascularization
potential. We therefore wanted to assess the role of these cells in the presence of an
implanted parenchymal cell model – in this case, HepG2 model hepatocytes (Figure 9).
Here, we used human SVF as the HepG2 were also derived from a human source and we
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Figure 8. Flow cytometry performed on cultured versus fresh SVF cells show
compositional differences between the two cell populations, the most significant of which
are reductions in CD-31+ endothelial cells (*p = 0.009) and cKit+ progenitor cells (*p =
0.02) in cultured SVF. Results shown as mean ± S.E.M.
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Figure 9. Figures A-C show human SVF within 3D collagen I gels that were implanted
for 4 weeks, explanted, and labeled with UEA-1 TRITC. Figures D-F show that at 6
weeks, human SVF form as vascular cage around implanted HepG2 model hepatocyte
spheroids.
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sought to create a completely human mimic. Thus, because these SVF cells were isolated
from discarded human lipoaspirate instead of from rat fat pads, we opted for a 6-week
implant time instead of a 4-week implant time. This would allow us to begin accounting
for potential species-dependent differences in network formation.
Our first observation was that indeed, like rodent SVF, human SVF was also
capable of spontaneously self-assembling into a vascular network. However, at 6 weeks,
it is possible that human SVF cells required even more time to reach the same degree of
maturation as the rodent-derived SVF vascular networks seen at 4 weeks. Secondly, we
wished to see if human SVF could spontaneously form a vascular network in the presence
of parenchymal cells. To this end, we generated 3D constructs containing HepG2 (grown
on cytodex beads to facilitate hepatocyte survival and function) and human SVF cells.
Here too, human SVF spontaneously formed a vascular network. However, in this
particular arrangement, human SVF networks could also be seen forming cage-like
structures around HepG2 clusters (Figure 9).

Human fresh SVF-derived vasculatures inosculate implanted parenchymal
cells. Since we observed human SVF-derived vascular networks surrounding HepG2
clusters, we next wanted to determine the degree of association between the vasculature
and the parenchyma. Because HepG2 can bind and internalize LDL cholesterol similar to
primary hepatocytes, this provided us with a suitable assay to assess SVF-vascular
inosculation of the parenchyma.
After injecting fluorescent DiI-LDL cholesterol intravenously and allowing for
sufficient circulation time, we observed the accumulation of DiI-LDL within implanted
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HepG2 cells (Figure 10). Conversely, 3D constructs lacking SVF (but containing
HepG2) were not able to localize DiI-LDL. To compliment these findings, image analysis
revealed that in 3D constructs containing both cell types, 83% of HepG2 clusters were
associated with either vasculatures or DiI-LDL internalization, while 67% were
associated with both.
Thus, these findings indicate that human SVF cells form a vascular network that
facilitates, and perhaps even enables, the functionality of parenchymal implants.
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Figure 10. Figures A-D show confocal microscopy images of GFP+ HepG2, injected DiILDL, and rodent SVF (labeled with GS1-Cy5) all co-localizing. Figures E-F demonstrate
that without SVF, peripherally injected DiI-LDL does not accumulate in implanted
HepG2 cells (E), though it does accumulate in the host liver (F). Figure G quantifies the
association between GFP+ HepG2, GS1+ SVF, and DiI-LDL. Note that in HepG2-SVF
implants, the majority of HepG2 are associated with LDL localization and SVF-derived
endothelial cells (*p = 0.03, †p = 0.08). (H) This scatter plot demonstrates that in
HepG2-loaded implants, an increase in GS1+ SVF clusters drives corresponds with an
increased incidence of LDL co-localization in HepG2.
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DISCUSSION
The next stage of our effort involves combining parenchymal cells with a vascular
supply. As mentioned earlier, the development of a stable vasculature is critical to the
development of large volumes of engineered tissues. Because our goal is to ultimately
create a liver-tissue mimic that serves as a therapy for those with Familial
Hypercholesterolemia, we developed a proof-of-concept by combining HepG2 model
hepatocyte cells with adipose-derived stromal vascular fraction (SVF) cells. With this
combination, we were the first to generate a functional, vascularized liver-tissue mimic
model.
To date, it has been difficult to engineer mature vascular systems capable of
supporting tissues and organs

353,354

. Several have attempted to use endothelial cells

alone, but several have observed that multicellular, three-dimensional approaches are
required to form mature vasculatures355-357. To this end, perivascular cells are considered
critical constituents of the developing vasculature321,358. SVF cells show tremendous
therapeutic potential, as they are a heterogeneous mixture of various cell types that can be
applied in a variety of circumstances. The cells can be acquired relatively easily in
lipoaspirates, obtained through minimally invasive means and even at the patient’s
bedside. While this means that the cells can be acquired and used at the point of care333
(Tissue Genesis Clinical Trial # NCT02234778), an added benefit is that the patient’s
own cells can be used. This allows the entire process to remain autologous, minimizing
the chance of rejection.
Our findings indicate that cultured SVF can form perfused vasculatures in vivo as
well. Thus, with regards to clinical applicability, a pooled, cultured supply of SVF cells
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acquired from various donors could provide added convenience and potentially mitigate
deficiencies present within any one isolate. Though one hurdle with this approach is that
only cells from a low passage number can be utilized, one benefit here is that adipose
cells are limited in their ability to incite a host immune response302,359. Therefore, while
an autologous approach may be desirable, SVF allografts may also be clinically
acceptable by providing a workaround under non-ideal circumstances. Additionally, the
use of allografted SVF may facilitate the use of allogenic parenchymal cells205,360
In this light, adipose-derived SVF cells constitute a vital part of the liver-tissue
mimic. While previous attempts at vascularizing engineered liver grafts involved
incorporating VEGF into constructs containing transplanted hepatocytes, it is unknown if
any resulting vessels were perfused, or if those vessels enabled or enhanced hepatocyte
functionality361. To contrast, freshly isolated, cultured and frozen SVF cells can all
spontaneously form mature, hierarchical vasculatures. Furthermore, SVF cells have been
used in Phase I clinical trials and are considered to be very safe362.
To demonstrate SVF cell functionality in the context of a liver-tissue mimic,
mimics with and without SVF were implanted for six weeks. Just prior to explantation,
host animals were given fluorescent DiI-LDL cholesterol to assess SVF’s role in forming
a functional interface between implanted HepG2 cells and the host vasculature. Our
findings demonstrate that HepG2 cells within constructs containing SVF were able to
internalize circulating DiI-LDL cholesterol. To contrast, mimics without SVF were not
able to internalize DiI-LDL. These findings indicate that the SVF cells serve in a key
capacity by functionalizing co-implanted parenchymal cells. Additionally, SVF-derived
vessels have lumens, anastomose with the host vasculature, are perfused, and thus serve
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as a conduit for circulating macromolecules. All of this suggests that SVF cells could be
combined with parenchymal cells to enable and facilitate parenchymal metabolism of
various biomolecules.
Our liver-tissue mimic (comprised of parenchymal and SVF cells) was designed
as a modular implant. This poses several potential advantages. First, let us consider the
impact of a single module. In this case, our liver-tissue mimic would be responsible for
LDL cholesterol uptake, but in other circumstances, such modules could be used for
hormone production or drug clearance. Benefits of this approach are that (a) modules are
easily scalable, and (b) their arrangement can be customized. For instance, modules of
different compositions could be combined together to perform a whole host of functions.
Second, a module like this could be implanted anywhere there is access to a host blood
supply. The placement of a modular scaffold subcutaneously has the added benefit of
being easily accessible, modifiable, and in deleterious circumstances, removable. With
respect to FH, a modular liver-tissue mimic could be ideal. While FH patients have
impaired LDLR function, their other liver functions are normal. Though curative from an
LDLR standpoint, performing a full liver transplant could be heavy-handed, as
transplant-associated complications may impair functions that were once normal.
Therefore, an organ-mimic module may enable a targeted approach to treating a specific
deficiency. Third, modules such as these could serve as drug toxicity testing platforms for
testing drug effects on various parenchymal phenotypes.
Cultured SVF cells can spontaneously form vasculatures at low passages, as
mentioned earlier, though there are a few caveats. First, compared to cells that were
freshly isolated, the proportion of cultured SVF cells that incorporate into neovessels is
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decreased. Secondly, the positioning of these incorporated cells is different, as fresh
isolates take on vascular and mural positions while cultured cells are predominantly
located in the perivascular space. Third, culturing the cells decreases the quantity of
CD31+ and cKit+ cells, suggesting that endothelial cell presence is diminished by
culturing363-365. Because SVF-driven vasculogenesis is endothelial cell-driven299, and
cultured SVF has fewer endothelial cells, cultured SVF possesses a reduced (but not
nonexistent) ability to form vasculatures in vivo. Therefore, culturing impairs SVF cells’
ability to participate in neovascularization.
While culturing reduces the number of endothelial cells in SVF, it appears to have
no effect on the amount of PDGFR-ß1+ perivascular cells366,367. This finding corresponds
with the observation that cultured SVF cells predominantly reside in mural positions.
Since culturing clearly effects SVF cell dynamics, it is important to acknowledge that our
SVF culture methods differ from those used by others to select for adipose-derived stem
cells (ADSC)298,368. Our low-passage cultured SVF expresses markers associated with
several mesenchymal stem cell phenotypes. We also have other phenotypes that do not
appear to be present in the ADSC populations that others have isolated. Therefore, the
presence of unique phenotypes in our cultured isolates may dictate SVF’s ability to
spontaneously assemble into a functional neovasculature, though this ability is impaired
compared to SVF cells from fresh isolates. Additionally, the effect of long-term culture
(beyond P1) on vascular network formation is a subject for further investigation (and is
discussed in Chapter 3).
Again, SVF is unique because of its ability to spontaneously assemble into a
mature, hierarchical, perfused, functional vascular system in vivo. Koh demonstrated that
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this phenomenon was dependent on endothelial cells, and that vascular network
formation was abrogated in the absence of endothelial cells299. Yet, endothelial cells
alone are unable to form as dynamic a vasculature, with the aforementioned
characteristics, in vitro316 or in vivo317. Therefore, perivascular cells appear to play a
critical role in shaping, maturing, stabilizing, and functionalizing an SVF-derived
developing vasculature316,318.
While several tissues possess complex vasculatures, isolating and utilizing vessels
from these sources does not guarantee the same level of performance as that seen with
SVF cells. This is likely because SVF is derived from adipose tissue, which is thought to
have a less mature vasculature with a high degree of plasticity321. Such plasticity may be
required to meet adipose tissue’s complex metabolic needs321.
This is the first effort that demonstrates that human and rodent adipose-derived
SVF cells can inosculate with the host vasculature and vascularize implanted parenchyma
(in this case, HepG2 hepatocyte model cells), to form a proof-of-principle organ-tissue
mimic. This mimic poses several implications for a variety of organs and disease states.
The nature of its design allows different parenchymal cells to be used to meet different
needs. With respect to Familial Hypercholesterolemia, a disease of LDLR dysfunction,
our liver-tissue mimic enabled the uptake of injected, circulating LDL cholesterol by
hepatocytes within the mimic. This suggests that SVF-derived vessels can help impart
critical functionality to implanted hepatocytes, and allows us to take a critical step
towards developing a therapeutic device for this patient population. This mimic also
opens the doors for further mechanistic and translational investigations.
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CHAPTER IV
WNT5A MODULATES THE SELF-ASSEMBLY OF HUMAN STROMAL
VASCULAR FRACTION-DERIVED MICROVASCULATURES

OVERVIEW
Human adipose-derived stromal vascular fraction (hSVF) cells are an easily
accessible, heterogeneous cell system that can spontaneously self-assemble into
functional microvasculatures in vivo. However, the mechanisms underlying this vascular
self-assembly and maturation remain poorly understood. Thus, our objective was to
identify regulatory pathways mediating this endogenous process. It has been shown that
culture of SVF reduces its vascularization capacity. Here, we found that EC network
densities were significantly diminished as early as two passages (P2) and was almost
eliminated by the fourth passage (P4). For investigating vascularization mechanisms,
subsequent experiments only used P1 cells. After exposing hSVF cells to common
angiogenesis inhibitors, we found that the pan-Wnt inhibitor IWP2 produced the most
significant networking decrease (~25% reduction), implicating Wnt signaling in this
phenomenon. To determine which Wnt isoform(s) and receptor(s) may be involved,
hSVF was screened by PCR for those isoforms associated with angiogenesis. Of these,
only WNT5A and its receptor, FZD-4, were stably expressed. Immunocytochemistry
showed that Wnt5a protein was expressed in hSVF cultures. To see if Wnt5a alone could
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restore IWP2-induced EC network inhibition, recombinant human Wnt5a (0–150 ng/ml)
was added to IWP2-treated cultures. Addition of rhWnt5a to such cultures significantly
increased EC network area and significantly decreased the ratio of total EC network
length to EC network area compared to untreated controls. To determine if Wnt5a
mediates in vivo microvascular self-assembly, 3D hSVF constructs containing an IgG
isotype control, anti-Wnt5a neutralizing antibody or rhWnt5a were implanted
subcutaneously for two weeks. Compared to IgG controls, anti-Wnt5a treatment
significantly reduced vessel length density by ~41%, while rhWnt5a significantly
increased vessel length density by ~62%. However, anti-Wnt5a or rhWnt5a did not affect
the density of segments and nodes, both of which measure vascular complexity. Taken
together, this data demonstrates that hSVF microvascular self-assembly is mediated by
Wnt5a. These findings also suggest that manipulating Wnt signaling could enhance
control of hSVF vascularization in tissue engineering applications.

INTRODUCTION
The vascularization of engineered tissues remains a significant challenge in tissue
engineering. Adipose-derived stromal vascular fraction (SVF) is a heterogeneous cell
population

314,319,344,369

that has been shown to spontaneously self-assemble into

functional, hierarchical, and perfused vasculatures in vivo
networks in culture

371,372

9,299,370

and vessel-like

. These findings suggest that SVF may have potential

applications toward the accelerated formation of new microvascular structures in
therapeutic applications. Our lab has previously demonstrated that SVF can accelerate the
vascularization and engraftment of co-implanted model hepatocyte cells
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9

and induced

pluripotent

stem

cell-derived

hepatocytes1.

Spontaneous

self-assembly

into

microvasculatures by the SVF cells requires the presence of endothelial cells (EC) within
the isolate, as their removal eliminates the vascular assembly activity9,299. Yet, the
mechanism(s) by which SVF EC assemble into a functional microvasculature is not well
defined.
To date, vascular assembly in SVF has been described as being VEGFdependent299, but experience with other systems suggests that multiple signaling
pathways mediate the final microvascular system316,344,345,373-375. To better understand
how human SVF (hSVF) cells self-assemble a microvasculature, we investigated several
angiogenesis-related signaling pathways to determine their role. Here, we used an in vitro
model to identify Wnt5a as a potential mediator of vascular assembly. We demonstrate
that Wnt5a affects parameters such as vessel length and area coverage – effects that were
absent when hSVF was supplemented with canonical Wnt3a in lieu of Wnt5a. In threedimensional in vivo implants, the treatment of hSVF with a Wnt5a-specific neutralizing
antibody significantly reduced hSVF EC network assembly as quantified by total EC
length density compared to IgG controls. In contrast, the addition of recombinant human
Wnt5a significantly increased the total EC length density. Both anti-Wnt5a and
recombinant human Wnt5a did not significantly affect the densities of segments and
nodes, suggesting that Wnt5a alone may not modulate vascular complexity. To our
knowledge, this is the first report to characterize the role of Wnt5a in spontaneous hSVF
EC microvascular self-assembly. Our data suggests that Wnt5a is a potential target for
therapeutic angiogenic modulation to regulate hSVF vascularization.
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MATERIALS & METHODS
Animals and Ethics Statement. All animal procedures were conducted in
compliance with University of Louisville School of Medicine IACUC-approved
protocols and NIH guidelines. Isoflurane gas was administered for anesthesia. For
analgesia, Ketoprofen was delivered subcutaneously at the time of surgery and postoperatively every 24h for 2d.
hSVF Isolation, Long-Term Storage, and General Culture. hSVF cells were
isolated from the discarded lipoaspirate of three patients (identifying information was
unavailable) obtained under IRB exemption #09.0037. The lipoaspirate was acquired and
processed as previously described9,370. The resulting cell pellet was divided and stored in
liquid nitrogen. Thawed cells were resuspended in hSVF growth media (M199, 1X Lglutamine, and HEPES (Invitrogen), 10% FBS (VWR International), and EC growth
supplement (developed in-house and augmented with heparin)) and plated into a 75cm2
NUNC tissue culture flask (Thermo-Fisher Scientific) pre-coated with 1% gelatin
(Sigma-Aldrich). Cells were cultured overnight at 37˚C and 5% CO2. A media change
was performed the following morning to remove non-adherent cells, with subsequent
media changes performed every other day. Once confluent, hSVF cells were passaged
with 0.05% Trypsin-EDTA (Invitrogen).
In Vitro Network Assembly. hSVF cells from passages 1 through 4 (P1 – P4)
were plated at a density of 6x104 cells/cm2. At days 1, 3, and 5 post-plating, all
supernatant was aspirated and the cells were fixed in 1% paraformaldehyde (PFA;
Electron Microscopy Sciences) for 10 minutes at RT before being washed with PBS
(Invitrogen) for 5 minutes. All wells were labeled with Ulex Europaeus Agglutinin-1
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(UEA1; Vector Laboratories) for human EC as well as DAPI nuclear dye (Thermo
Fisher). Cells were imaged using an IX81 inverted fluorescence microscope (Olympus).
Inhibitor Treatment. P1 hSVF cells were plated as described and, the following
day, subjected to treatment with the Wnt release inhibitor IWP2 (Tocris Biosciences) (at
0, 6.25, 12.5, and 25µM; also see Table 1 and Figure 11 for a listing and the effects,
respectively, of the other tested angiogenic inhibitors) for 5 days376. Media changes were
performed every other day. At the end of day 5, the cells were processed and imaged as
described above.
Cytotoxicity Assay. hSVF cells were cultured in different IWP2 concentrations
(0, 6.25, 12.5, 25µM, and 50µM) and assayed for cytotoxicity using CCK-8 (Dojindo
Molecular Technologies) according to the manufacturer’s instructions. We measured
absorbance using a Synergy 4 plate reader (BioTek).
Gene and Protein Expression. Samples from P1 hSVF cell cultures were
acquired on days 1, 3, and 5 and processed for mRNA isolation using QIAShredder and
RNeasy kits (Qiagen) according to the manufacturer’s instructions. cDNA production,
RT-PCR, and gel electrophoresis were all conducted as previously described1. RT-PCR
reactions (primers can be found in Table 2) utilized the following settings: 25 cycles,
with denaturation at 95˚C, annealing at 59˚C, and extension at 70˚C for 30 seconds.
Detected bands were normalized to GAPDH via densitometry analysis with Image J
software (NIH). For analysis of protein expression, wells were prepared for fluorescence
microscopy as previously described1. Cells were permeabilized in 0.5% Triton X-100
(MP Biomedicals) for 10 minutes, blocked in 5% goat serum (Thermo Fisher) for 1 hour,
and incubated with anti-human Wnt5a antibody (Abcam) at 1:250 and 4˚C overnight.
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Significant
Effect
Observed?

Inhibitor

Designation

Vendor (Catalog
No).

Dose Range

Wnt
Palmitoylation

IWP2

Tocris (3533)

Yes

VEGF-R2

ZM323881

Tocris (2475)

PDGF-Rβ

AG1296

TGF-β1 / Alk-5

SB431542

HGF / cMet

SU11274

Calbiochem
(658551)
Stemcell
Technologies
(72232)
Selleck Chemicals
(S1080)

0, 6.25, 12.5,
25, and 50
µM
0, 0.5, 2.5, 5,
and 10 µM
0, 0.5, 5, 25,
and 50 µM
0, 0.5, 1, 5,
and 10 µM
0, 0.5, 1, 5,
and 10 µM

No

Yes
Yes
No

Table 1. List of common angiogenic inhibitors used to isolate potential mechanisms of
hSVF vascular self-assembly.
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Figure 11. hSVF EC network quantification after inhibitor treatment. hSVF was
treated with small molecule inhibitors to identify potential pathways mediating vascular
self-assembly. For each inhibitor tested, UEA1+ network length was normalized to the
untreated control (also see Table 4). The VEGF-R2 and PDGF-Rβ inhibitors
significantly reduced total hSVF EC network length at their two highest concentrations
(*p ≤ 0.05), whereas no significant differences were seen with any concentration of the
TGF-β/Alk5 or HGF/cMet inhibitors. Results shown as mean ± S.E.M.
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Gene

NCBI
Reference
Sequence

5’ à 3’ Primer Sequence
(Forward / Reverse)

Size
(bp)

Expressed
in hSVF?

943

Annealing
Temp. ˚C
(Forward /
Reverse)
61.49 / 60.03

WNT2

NM_003391.2

WNT3A

NM_033131.3

WNT4

NM_030761.4

WNT5A

NM_003392.4

WNT5B

NM_030775.2

CTGGCCTTTATCGCTCGCTG /
TTCATGACCACCTGGATGG
CCTCCCTGGAGCTAGTGTCT /
GGAACCTTACAGGGGGTTGG
TCGTCTTCGCCGTCTTCTCAG /
GAGTCGAGTGTGGAGCAGTT
AAGCAGACGTTTCGGCTACA /
TTTCCAACGTCCATCAGCGA
CTCAAGAGAGCGAGAAGACTGG /
CCCTCCCCTATGTAGGCCAT

632

60.03 / 59.96

No

244

62.12 / 59.68

No

287

59.97 / 59.97

Yes

309

60.16 / 60.18

No

WNT7B

NM_058238.2

GGAGGCTTCCACCTTTCTCC /
TCTCCGGTACCCAGTGTAGG

715

60.03 / 60.03

Yes

WNT10B

NM_003394.3

TGAGCTCGGTGAGAGCAAAG /
TTAAACCGTGGGGAGACTGC
CACAAGACAGGCAGTGCAAC /
TGCCGAGTTCACTTGACGAG
CCAACTGGGCACTTTTTCGG /
TCTAAACAGCAGACAGCGCA
TGCTTCATCTCCACGTCCAC /
AGGATGACCCACCAGATGGA
TCCTTCTGCCACTTCGTCTT /
TTGTAGCACTGGTGGTAGCG
AATCCCATCACCATCTTCC /
CATCACGCCACAGTTTCC

204

60.04 / 59.96

No

WNT11

NM_004626.2

883

59.97 / 60.32

No

FZD4

NM_012193.3

783

59.97 / 59.97

No

FZD5

NM_003468.3

272

60.04 / 59.96

No

ROR2

NM_004560.3

266

58.95 / 60.04

No

GAPDH

NM_001289745.1

382

54.14 / 56.43

No

Table 2. List of primers used in RT-PCR with hSVF cDNA.
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No

Goat anti-Rabbit 594 secondary antibody (Thermo Fisher) was added the following day
at 1:1000 for 1 hour at RT (refer to Table 3 for further details). Wnt5a was visualized
using an IX81 inverted microscope (Olympus) and MPE FV1000 confocal microscope
(Olympus).
Exogenous Wnt5a Treatment. After plating overnight in hSVF Growth Media
(GM), hSVF cells were treated with 25µM IWP2 and varying concentrations of
recombinant Wnt5a (0, 0.75, 7.5, 75, and 150 ng/ml; R&D Systems) for 5 days. As a
comparison, recombinant human Wnt3a was added to 25µM IWP2 in hSVF GM at the
same concentrations. Media changes were performed every other day. At the end of day
5, all of the wells were labeled with UEA1 and quantified as previously described.
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Antibody/Lectin/Stain
(Concentration)
Wnt5a (1:250)
Wnt5a (20µg/ml)
IgG (20µg/ml)
Fluorescein-Labeled Ulex
Europaeus Agglutinin Type I
(UEA1; 1:500)
DAPI (1:10000)
2˚ Antibody
(Concentration)
Goat anti-Rabbit DyLightTM
594 (1:1000)

Manufacturer
(Catalog Number)
Abcam (ab72583)
R&D Systems (AF-645)
R&D Systems (AB-108-C)
Vector Laboratories (FL1061)
Thermo Fisher Scientific
Manufacturer
(Catalog Number)
Thermo Fisher Scientific
(35560)

Table 3. List of the antibodies, lectins, and stains used.
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Purpose
Immunocytochemistry
Neutralization
Control
Immunocytochemistry
Immunocytochemistry
Purpose
Immunocytochemistry

Wnt5a-Specific Neutralization and In Vivo Analysis. P1 hSVF cells were
cultured as described in hSVF GM containing 0, 5, 10, or 20µg/ml of anti-Wnt5a
antibody or Normal Goat IgG control antibody (R&D Systems). Of note, though the antiWnt5a antibody used here is specific for mouse and rat, others have successfully used it
to neutralize human Wnt5a as well 377-379 Media changes occurred every other day. At the
end of day 3, all of the wells were labeled with UEA1 and quantified as previously
described.
To validate Wnt5a’s role in vivo, hSVF was incorporated into 3 mg/ml collagen-I
constructs as previously described

9,370

. One of three treatments was incorporated into

each construct: (A) 20 µg/ml IgG control antibody, (B) 20 µg/ml anti-Wnt5a antibody, or
(C) 7.5 ng/ml recombinant human Wnt5a. Constructs were placed bilaterally in the
subcutaneous dorsum of 9 Rag1-/- C57BL6 mice (Jackson Laboratories) as previously
described9,370. After 2 weeks, animals were sacrificed and the constructs explanted.
Constructs were fixed in 4% PFA for 1 hour, washed, permeabilized in 0.5% Triton X100 (MP Biomedicals) for 15 minutes, and blocked with 5% goat serum (Thermo Fisher)
for 1 hour. Constructs were incubated in 1:500 UEA1 overnight. The following day, they
were washed and incubated with DAPI (1:10000) for 10 minutes. Imaging was conducted
via fluorescence confocal microscopy (Olympus MPE FV1000).
2-D (In Vitro) Image Analysis. Fluorescence images were analyzed using Image
J software (NIH) with the Neuron J plugin (ImageScience.org). Images were assessed for
total EC network length and EC area. Sheets of ECs were not considered to be discrete
segments and were omitted from total EC network length calculations, though they were
incorporated into EC network area measurements. With regards to calculating the EC
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area, images were first given a color threshold to identify all UEA1+ structures. A size
threshold of 0.065 cm2 was then applied to remove background noise. Resulting areas in
a field-of-view were automatically quantified; images containing blatant outliers (for e.g.,
UEA1+ particles not associated with a vascular structure) were manually excluded from
EC area calculations. Regarding calculations and graphical representation, we normalized
our in vitro rhWnt5a, rhWnt3a, and anti-Wnt5a quantitative data to their respective 0
ng/ml or 0 µg/ml treatment controls. This was done to account for the inherent
differences between three different hSVF isolations from three patients. Examples of
length and area measurements are shown in Figure 12.
3D (In Vivo) Image Analysis. Z-stacks of confocal images were combined into a
3D composite image using AMIRA 6.0 software (FEI Visualization Sciences Group).
After measuring UEA1+ volume, we converted UEA1+ signals into a skeleton and
measured total EC network length, segments, and nodes. Network segments were
considered to be structures with easily discernible origins and end points. The longest
measurable vascular structure devoid of branching vessels was considered to be one
segment. Each branch point was considered to be one node. All image manipulation and
measurement was conducted based on instructions present in the AMIRA 6.0 User Guide.
Statistics. Experiments were conducted in triplicate. Error is presented as the
mean ± standard error of the mean (SEM). Significance was determined using the
Student’s t-test (p < 0.05). Overall significance of each treatment was determined by oneway ANOVA with follow-up Holm-Sidak or Tukey comparison tests, as determined by
SigmaPlot (Systat Software). Outliers were identified using Chauvinet’s criterion380 and
removed.
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Figure 12. EC network tracing and area determination. (A) Image J was used to
convert standard UEA1+ EC images to 8-bit. Images were then traced to measure total
EC length using the NeuronJ plugin. (B) 8-bit images were also used for area
measurement. Images were processed for size threshold (shown in red) and enumerated
as described in the Materials and Methods.
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RESULTS
hSVF EC networks are reduced with increasing culture. hSVF is a
heterogeneous single-cell suspension of ECs, fibroblasts, smooth muscle cells,
macrophages, mural cells, and various stem cell populations

9,297-299,369

. Its inherent

ability to rapidly and spontaneously self-assemble into a complex, hierarchical, and
branched vasculature in vivo makes it a compelling candidate for therapeutic
vascularization. We cultured hSVF as a means of interrogating potential mechanisms
regulating vascular self-assembly

9,381

. After several days of culture, we observed the

appearance of network-like structures in our cultures. Labeling of the cells with UEA1 (a
lectin that binds human endothelium) and DAPI confirmed the presence of extensive EC
networks in hSVF surrounded by an abundant stromal support system (Figure 13A).
Based on prior experience working with rodent and human SVF cells, we
observed that high-passage SVF cells lose their ability to form vasculatures in vivo9.
Therefore, we wanted to determine if this phenomenon also occurred in vitro. We
performed an analysis of EC network formation as a function of passage, using hSVF
cells from passages 1 through 4. Figure 13B shows that EC network density increased
within a given passage over 5 days. Conversely, the overall EC density decreased with
increasing passage. We observed significant reductions in normalized EC network length
at day 5 as the passage number increased (Figure 13C). Normalized to P1, which
exhibited the highest total EC length, P2, P3, and P4 cells exhibited lengths that were
0.59 ± 0.02 (p < 0.001), 0.44 ± 0.03 (p < 0.001), and 0.26 ± 0.09 (p = 0.001) times as
large, respectively. Thus, successive culturing decreases hSVF EC networking capacity.
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Figure 13. Culture reduces hSVF vascularization potential. (A) Within 5 days of
culture, hSVF displayed complex EC networks, seen here after labeling cells with UEA1,
a lectin that binds human endothelium. Scale = 10x, 200µm. (B) hSVF networks increase
in complexity over time in low passage culture, but rapidly loose EC networking capacity
with subsequent passaging. Scale = 10x, 200µm. (C) The average total hSVF EC length
at day 5 was quantified and normalized to measurements of P1, day 5. Significant
decreases in total hSVF hSVF EC length are seen by day 5 as a function of increasing
passage (***p ≤ 0.001). Results shown as mean ± S.E.M.
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While lower passages of hSVF achieved a greater quantified total EC network
length by day 5 (Figure 13C), this self-assembly appears to be dependent on the number
of UEA1+ EC within the culture at time of plating. As our analysis depends on having
quantifiable EC networks, all subsequent in vitro and in vivo experiments utilized P1 cells
due to their observed higher EC networking potential.

Wnt signaling is implicated hSVF EC network self-assembly. To identify the
mechanisms regulating the self-assembly of adipose-derived hSVF into EC networks, we
treated hSVF cultures with angiogenic inhibitors, including those for VEGF-R2
(ZM323881), PDGF-Rβ (AG1296), HGF receptor/cMet (SU11274), the TGF-β type-I
receptor/Alk5 (SB431542) (Figure 11 and Table 1), and Wnt palmitoylation (IWP2)
(Figure 14). In our preliminary tests, IWP2-induced inhibition yielded the most
significant decreases in total EC length at the two highest concentrations (25 and 50µM;
data not shown). Because the role of Wnt signaling in vessel assembly is not as well
characterized as it is in cancer, stem cell, and developmental biology, we focused our
efforts here.
Before proceeding, we wanted to determine if our preliminary findings were due
to IWP2-induced cytotoxicity (Figure 14A). At 50µM IWP2, cell death was determined
to be due to cytotoxic effects (1.05 ± 0.08 AU with p ≤ 0.001), while the 25µM and lower
concentrations displayed absorbance readings that were not significantly different from
control cultures. Thus, we used the 25µM IWP2 dose for all subsequent experiments.
We next wanted to determine the effect of IWP2 concentration on hSVF network
formation (Figure 14B.i). Treatment of hSVF with 6.25 or 12.5µM IWP2 showed no
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Figure 14. Wnt mediates hSVF vascular self-assembly. (A) The CCK-8 cell cytotoxicity
assay demonstrated that IWP2 concentrations ≤ 25µM were not cytotoxic, whereas 50µM
was cytotoxic (***p ≤ 0.001). All subsequent experiments utilized 25µM. (B) (i.)
Increasing IWP2 concentrations reduce hSVF EC networking, as visualized by UEA1+
EC labeling. Scale = 10x, 200µm. (ii.) Quantification of hSVF EC networks shows 25µM
IWP2 significantly decreases the total network length with respect to control (***p ≤
0.001). NS = not significant. Results shown as mean ± S.E.M.
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changes in EC network formation compared to control cultures. However, after treating
hSVF cells with 25µM IWP2, total EC network length was significantly reduced,
measuring only 0.75 ± 0.12 times that of the untreated control (p < 0.001; Figure 14B.ii).
These findings demonstrate that inhibition of endogenous hSVF Wnt signaling has a
downstream effect of reducing EC self-assembly and total EC network length.

Wnt5a and Fzd4 are expressed in hSVF. Since IWP2 blocks Wnt
palmitoylation376 and all Wnt isoforms are palmitoylated382, we wanted to determine
which Wnt isoforms were expressed in hSVF. We isolated mRNA from hSVF cultures at
days 1, 3, 5, and ran PCR for Wnt isoforms associated with angiogenesis383-392 (Figure
15A). In each experimental replicate, Wnt5a mRNA was consistently present with stable
levels of expression over the 5 days of culture (Figure 16A). To determine if Wnt5a
protein was present in hSVF, we immunolabeled cultures with anti-Wnt5a antibody and
UEA1 (Figure 16B). We found that Wnt5a was abundant in the hSVF culture (Figure
16B.i), and that Wnt5a was not detectable in the fluorescent secondary antibody-only
control (Figure 16B.ii).
Given that Wnt5a was present in the culture, we next wanted to determine which
Wnt5a receptors were expressed in hSVF (Figure 15B). Wnt5a has been shown to
interact with a number of receptors, including Frizzled-4
395,396

393

, -5

378,388,394

, and ROR2

. Similar to our Wnt PCR, we tested hSVF cDNA from day 1, 3, and 5 cultures for

expression of these receptors. In certain replicates, we noticed a weak expression of
FZD5 and ROR2 (Figure 15B), but in all replicates, we observed the consistent
expression of FZD4 (Figure 16C), whose expression (like that of Wnt5a) was stable
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Figure 15. Wnt and Wnt5a-Receptor PCR Screening. (A) hSVF cDNA was initially
screened by PCR using primers for Wnt isoforms associated with angiogenesis. Of these,
WNT5A was most strongly expressed, while WNT7B was expressed to a lesser degree
(arrows). (B) Once WNT5A was identified, WNT5A receptors underwent similar
screening, with a focus on FZD4, FZD5, and ROR2. FZD4 was consistently expressed for
all experiments, while FZD5 and ROR2 expression was inconsistent.

102

Figure 16. Wnt5a and Fzd4 are highly expressed in hSVF cultures. (A) A time course
of hSVF cDNA isolated was interrogated by RT-PCR for expression of WNT5A at days 1,
3 and 5. WNT5A was robustly expressed at all time points. Normalization of WNT5A
expression to the GAPDH loading control indicates stable expression of transcripts over
5 days. (B) (i.) hSVF was examined by immunocytochemistry for Wnt5a expression. EC
were labeled with UEA1 (green), nuclei with DAPI (blue), and the entire culture with
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anti-Wnt5a 1˚ + AF594 2˚ antibodies (red). The merged image shows robust Wnt5a
expression throughout the culture. Scale = 20x, 100µm. (ii.) A negative control run in
parallel used only the AF594 2˚ antibody to rule out non-specific fluorophore binding.
Scale = 20x, 100µm. (C) Wnt5a receptor expression was also tested by RT-PCR (also see
Figure 25B). FZD4 was stably and consistently expressed, as shown by gel
electrophoresis. Densitometry demonstrates no change in FZD4 transcripts over 5 days.
NS = not significant. Results shown as mean ± S.E.M.
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through day 5. These findings confirm the expression of Wnt5a and its receptor Frizzled4 within cultured hSVF and suggest a possible mechanism for regulating hSVF EC selfassembly.
Recombinant Wnt5a mediates the self-assembly of hSVF EC networks in
IWP2-treated cultures. We next wanted to determine if Wnt5a played a specific role in
the self-assembly of hSVF EC networks. hSVF cultures were exposed to a combination
of 25µM IWP2 and varying concentrations (0 – 150 ng/ml) of exogenously supplied
recombinant human Wnt5a protein (rhWnt5a; Figure 17). Since IWP2 (a) inhibits the
release of all endogenous Wnt isoforms from hSVF cells without affecting cognate
receptors and (b) impairs hSVF EC networking, we wanted to determine if the selective
addition of rhWnt5a alone would restore hSVF EC network assembly.
After five days of rhWnt5a co-administration with IWP2, we labeled hSVF
cultures with UEA1 (Figure 17A) and quantified the magnitude of hSVF EC networking.
As expected, the addition of 25µM IWP2 alone (negative control, with no supplemental
rhWnt5a) inhibited EC network assembly. Supplementing the cultures with as little as
0.75 ng/ml rhWnt5a yielded significant increases in UEA1+ area (Figure 17B) compared
to cultures given IWP2 alone, resulting in a 2.44 ± 0.36-fold increase (p ≤ 0.01). The 7.5
ng/ml concentration elicited the largest increase in area, measuring 3.34 ± 0.87 times (p ≤
0.05) larger than cultures treated with IWP2 alone, while 75 ng/ml elicited a 2.93 ± 0.76fold increase (p ≤ 0.05) and 150 ng/ml yielded an increase of 2.98 ± 0.72 fold (p ≤ 0.05).
ANOVA analysis further indicated that treatment with any concentration of rhWnt5a was
significant compared to controls lacking rhWnt5a, but that there were no significant
differences between the various rhWnt5a treatments.

105

Figure 17. Exogenous recombinant Wnt5a mediates hSVF vascular self-assembly
during IWP2 inhibition. All hSVF cultures were treated with 25µM IWP2 and given
increasing concentrations of rhWnt5a. (A) Representative images of UEA1+ (green)
labeling of hSVF EC networks are seen for all conditions. Scale Bar = 4x, 500µm. (B)
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The UEA1+ area for each rhWnt5a-treated condition was normalized to the non-treated 0
ng/ml rhWnt5a control. rhWnt5a significantly increased the total UEA1+ area compared
to the control (*p ≤ 0.05; **p ≤ 0.01). (C) The total UEA1+ network length was
normalized to the total UEA1+ area. Compared to the 0 ng/ml rhWnt5a control,
supplemental rhWnt5a produced areas of hSVF EC sheeting, which is characterized by
lower ratios of total EC length to EC area. Results shown as mean ± S.E.M.
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Interestingly, while addition of rhWnt5a significantly increased UEA1+ EC area
in the presence of IWP2, it also promoted the aggregation of EC in monolayers that
resemble sheets To quantitatively characterize this, we measured total EC network length
in each field-of-view and normalized this length to the measured EC area in that same
field-of-view (Figure 17C). Compared to cultures given IWP2 alone, the addition of 0.75
ng/ml rhWnt5a yielded ratios that were only 0.51 ± 0.06 times as large (p ≤ 0.001).
Similarly, the 7.5, 75, and 150 ng/ml concentrations exhibited ratios that were 0.56 ± 0.08
(p ≤ 0.001), 0.72 ± 0.1 (p ≤ 0.05), and 0.55 ± 0.09 (p ≤ 0.001) times that seen with the
control. Thus, considering that rhWnt5a increased EC area and reduces the ratio of total
EC length to EC area, rhWnt5a appears to specifically play a role in modulating hSVF
vascular network assembly in a process that depends on EC proliferation.
Wnt signaling is divided into canonical and non-canonical pathways, which
utilizes β-catenin or non-β-catenin pathways to transduce the signal397. Wnt5a utilizes
multiple receptors but is generally categorized as a non-canonical Wnt379,398. To
determine if the same effect on hSVF EC networking could be produced by a different
Wnt, we repeated the above experiment using the prototypical canonical Wnt, Wnt3a at
the same concentrations as those used for the rhWnt5a in vitro experiment (Figure 18A).
The quantification of the total hSVF EC area normalized to the 0ng/ml Wnt3a control
indicated that Wnt3a supplementation did not significantly increase networking area
(Figure 18B) or the ratio of EC network length to EC area of IWP2-treated cultures
(Figure 18C). Further, ANOVA analysis demonstrated that treatment with any
concentration of Wnt3a did not yield a significant outcome. These findings suggest that
Wnt5a alone can partially restore the assembly of hSVF EC networking when
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Figure 18. IWP2-treated hSVF EC networks are not affected by supplemental
rhWnt3a. (A) hSVF was treated with 25µM IWP2 for 5d and supplemented with varying
concentrations of rhWnt3a, except where noted. Human EC were labeled with UEA1
(green), imaged and quantified. (B) The total UEA1+ EC area seen with each treatment
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was normalized to that for the untreated IWP2 control. Quantification demonstrates that
rhWnt3a supplementation yielded no significant changes to network area compared to
the IWP2 control. (C) Likewise, the normalization of total UEA1+ EC network length to
the total UEA1+ EC area was not significantly affected by exogenous rhWnt3a addition.
NS = not significant. Results shown as mean ± S.E.M.
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endogenous Wnt release is prevented. It also demonstrates that the effect on network
assembly is not universally mediated by all Wnt isoforms, since Wnt3a substitution was
ineffective.

Wnt5a mediates hSVF microvascular self-assembly in vivo. Our data supports
that Wnt5a plays a specific role in hSVF microvascular self-assembly in vitro. Therefore,
we wanted to determine its role in the self-assembly that others and we have reported in
vivo 1,9,299. We initially exposed hSVF cultures to varying concentrations (0-20 µg/ml) of
Wnt5a neutralizing antibody (referred to as anti-Wnt5a)

377,378,399

to determine an

appropriate concentration for use (Figure 19). Compared to the negative control (0
µg/ml), there were no significant differences observed with 5 or 10 µg/ml anti-Wnt5a,
while treatment with 20 µg/ml significantly reduced the total EC length (0.68 ± 0.06 fold,
p ≤ 0.05; Figure 19A) and segment number (0.52 ± 0.09 fold, p ≤ 0.05; Figure 19B).
The addition of an IgG control antibody at the same concentrations did not affect total EC
length or segment number (data not shown).
Based on these in vitro findings, we utilized 20 µg/ml anti-Wnt5a in subsequent
in vivo experiments to determine if Wnt5a modulated hSVF microvascular assembly in
that setting as well. We combined hSVF in 3D collagen-I constructs with 20 µg/ml IgG
isotype control antibody, 20 µg/ml anti-Wnt5a neutralizing antibody, or 7.5 ng/ml
rhWnt5a (Figure 20). After implantation for two weeks, host animals were sacrificed and
the constructs explanted, processed and analyzed as described in the Materials and
Methods (Figure 20A). Each experimental condition was quantified for length density
(i.e., a ratio of the total EC length to the 3D scan volume; Figure 20B) as well as the
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Figure 19. Wnt5a neutralizing antibody inhibits hSVF total EC length and segments.
The largest concentration of anti-Wnt5a (20 µg/ml) significantly reduced the (A) hSVF
EC total length (*p ≤ 0.05) and (B) number of segments (*p ≤ 0.05). This concentration
was used to examine Wnt5a’s role in hSVF vascular self-assembly in vivo. In both (A)
and (B), values obtained for length and segments with each treatment were normalized to
the 0 µg/ml control. NS = not significant. Results shown as mean ± S.E.M.
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Figure 20. Wnt5a drives hSVF EC microvascular assembly in vivo. (A) 3D collagen-I
constructs containing hSVF with 20 µg/ml IgG isotype control, 20 µg/ml Wnt5a
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neutralizing antibody (anti-Wnt5a), or 7.5 ng/ml rhWnt5a were subcutaneously
implanted in immunodeficient mice for 2w. In situ images show 2w constructs before
harvest. Constructs were labeled with UEA1 (green) and imaged by confocal microscopy.
Scale bar = 20x, 100µm. (B) The total EC length was normalized to the 3D scan volume
(length density). Construct treatment with anti-Wnt5a exhibited a significantly reduced
length density ((2.25 ± 0.16) x 10-5 µm/µm3; *p ≤ 0.05) compared to the IgG control
((3.81 ± 0.1) x 10-5 µm/µm3). Conversely, rhWnt5a significantly increased this ratio
((6.17 ± 0.43) x 10-5 µm/µm3; *p ≤ 0.05) compared to the control. (C) The normalization
of segment number to length density showed no significant affect with either the antiWnt5a treatment ((1.24 ± 0.13) x 107 segments/µm/µm3) or the rhWnt5a treatment ((1.28
± 0.34) x 107 segments/µm/µm3) compared to IgG controls ((1.34 ± 0.07) x 107
segments/µm/µm3). (D) The ratio of node number to length density also shows no
significant difference between the IgG control ((1.19 ± 0.07) x 107 nodes/µm/µm3), the
anti-Wnt5a treatment (1.31 ± 0.02 nodes/µm/µm3), and treatment with rhWnt5a ((1.06 ±
0.27) x 107 nodes/µm/µm3). NS = not significant. Results shown as mean ± S.E.M.
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ratios of segment (Figure 20C) and node (Figure 20D) numbers to length density. Thus,
length density is a measure of assembly, while the segment and node ratios serve to
characterize hSVF vascular complexity.
IgG controls exhibited an average length density of (3.81 ± 0.1) x 10-5 µm/µm3.
Treatment with anti-Wnt5a significantly reduced the length density ((2.25 ± 0.16) x 10-5
µm/µm3; p ≤ 0.05), while rhWnt5a significantly increased this ratio ((6.17 ± 0.43) x 10-5
µm/µm3; p ≤ 0.05). Put a different way, compared to the IgG control, anti-Wnt5a reduced
total vascular length by approximately 41 ± 5.6%, while rhWnt5a increased overall
vascular length by approximately 62 ± 15%.
With regards to vascular complexity, the addition of anti-Wnt5a to 3D implants
did not significantly affect the ratio of segments to length density ((1.24 ± 0.13) x 107
segments/µm/µm3; p = 0.56) compared to IgG controls ((1.34 ± 0.07) x 107
segments/µm/µm3). Anti-Wnt5a also bore no significant effect on the ratio of nodes to
length density, with (1.31 ± 0.02) x 107 nodes/µm/µm3 (p = 0.22) compared to the (1.24 ±
0.07) x 107 nodes/µm/µm3 seen with the IgG control. Also, rhWnt5a did not significantly
influence complexity either ((1.28 ± 0.34) x 107 segments/µm/µm3 (p = 0.86) and (1.06 ±
0.27) x 107 nodes/µm/µm3 (p = 0.67)). These results also correlate with the qualitative
observation that 3D implants did not exhibit noticeable EC sheeting.
ANOVA analysis indicated that the anti-Wnt5a and rhWnt5a treatments only
imparted significant effects on EC lengths within a 3D construct. Thus, this data
demonstrates that in a 3D implant, the supplementation of rhWnt5a in vivo significantly
increased the overall length of the hSVF microvasculature, while the specific blockade of
Wnt5a with a neutralizing antibody significantly reduced hSVF cells’ capability to form a
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microcirculation. Together, these findings support a role for Wnt5a in mediating hSVF
microvascular self-assembly in vivo.

DISCUSSION
The main and novel findings of this report are that (a) human adipose SVF
(hSVF) spontaneously forms endothelial networks in vitro, but loses this capacity due to
a reduction in system endothelium, (b) pan-inhibition of hSVF-endogenous Wnt isoforms
by IWP2 significantly reduces EC networking, (c) the addition of exogenous Wnt5a, but
not Wnt3a, to IWP2-treated cultures modulates EC network assembly in vitro, (d) the
spontaneous assembly of hSVF microvascular networks in vivo is inhibited by a Wnt5a
neutralizing antibody and enhanced by addition of recombinant human Wnt5a protein,
and (e) Wnt5a does not influence the complexity of hSVF-derived microvessels.
Adipose SVF is a heterogeneous cell population that contains EC, perivascular
cells, macrophage, fibroblasts and stem cells9,369,400. This endogenous heterogeneity is
likely what imbues the cellular system with the specific capacity to form functional
microvasculatures in vivo1,9,370. In prior efforts, we leveraged this functionality to support
the engraftment of hepatic parenchymal cells1,9. Koh and colleagues demonstrated that
the formation of vascular networks by mouse SVF (mSVF) depended on the presence of
EC and is VEGF-dependent299. We reported that the removal of EC from rat SVF cells
yielded a significantly altered vascular interaction9. These findings support the hypothesis
that the heterogeneity of SVF is crucial to its biological functionality. However, the
mechanisms regulating this functionality are poorly defined.
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It is a common practice to subculture adipose SVF to isolate the putative ADSC
401

. This “pure” population of mesenchymal cells is explicitly void of endothelium (i.e.

CD31-) 402. In early culture, the endogenous EC population is enriched and capably forms
robust EC networks. This capacity diminishes rapidly with each successive passage. The
reasons for this decrease are not clear, but could be due to EC depletion by our sequential
network assays, differential proliferation rates between EC and stromal cells favoring the
latter, or culture-induced loss by EC phenotypic drift. There are multiple reports in the
literature of ADSC combined with various EC populations to create a synthetic vascular
and stromal cell system298,403,404. Our data supports the conclusion that the hSVF cellular
system is a complex heterogeneous cell mixture that endogenously retains the functional
capacity for microvascular self-assembly, which the artificially generated EC-ADSC coculture may not fully replicate.
To determine the mechanisms that regulate hSVF EC network self-assembly in
vivo, we investigated several angiogenesis-associated pathways. Inhibition of receptors
for VEGF and PDGF-B significantly reduced hSVF EC networking, while blockade of
the TGFβ1 receptor Alk5 and HGF receptor c-Met did not. This data agrees with Koh, et
al.299 with regards to the role of VEGF and further suggests that a blockade of PDGFB/PDGFR-β signaling may prevent perivascular cell recruitment as demonstrated in other
vascular beds405-408. The lack of effect from Alk5 inhibition may be due to (a)
TGFβ1/Alk5 having a role in later stages of vascular stabilization348,409, or (b) TGFβ1
could be signaling through Alk1 on EC410,411. In other model systems, we demonstrated
that HGF/c-Met signaling modulates vascular assembly and angiogenesis9,316. The lack of
effect on hSVF could be due to limitations of our hSVF in vitro assay to mimic the stages
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when HGF/c-Met are active. Our battery of inhibitors also included the Wnt
palmitoylation inhibitor IWP2376, which showed a significant effect on hSVF network
self-assembly. Though Wnt biology is extensively studied in other contexts, its functions
in EC biology and angiogenesis have only recently been investigated392,399,412-414 with
defined roles for canonical and non-canonical Wnt isoforms388,392,412 in vascularization.
Since IWP2 inhibits the release of all Wnt isoforms, we tested hSVF for
expression of Wnt isoforms previously affiliated with angiogenesis. Since our PCR panel
identified Wnt5a as being highly expressed within hSVF, we hypothesized that Wnt5a
mediates hSVF EC network assembly. The addition of various concentrations of
exogenous rhWnt5a significantly increased the areas of IWP2-inhibited EC networks,
though these treatments also significantly reduced the ratios of lengths to EC areas. These
effects were not seen when the canonical rhWnt3a was supplemented in place of
rhWnt5a. Together, these findings suggest that while Wnt5a is an essential modulator of
hSVF EC network assembly in vitro, other Wnt isoforms (alone or in conjunction with
Wnt5a) likely modulate vascular complexity (characterized by reduced EC sheeting and
increased branching).
To determine if our in vitro findings provided the mechanisms controlling in vivo
microvascular self-assembly, we implanted hSVF1,9,370 in 3D constructs supplemented
with a Wnt5a-specific neutralizing antibody378,379,415, rhWnt5a, or IgG isotype control.
Compared to IgG controls, implants containing anti-Wnt5a exhibited reduced the
volumetric total vessel length, whereas the numbers of nodes and segments per unit of
length density were essentially unchanged. To contrast, constructs containing rhWnt5a
exhibited a significantly increased length density, but like anti-Wnt5a, rhWnt5a had little
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effect on the numbers of segments and nodes per unit of length density. This suggests that
Wnt5a does not influence the complexity of the resulting hSVF-derived vascular system.
This data agrees with the results from other reports in the literature that Wnt5a signaling
modulates EC vascular assembly392, but this is the first time that this has been
demonstrated in hSVF – a clinically relevant, natively heterogeneous population.
Our in vivo findings also correspond with those seen in vitro, in spite of the fact
that in vitro experiments utilized IWP2 (the pan-Wnt release inhibitor) and in vivo
experiments did not. It is possible that a bolus delivery of rhWnt5a in a 3D implant could
decrease, but not necessarily eliminate, the influence of other Wnt isoforms released by
hSVF cells or host tissues, since certain Wnt isoforms can compensate for one another in
development416. While rhWnt5a did not significantly influence hSVF microvascular
complexity in vivo (potentially based on a compensatory, decreased influence of other
Wnt isoforms), the incidence of EC sheeting in vivo appeared to have been mitigated
(perhaps due to the basal presence of other Wnt isoforms or other biomolecules
associated with angiogenesis). Though this seems paradoxical, it is clear that Wnt5a is
only one constituent of a complex system that imparts control over hSVF spontaneous
microvascular self-assembly.
A key consideration in our experiments is that we obtained our hSVF cells from
three different patient sources of discarded human lipoaspirate. Undoubtedly, the
characteristics of adipose exhibits variability between patients. The cellular composition
of each hSVF batch is likely to be different depending on factors such as gender, age, and
social lifestyle (e.g. smoking, alcohol use), all of which likely have significant effects on
cell viability and cellular function., Prior studies have indicated that the proportion of
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CD31+ EC is decreased with culture SVF cells as opposed to freshly isolated cells9,400. In
spite of these factors, we observed the same trends with each hSVF isolation, regardless
of the patient demographics. This supports our finding that Wnt5a signaling may play a
general role in mediating hSVF microvascular assembly in vivo. At this stage, it is
unclear how Wnt5a may be involved. We show robust expression of Wnt5a within hSVF,
but it is unknown if there is a specific cell lineage within hSVF that is responsible for
affecting the EC response. We show robust expression of FZD4 in hSVF and Wnt5a
utilizes this receptor in EC393, but Wnt5a also signals through FZD5388 and ROR2396,417.
Thus, the downstream signaling events still need to be defined. Though more work is
required to understand how the hSVF cellular system functions to self-assemble a
microvasculature, our data identifies Wnt5a signaling as a component that potentiates this
process.
In this endeavor, our goal was to define the mechanisms controlling hSVF
spontaneous EC microvascular network formation in vivo. Our findings are novel, as this
is the first report that identifies Wnt5a as a modulator of hSVF vascular assembly. This
work underscores the fact that adipose SVF is a potential regenerative cell system.
Understanding how the mixture of heterogeneous cell types within hSVF works together
could enhance efforts to better vascularize tissues or promote the engraftment of
engineered therapeutic cells1,9.
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CHAPTER V
RESTORATION OF PHYSIOLOGICALLY RESPONSIVE LOW-DENSITY
LIPOPROTEIN RECEPTOR-MEDIATED ENDOCYTOSIS IN GENETICALLY
DEFICIENT INDUCED PLURIPOTENT STEM CELLS

OVERVIEW
Acquiring sufficient amounts of high-quality cells remains an impediment to cellbased therapies. Induced pluripotent stem cells (iPSC) may be an unparalleled source, but
autologous iPSC likely retain deficiencies requiring correction. We present a strategy for
restoring physiological function in genetically deficient iPSC utilizing the low-density
lipoprotein receptor (LDLR) deficiency Familial Hypercholesterolemia (FH) as our
model. FH fibroblasts were reprogrammed into iPSC using synthetic modified mRNA.
FH-iPSC exhibited pluripotency and differentiated toward a hepatic lineage. To restore
LDLR endocytosis, FH-iPSC were transfected with a 31kb plasmid (pEHZ-LDLR-LDLR)
containing a wild-type LDLR (FH-iPSC-LDLR) controlled by 10kb of upstream genomic
DNA as well as Epstein-Barr sequences (EBNA1 and OriP) for episomal retention and
replication. After six months of selective culture, pEHZ-LDLR-LDLR was recovered from
FH-iPSC-LDLR and transfected into Ldlr-deficient CHO-a7 cells, which then exhibited
feedback-controlled LDLR-mediated endocytosis. To quantify endocytosis, FHiPSC±LDLR were differentiated into mesenchymal cells (MC), pretreated with excess
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free sterols, Lovastatin, or ethanol (control), and exposed to DiI-LDL. FH-MC-LDLR
demonstrated a physiological response, with virtually no DiI-LDL internalization with
excess sterols and an ~2-fold increase in DiI-LDL internalization by Lovastatin compared
to FH-MC. These findings demonstrate the feasibility of functionalizing genetically
deficient iPSC using episomal plasmids to deliver physiologically responsive transgenes.

INTRODUCTION
Induced pluripotent stem cells (iPSC) derived from patients are a unique, potential
alternative for replacing diseased tissue because of their virtually unlimited supply,
differentiation potential, and tolerance by the immune system418. However, in the context
of treating genetic disorders, autologous iPSC are challenged by their genetic homology
with patient DNA, as they may retain functional deficiencies. Such shortcomings must be
addressed before these cells attain broad therapeutic value.
Familial Hypercholesterolemia (FH) is one example of a monogenic autosomal
dominant disorder that affects low-density lipoprotein cholesterol (LDL) metabolism419.
In FH, LDL receptor (LDLR) deficiency (attributed to at least one of 1200 documented
mutations420,421) impedes receptor-mediated endocytosis of LDL, resulting in
pathologically elevated serum LDL levels. Consequently, the formation of atherosclerotic
plaques and cardiovascular disease are both accelerated. Because healthy liver
hepatocytes contain the body’s highest density of functional LDLR82, liver transplant is
regarded as the only cure for FH. Yet, the number of available livers is far outstripped by
significant demand422, while long-term transplant issues such as immunomodulation and
transplant rejection remain key hurdles. Further, liver hepatocytes culture poorly423,
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complicating efforts such as banking and expansion.

For such reasons, generating

hepatocytes from patient-specific iPSC (FH-iPSC) may be a possible therapeutic
alternative.
We used FH as a model system for interrogating the LDLR functionalization of
FH-iPSC. We restored FH-iPSC LDLR-mediated endocytosis using a novel 31kb
plasmid containing (a) wild-type LDLR physiologically controlled by 10kb upstream
genomic regulatory control sequence and (b) the minimum number of required EpsteinBarr Virus (EBV) replication and retention sequences (Epstein-Barr Nuclear Association
1 (EBNA1) and origin of plasmid replication (OriP))424. This large plasmid was
transfected into iPSC via electroporation and retained as a stable episome. FH-iPSC were
differentiated into hepatocyte-like cells (FH-HLC) and mesenchymal cells (FH-MC) to
investigate LDL internalization. Transfected FH-iPSC derivatives demonstrated a
significant, physiologically sensitive restoration of LDLR-mediated endocytosis
compared to non-transfected controls. The technologies and methods discussed herein
represent a unique approach for functionalizing genetically deficient iPSC using episomal
plasmids that contain genomic transgene control sequences.

MATERIALS & METHODS
Ethics Statement. All animal procedures were conducted in compliance with
University of Louisville School of Medicine IACUC-approved protocols and NIH
guidelines. All recombinant DNA work was approved by the University of Louisville
Institutional Biosafety Committee and performed in accordance with NIH guidelines.
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General Cell Culture. Mouse embryonic fibroblasts (MEF) were cultured in
MEF media comprised of DMEM-HG, 2 mM L-glutamine, and 10% standard fetal
bovine serum (FBS; Invitrogen). Chinese hamster ovary wild-type (CHO-WT) and LDLR
deficient (CHO-a7) cells (generously provided by Prof. Monty Krieger, Massachusetts
Institute of Technology) were cultured in media containing DMEM/F12 (Invitrogen),
2mM L-glutamine, and 10% standard FBS. All cells were maintained at 37˚C and 5%
CO2 and passaged at confluence with 0.05% Trypsin-EDTA (Invitrogen).
Parent Fibroblast Culture. Dermal fibroblasts from an FH patient (GM01355;
Coriell Cell Repositories) were cultured in FH growth medium consisting of MEM
(Invitrogen), 15% HyClone™ defined FBS (Thermo Fisher Scientific), 2 mM Lglutamine, 0.1 mM Non-Essential Amino Acids (MNEAA), 50 units/ml penicillin and 50
µg/ml streptomycin (Invitrogen). WT IMR90 fibroblasts were cultured in MEF media as
described above. All cells were maintained in standard cell culture conditions and
passaged with 0.05% Trypsin-EDTA.
iPSC Generation and Culture. Reprogramming was performed in 6-well tissue
culture dishes coated with 0.2% gelatin (Sigma-Aldrich). On Day -2, Mitomycin-Cinactivated human foreskin fibroblast feeder cells (Nuff; GlobalStem) were plated at a
density of 2.5x105 cells/well and cultured in Nuff growth media, comprised of DMEMHG, 10% HyClone defined FBS, 1% GlutaMAX, 50 units/ml penicillin and 50 µg/ml
streptomycin (Invitrogen). On Day -1, 2.5x104 FH parent fibroblasts were seeded atop the
Nuff feeder layer in FH growth medium. After overnight plating, fibroblasts were
transfected daily for 20 days in Pluriton reprogramming medium supplemented with 200
ng/ml B18R interferon inhibitor (Stemgent), the mRNA cocktail, and Lipofectamine-
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RNAiMax Transfection Reagent (Invitrogen) per the manufacturers’ instructions. Fresh
reprogramming medium was substituted after 4 hours of incubation. Pluripotent colonies
(FH-iPSC; TRA-1-60+ via staining with StainAlive TRA-1-60 (Stemgent)) were
identified and manually passaged from transfected cultures onto Mitomycin C-inactivated
(Sigma-Aldrich) MEF every three days. FH-iPSC were cultured with human iPSC
medium (DMEM/F12 supplemented with 20% Knockout Serum Replacement (KSR), 2
mM L-glutamine, 0.1 mM MNEAA (Invitrogen), 0.1 mM β-mercaptoethanol (SigmaAldrich) and 20 ng/ml fibroblast growth factor-2 (bFGF; Stemgent))425. For feeder-free
culture, FH-iPSC were passaged onto hESC-Qualified Matrigel coated plates (BD
Biosciences) and gradually adapted to mTeSR1 media (Stemcell Technologies) by serial
transition from 20% KSR culture media over a 10-day period with daily media changes.
Cells in feeder-free culture were used for parenchymal cell generation before the 10th
passage426.
FH Cell Characterization. DNA karyotyping and fingerprint analysis (Cell Line
Genetics) was completed on FH skin fibroblasts and reprogrammed iPSC (P21) to ensure
that both populations were karyotypically normal and maintained identical DNA
fingerprints. To verify disease phenotype, FH fibroblasts were compared against wildtype IMR90 fetal lung fibroblasts on the basis of their ability to internalize LDL
cholesterol. FH-iPSC pluripotence was then assessed via in vitro spontaneous
differentiation and in vivo teratoma assays. In vitro, FH-iPSC were plated on glass slides
in differentiation medium (human iPSC medium without bFGF) and differentiated for 20
days. 50% media changes were performed every other day. After 20 days, we assessed
the iPSC for pluripotent marker expression via immunocytochemistry. For in vivo
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teratoma generation, we utilized FH-iPSC that were passaged with 0.05% Trypsin-EDTA
at least five times prior427. Growth-Factor Reduced Matrigel (BD Biosciences) was mixed
with an FH-iPSC cell pellet to a final concentration of 2.5x104 cells/µl; 200 µl was loaded
into sterile 1ml syringes with 18G needles (BD Biosciences). Control syringes containing
only Matrigel were also prepared. iPSC and controls were injected on opposing sides
into the subcutaneous dorsum of isoflurane-anesthetized NOD/SCID-γ mice (Jackson
Laboratories). Injected mixtures were allowed 15 minutes to polymerize before the
cessation of anesthesia. At 7 weeks post injection, masses were palpable in the flanks of
the animals; at 14 weeks, the teratomas were visualized in situ, excised with gross
margins and processed for histological examination.
Verification of Plasmid Functionality. To verify plasmid functionality, Ldlrdeficient CHO-a7 cells were first plated to confluence in a 48-well tissue culture dish.
Once confluent, CHO-a7 cells were transfected with a complex of plasmid and
Lipofectamine 2000 (Invitrogen) in a 1 µg : 1 µl ratio in Opti-MEM (Invitrogen) per
manufacturer instructions11. Cells were cultured overnight in standard culture conditions.
The following day, transfection media was removed and replaced with standard CHOculture media (described above). 24 hours later, selection for transfected CHO-a7 (CHOa7-LDLR) took place via exposure to 750 µg/ml Hygromycin B in CHO culture media.
Afterwards, cells were starved overnight in media comprised of DMEM-HG, 1X Lglutamine and 5% lipoprotein-deficient serum (Alfa Aesar). Starvation media was
augmented with 2 µM of Lovastatin (EMD Millipore), excess sterols (12 µg/ml
cholesterol and 0.6 µg/ml 25-hydroxysterol; Sigma-Aldrich), or ethanol (vehicle control;
Sigma-Aldrich)424. The following day, the starvation media was removed and replaced
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with 5 µg/ml DiI-LDL (Alfa Aesar) in DMEM-HG for 4.5 hours, after which the cells
were thoroughly washed with di-cationic PBS and imaged using an Olympus IX81
fluorescence microscope.
FH-iPSC Electroporation and Selection. We transfected FH-iPSC with the
corrective plasmid using both decayed-exponential and square-wave electroporation
modalities. For FH-iPSC used in decayed-exponential electroporation (conducted at 4˚C),
cells grown in feeder-free culture were pretreated with 10 µM of Y-27632 (EMD
Millipore) two hours prior to electroporation. The cells were treated with 1 mg/ml
Collagenase Type IV (Invitrogen) for 10 minutes, resuspended in DMEM/F12, and
counted. We utilized a minimum of 107 cells per electroporation. Cells were pelleted and
resuspended in 700 µl of ice-cold (4˚C) di-cationic PBS or ES-qualified electroporation
buffer (MEB; EMD Millipore). 100 µg of plasmid DNA (per 107 cells) was Q.S. to 50 µl
with electroporation buffer. Cell and plasmid solutions were combined; the resulting
750µl volume was added to a pre-chilled (4˚C) 4mm gap cuvette (BTX) and gently mixed
by flicking. Cells were electroporated using an ECM 630 Electro Cell Manipulator (BTX;
generously provided by Dr. Scott Whittemore, University of Louisville; see Table 4).
Electroporated cells were incubated on ice for 5 minutes and suspended in 10 ml
DMEM/F12 before pelleting. The pellet was resuspended in mTeSR1 with 10 µM Y27632 and plated into 3 Matrigel-coated wells of a 6-well tissue culture dish. For FHiPSC used in square wave electroporation (carried out at room temperature), cells were
pretreated with 10 µM Y-27632 2 hours prior to electroporation. The cells were harvested
via a 10-minute application of 1 mg/ml Collagenase Type IV and washed twice with
Opti-MEM. Cells were placed into microcentrifuge tubes at a ratio of 106:90 µl
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Table 4. Greyed rows indicate successful decayed-exponential and square-wave
electroporation parameters that yielded surviving, transfected FH-iPSC with pEHZLDLR-LDLR.
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OptiMEM. Plasmid DNA was maintained in a separate tube at 1 µg/µl in TE Buffer
(Ambion). Recipient 6-well tissue culture dishes were pre-loaded with mTeSR1 and 10
µM Y-27632 and kept at 37˚C. Prior to electroporation, 10 µl of plasmid was mixed with
90 µl of iPSC (total electroporation volume = 100 µl) and transferred to an
electroporation cuvette (NepaGene). The cuvette was gently flicked to ensure adequate
mixture. Cells were electroporated using a NEPA21 cell electroporator (NepaGene;
generously provided by Dr. Michal Hetman, University of Louisville; parameters are
outlined in Table 4). Transfected cells were directly transferred into each well of the 6well tissue culture recipient plate. For both conditions, after electroporation, cells were
cultured for 2 days in mTeSR1 before a 5-day selection with 10 µg/mL Hygromycin B
and subsequent maintenance in 0.5 to 1 µg/mL Hygromycin B, indicating successful
transfection. Media was changed daily.
Hepatocyte-Like Cell Production. FH-iPSC were plated to confluence in
Matrigel-pretreated wells of a 6-well tissue culture plate or 6 Permanox chamber slides
(Sigma-Aldrich). Each well of the 6-well plate (used for PCR analysis) and each
Permanox slide (used for immunocytochemistry) corresponded with one of the six stages
of differentiation (including Stage 0, which represented untreated iPSC). To generate
HLC, we used a modified version of the protocols and medias proposed by Song et al428.
In lieu of Song’s Stage 1 media, we utilized the StemDiff definitive endoderm kit (Stem
Cell Technologies) per the manufacturer’s instructions. Media changes were performed
daily and cells were characterized by the end of Stage 5.
Hepatocyte-Like Cell General Functional Assessment. Indocyanine green
(ICG; Sigma-Aldrich; 5 mg/ml in sterile water) was used to measure overall cell
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metabolic activity. ICG and Stage 5 media were mixed per manufacturer’s instructions
and applied to FH-HLC for 1 hour. FH-HLC were thoroughly washed with di-cationic
PBS to remove residual dye before being imaged on an Olympus IX81 microscope via
phase and bright field settings. FH-HLC were then incubated in Stage 5 media overnight
before assessment 24 hours later using the same microscope settings. An Oil-Red-O
assay was used to evaluate cell lipid accumulation. A different population of FH-HLC
was treated with Carnoy’s fixative for 2 minutes at RT before being washed with distilled
water. Working Oil-Red-O solution (Sigma-Aldrich) was prepared per the manufacturer’s
instructions and applied to FH-HLC for 30 minutes at RT. Cells were thoroughly washed
with distilled water and imaged on an Olympus IX81 microscope with phase and bright
field settings.
Imaging of Hepatocyte-Like Cell LDLR-Mediated Endocytosis. FH-HLC
derived from transfected FH-iPSC (FH-HLC-LDLR) were starved overnight in 5%
lipoprotein-deficient serum supplemented with 2 µM of Lovastatin, excess sterols (12
µg/ml cholesterol and 0.6 µg/ml 25-hydroxysterol), or ethanol (vehicle control). The
following day, the starvation media was replaced with 5 µg/mL DiI-LDL in DMEM-HG
for 4.5 hours. Cells were thoroughly washed with di-cationic PBS prior to imaging via an
Olympus IX81 fluorescence microscope.
Transfected Hepatocyte-Like Cell Qualitative Imaging. FH-HLC derived from
transfected FH-iPSC (FH-HLC-LDLR) were grown in 3 wells of a 12-well tissue culture
plate. Cells were starved overnight in 5% lipoprotein-deficient serum supplemented with
2 µM of Lovastatin, excess sterols (12 µg/ml cholesterol and 0.6 µg/ml 25hydroxysterol), or ethanol (vehicle control). The following day, starvation media was
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removed and replaced with 5 µg/mL DiI-LDL in DMEM high glucose for 4.5 hours.
Cells were thoroughly washed with di-cationic PBS prior to imaging via an Olympus
IX81 fluorescence microscope.
Hepatocyte-Like Cell In Vivo Assessment. Human SVF (hSVF) was grown to
confluence in vitro in a gelatin-coated T75 flask while FH-HLC were grown to
confluence through end of Stage 2. On the day of implantation, both hSVF and HLC
were prepared using 0.05% Trypsin-EDTA. Constructs were prepared using 106/ml HLC
± 106/ml of SVF in a master mixture of 3 mg/ml Collagen I (comprised of Rat Tail
Collagen I (BD Biosciences), 4X DMEM (Invitrogen; made from 10X powdered
concentrate), Sterile Water, and 0.1N NaOH (Ricca Chemical Company)). 250 µl of the
cellular mixture was pipetted into each well of a 48-well plate and maintained at 37˚C to
polymerize for 30 minutes. Afterwards, the constructs were immersed in a mixture of
50% Stage 2 HLC differentiation medium and 50% Human Complete hSVF culture
media (comprised of Medium 199 (Invitrogen), ECGS (derived in-house), HEPES, 1X Lglutamine (Invitrogen), and 10% heat-inactivated FBS (Thermo Fisher Scientific)).
Constructs were implanted in the subcutaneous dorsa of isoflurane-anesthetized Rag1-/- x
LDLR-/- double knockout mice (generously provided by Dr. Catherine Reardon-Alulis,
University of Chicago). Animals were sacrificed at 2 weeks, at which point the implanted
constructs were extricated and fixed in 4% PFA for 1h. Constructs were then
permeabilized in 0.5% Triton X-100 (MP Biomedicals) for 20m and blocked in 5% Goat
Serum (Invitrogen) for 1h. The explants were then incubated overnight in Albumin (MP
Biomedicals) and UEA-1 biotin (Vector Labs) at 1:200 in 5% Goat Serum at 4˚C. The
following day, the constructs were washed in di-cation-free PBS and exposed to Goat-
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anti-Rabbit 488 (Thermo Fisher Scientific; for Albumin) and Streptavidin-Cy5
(Invitrogen; for UEA-1 biotin) at 1:1000 for 1h. Constructs were labeled with DAPI at
1:10000 for 10 minutes prior to confocal fluorescence microscopy imaging. All animal
procedures were conducted in accordance with University of Louisville School of
Medicine IACUC regulations.
Plasmid Rescue and Restriction Digest. Plasmid rescue was performed on
transfected FH-iPSC-LDLR using methods described by Lufino and colleagues429. The
rescued plasmid was characterized using AgeI-HF restriction enzyme (New England
BioLabs) per manufacturer instructions. Restriction products were run on a 0.4% agarose
gel at 20 V for 16 hours. Gels were analyzed via a Typhoon 9400 variable mode imager
(GE Healthcare Bio-Sciences). After confirming plasmid isolation, the rescued plasmid
was also re-transfected into Ldlr-deficient CHO-a7 cells (generously provided by Prof.
Monty Krieger, Massachusetts Institute of Technology) via Lipofectamine 2000 to
demonstrate non-integration and preservation of plasmid functionality after rescue.
FH Mesenchymal Cell Generation and Culture. Mesenchymal cells were
generated as previously described425. FH-iPSC±LDLR were passaged onto Matrigelcoated plates using Gentle Cell Dissociation Buffer (Stem Cell Technologies) and
introduced to 100% mTeSR1 in a graded manner. One day after passaging, transfected
cultures received 1 µg/ml Hygromycin B to maintain selective pressure. Once confluent
and in 100% mTeSR1, the media was changed to EGM2-MV (Lonza) for 20 days for
differentiation into FH-MC. Once fully differentiated, FH-MC were passaged and used in
LDL internalization assays.
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Quantification of pEHZ-LDLR-LDLR Activity. FH-MC±LDLR were plated in
gelatin-coated wells of a 24-well tissue culture plate. We utilized an established
protocol430, but used fluorescent DiI-LDL (Alfa Aesar) in place of
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Iodinated-LDL.

Specific receptor-mediated internalization was determined by subtracting the
internalization of [DiI-LDL + 50-fold excess of unlabeled LDL (Alfa Aesar)] from the
internalization quantified with DiI-LDL alone. Cells were then lysed with 250 µl 0.1N
NaOH (Ricca Chemical Company). Fluorescence was quantified using a 96-well plate
reader (BioTek), with the excitation and emission set to 514 nm and 550 nm,
respectively. Fluorescence units were normalized to total protein content, which was
determined via a DC Protein Assay kit (Bio-Rad).
Polymerase Chain Reaction (PCR) and Gel Electrophoresis. Differentiating
FH-iPSC were lysed at the end of each stage using 350 µl of 0.1% β-mercaptoethanol in
RLT Buffer (Qiagen).

Lysates were purified using Qiashredder and RNeasy kits

(Qiagen) according to the manufacturer’s instructions. RNA was quantified using a
NanoDrop 1000 Spectrophotometer (generously provided by Ronald Gregg, University
of Louisville). cDNA was generated from purified RNA via a SuperScript II Reverse
Transcriptase kit (Invitrogen). 200 ng of stage-specific cDNA was added to 45 µl of PCR
SuperMix (Invitrogen) and 1µl each of 10µM forward and reverse primers (Integrated
DNA Technologies; primer sequences can be found in Table 5). PCR was performed for
25 cycles, with denaturation at 95˚C, annealing at 58˚C, and extension at 72˚C.
Amplicons were assessed via 3% agarose gels (Bio-Rad). 10 µl of amplicons were
combined with 2 µl of TrackIt™ Cyan/Yellow Loading Buffer (Invitrogen) and 2 µl of
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Gene Name

Primer Sequence
(5’ à 3’)

Size (bp)

POU5F1

Forward:
TGATCCTCGGACCTGGCTAA
Reverse:
AACCACACTCGGACCACATC
Forward:
CCGCGGTATATTACTGCAACTA
Reverse:
CACCCAGGACAACATTTCTTTG
Forward:
CCACGGGCAAACACTACGG
Reverse:
GGCAGGCTGCTGTCCTCAT
Forward:
GCTGACCTGGCTACCATATTT
Reverse:
GGGATGCCTTCTTGCTATCTC
Forward:
GGTGTTGATTGCCTTTGCTC
Reverse:
CCCTTCATCCCGAAGTTCAT
Forward:
TCTGCTGGACTGAGCTGGTT
Reverse:
GTGCACCAGGTCTGAGTGTT
Forward:
CTGTGGCATCCACGAAACTA
Reverse:
AGTACTTGCGCTCAGGAGGA
Forward:
AATCCCATCACCATCTTCC
Reverse:
CATCACGCCACAGTTTCC

744

SOX17

HNF4a

AFP

ALB

NANOG

β-ACTIN

GAPDH

Table 5. A listing of the primers used for RT-PCR.
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371

250

384

502

866

200

382

PrimerBLAST
Annealing
Temperature
Forward:
60.03˚C
Reverse:
59.97˚C
Forward:
58.1˚C
Reverse:
58.02˚C
Forward:
61.32˚C
Reverse:
62.34˚C
Forward:
57.8˚C
Reverse:
58.2˚C
Forward:
57.93˚C
Reverse:
57.28˚C
Forward:
61.12˚C
Reverse:
60.18˚C
Forward:
54.94˚C
Reverse:
58.03˚C
Forward:
54.14˚C
Reverse:
56.43˚C

SYBR Green 1 nucleic acid stain (Lonza). Gels were run at 70 V for 2.5 hours and
imaged via a Typhoon 9400 variable mode imager. Gel bands were plot profiled and
normalized to GAPDH via densitometry analysis with Image J software (US National
Institutes of Health).
Immunocytochemistry.

For

immunostaining,

cells

were

fixed

in

4%

paraformaldehyde (PFA; Electron Microscopy Sciences) for 15 minutes at RT and
washed with di-cation PBS. For intracellular iPSC staining, cells were permeabilized
with 0.1% Triton X-100 (Sigma-Aldrich) and 1% Polyvinylpyrrolidone (Sigma-Aldrich),
for iPSC analysis, in a PBS blocking solution containing 4% normal goat serum (SigmaAldrich). For extracellular staining, cells were blocked in di-cationic PBS containing 4%
goat serum. Primary antibody solutions (1:200; Table 6) were applied for 1 hour at RT
and washed cells with di-cation PBS. Secondary antibody solutions (1:500; Table 6)
were applied for 1 hour at RT. Cells were treated with ProLong® Gold Antifade Reagent
containing DAPI nuclear stain (Invitrogen). Images were taken using an Olympus IX81
fluorescence microscope using SlideBook Software (Intelligent Imaging Innovations,
Inc., Denver, CO). To assess FH-iPSC differentiation into FH-HLC, cells were fixed and
washed at the end of each stage as described above. After permeabilization with 0.5%
Triton X-100 for 10 minutes, cells were blocked with 5% goat serum for 1 hour before
being exposed to primary antibody overnight and secondary antibody the following day.
Histology. Explanted teratomas were fixed in paraffin (Leica Biosystems) and
sectioned via microtome. Sections were de-paraffinized with xylene (Thermo Fisher
Scientific) for 10 minutes and sequentially hydrated with decreasing proportions of
ethanol in 2-minute increments. Sections were then immersed in water and exposed to
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PRIMARY ANTIBODY (1:200)
OCT4
SOX2
SSEA4
TRA-1-60
StainAlive TRA-1-60 (DyLightTM 488)
TRA-1-81
βIII-TUBULIN
α – SMOOTH MUSCLE ACTIN
VIMENTIN

MANUFACTURER & LOCATION
R&D Systems, Minneapolis, MN
R&D Systems
Developmental Studies Hybridoma Bank,
Iowa City, IA
EMD Millipore, Billerica, MA
Stemgent, Cambridge, MA
EMD Millipore
Neuromics, Edina, MN
Santa Cruz Biotechnology, Dallas, TX
BD Bioscience, San Jose, CA

FLUOROPHORE (1:500)
Alexa Fluor® 405
Alexa Fluor® 594

MANUFACTURER & LOCATION
Invitrogen, Grand Island, NY
Invitrogen

TM

End-of-stage visual assessments
PRIMARY ANTIBODY (1:200)
OCT4
SOX17
GATA4
HNF3β
AFP (ZSA06)
Albumin

MANUFACTURER & LOCATION
Santa Cruz Biotechnology
R&D Systems
Santa Cruz Biotechnology
Santa Cruz Biotechnology
Invitrogen
MP Biomedicals, Santa Ana, CA

SECONDARY ANTIBODY (1:1000)
Goat anti-Mouse 488
Goat anti-Rabbit 488
Rabbit anti-Goat 594

MANUFACTURER & LOCATION
Thermo Scientific, Waltham, MA
Thermo Scientific
Invitrogen

Table 6. Primary antibodies were incubated at 1:200, Fluorophores at 1:500, and
secondary antibodies at 1:1000.
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Gill’s Hematoxylin (Leica Biosystems) for 10 minutes. Water was applied to the sections
for 1 minute; sections were then dipped once each in acid ethanol (comprised of 3 ml
37% HCl (Thermo Fisher Scientific) and 300 ml 70% EtOH) and water before 15
immersions in ammonia water (0.9 ml 30% Ammonium Hydroxide; Sigma Aldrich) and
exposure to running water for 20 minutes. Working Eosin (Leica Biosystems) was
applied to sections for 5 minutes before sequential dehydration with increasing
proportions of ethanol in 2-minute increments. After two more 2-minute immersions in
xylene, sections were mounted with coverslips and imaged via phase microscopy.
Statistical Analysis. Experiments were conducted in triplicate with replicated
data points per experiment. Values are presented as means ± S.E.M. Significance was
determined using a Student’s t-test. Treatment significance was verified by one-way
ANOVA using SigmaPlot (Systat Software).

RESULTS
FH-iPSC can be generated from FH fibroblasts. Skin fibroblasts from a patient
with clinically homozygous FH (Coriell Cell Repositories; #GM01355) were examined to
verify their inherent LDLR dysfunction using an LDL internalization assay (Figure 21).
After pretreatment with Lovastatin, excess free sterols, and ethanol (vehicle control) in
lipoprotein-deficient serum overnight, the cells were exposed to DiI-LDL the following
day and found to be impaired in their ability to internalize LDL when compared against
wild-type IMR90 fetal lung fibroblasts. Because concerns with iPSC generation include
(a) genomic integration of exogenous reprogramming factors and (b) unwanted
spontaneous transcriptional activation post genomic integration, we sought to utilize
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Figure 21. Upon receipt, source FH fibroblasts (GM03155) were compared to wild-type
IMR90 fetal lung fibroblasts to determine their ability to internalize fluorescent DiI-LDL
after pre-treatment with Lovastatin, excess free sterols, or ethanol (vehicle control) in
lipoprotein-deficient media. Reduced internalization of fluorescently labeled LDL
indicated a functional reduction in the capacity for receptor-mediated endocytosis.
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mRNA-based reprogramming technologies. FH patient fibroblasts were obtained from
Coriell Cell Repositories (#GM01355; Figure 22A) and transfected with synthetic
modified mRNA431 (modRNA) (encoding OCT4, SOX2, KLF4, cMYC and LIN28432).
Within 20 days of continuous transfection, the fibroblasts gradually attained a compacted
morphology broadly characteristic of iPSC, with a calculated reprogramming efficiency
of 0.012% (Figure 22B). Live-cell immunolabeling with the extracellular pluripotence
marker TRA-1-60 (Figure 22C) suggested successful iPSC reprogramming.
Over the next several days, we observed colonies that possessed increasingly defined
borders and cells with high nuclear-to-cytoplasmic ratios and prominent nucleoli. These
cell clusters were positive for the intracellular pluripotent markers OCT4 (Figure 22D)
and SOX2
(Figure 22E), which co-localized (Figure 22F), giving visual credence to the fact that
the source fibroblasts were fully reprogrammed into iPSC433. Additionally, the
extracellular surface pluripotent markers SSEA4 (Figure 22G), TRA-1-60 (Figure 22H),
and TRA-1-81 (Figure 22I) were also visualized. The expression of these intracellular
and extracellular pluripotent markers coupled with the aforementioned hPSC-specific
morphologic features suggested a successful development of FH patient-specific iPSC
from source fibroblasts. To further characterize their lineage and normality, FH
fibroblasts and FH-iPSC were subjected to karyotypic analysis (Figure 23) and DNA
fingerprinting (not shown), confirming genetic homology between the two cell
populations. This validated our production of autologous iPSC and ruled out any
experimentally induced genetic abnormalities or variations.
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Figure 22. (A) FH parent fibroblasts attained a compacted morphology characteristic of
(B) iPSC, which were positive for (C) the pluripotent marker TRA-1-60 during live
imaging. FH-iPSC were positive for (D) Oct4 and (E) Sox2, which (F) co-localized to the
cell nucleus. FH-iPSC were also positive for the pluripotence markers (G) SSEA4, (H)
TRA-1-60, and (I) TRA-1-81. Spontaneous in vitro differentiation yielded cells positive
for (J) β-III TUBULIN (ectoderm), (K) VIMENTIN (endoderm), and (L) α-Smooth
Muscle Actin (αSMA, mesoderm) (Scale bar = 10 µm). In vivo differentiation of
implanted FH-iPSC yielded teratomas positive for (M) ectoderm, (N) mesoderm, and (O)
endoderm.
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We next assessed FH-iPSC pluripotency by spontaneous differentiation in vitro and
teratoma formation in vivo. After 20 days of culture without supplemental bFGF, cells
expressed the extracellular markers β-III TUBULIN (ectoderm; Figure 22J),
VIMENTIN (endoderm; Figure 22K) and α-SMOOTH MUSCLE ACTIN (α-SMA;
mesoderm; Figure 22L). For in vivo testing, undifferentiated FH-iPSC were combined
with Matrigel and injected into the right subcutaneous dorsum of NOD/SCID-γnull
immunocompromised mice, while the left dorsum was injected with Matrigel alone as a
negative control. Injected FH-iPSC yielded teratomas with evidence of solid tissue
development and displayed a vasculature that anastomosed with that of the host.
Histologic assessment of the solid tissue showed clusters of neuroepithelial cells
(ectoderm; Figure 22M), regions of cartilage and immature bone formation (mesoderm;
Figure 22N), and organized ciliated columnar epithelium (endoderm; Figure 22O).
Expectedly, the Matrigel negative control yielded no teratomas (data not shown). This
data demonstrates the utility of transient, non-integrating mRNA reprogramming vector
systems in generating pluripotent, patient-specific iPSC. The FH-iPSC pluripotent
potential was assessed via in vitro spontaneous differentiation and in vivo teratoma
formation, with both assays demonstrating formation of the three germ layers (endoderm,
mesoderm, and ectoderm). Karyotyping (Figure 23) and DNA fingerprinting (not shown)
(a) revealed no reprogramming-attributed chromosomal abnormalities and (b)
demonstrated homology between the FH-iPSC and their source fibroblasts. These results
demonstrate that the GM01355 FH fibroblasts were successfully reprogrammed into
pluripotent FH-iPSC.
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Figure 23. (A) FH parent fibroblasts (GM01355) were tested to determine their
karyotype. (B) After reprogramming, FH-iPSC karyotype was also determined. The
karyotype of the starting population and reprogrammed daughter cells were both normal.
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FH-iPSC can differentiate towards a hepatic lineage. Since FH patients benefit
from a variety of interventions principally targeting hepatocytes, we wanted to determine
if FH-iPSC could differentiate towards a hepatic lineage using a modified version of an
established hepatic differentiation protocol that mimics developmental embryologic cues
(Figure 24A)428. At the end of each stage, we conducted RT-PCR (Figure 24B) and
immunocytochemistry (Figure 24C) to follow transcript and protein expression,
respectively, throughout the spectrum of HLC derivation. Being undifferentiated, the FHiPSC at Stage 0 expressed OCT4 transcripts and protein that rapidly decreased to
undetectable levels in the subsequent stages. In stages 1 and 2, marked cell- specification
into definitive endoderm and hepatic-defined lineages was evident from the nuclear
expression of SOX17, HNF3β/4α, and GATA4. Starting in Stage 2, cells were positive
for the hepatic markers Alpha-fetoprotein (AFP) and Albumin, which were initially
observed as cytoplasmic clumps before attaining a more uniform distribution by Stages 3
and 4. By the end of Stage 5, AFP and Albumin transcript and protein expression
predominated, indicating the generation of FH-HLC.
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Figure 24. (A) Phase microscopy demonstrates hepatocyte-like cell (HLC) morphology
at the end of the five-stage differentiation process (Scale bar = 500 µm). (B)
Representative gel electrophoresis image of PCR transcripts at the end of each
differentiation stage. GAPDH was used as a loading control. (C) Immunocytochemistry
at the end of each differentiation stage demonstrates a progressive shift in protein
expression towards a hepatic phenotype (Scale bars = 50 µm, *100 µm, and **200 µm;
images of varying magnifications were chosen for clarity). (D) Quantification of AFP
(blue)- and Albumin (red)-positive cells as a fraction of the total number of cells (DAPI),
shown for each differentiation stage as mean ± S.E.M.
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Semi-quantitative PCR densitometry conducted at the end of each stage depicted a
progressive change in gene expression, from pluripotence to markers associated with the
hepatic lineage (Figure 25). The number of cells expressing AFP and Albumin at each
stage was calculated as a percentage of all DAPI-labeled cells (Figure 24D; mean ±
S.E.M.). We noticed the following pattern of AFP expression over the course of the
differentiation – Stage 0: 0%, Stage 1: 0%, Stage 2: 24.74 ± 4.73%, Stage 3: 63.84 ±
13.25%, Stage 4: 81.83 ± 11.99%, and Stage 5: 75.71 ± 4.08%. We witnessed a similar
pattern of Albumin expression as well – Stage 0: 0%, Stage 1: 0%, Stage 2: 48.49 ±
3.31%, Stage 3: 55.3 ± 24.69%, Stage 4: 78.03 ± 14.92%, and Stage 5: 84.26 ± 5.73%.
Thus, with respect to differentiation efficiency, most of the cells were positive for the two
primary hepatic markers by the end of Stage 5 differentiation. During each round of FHHLC production, we noticed the presence of differentiating cells that took on an
increasingly granular, vacuolar appearance (especially present at Stage 3) that looked
lipid-like – an observation consistent with that of Fattahi and colleagues434. To determine
if these vacuoles were in fact accumulating lipids, we subjected the FH-HLC to Oil-RedO staining and subsequently confirmed the presence of numerous lipid droplets (Figure
26A), suggesting that these cells are not impaired in their ability to store lipids, but
perhaps only in their ability to bind and internalize LDL. This corresponds with what is
seen clinically, as FH patients often exhibit normal liver function tests435. To determine if
FH-HLC demonstrated any outward sign of maturation, the cells were treated with
Indocyanine green (ICG), a clinically relevant dye that is metabolized and cleared by
specific mature cell types including hepatocytes436. Though ICG was cleared, this
observation was a relatively rare event, suggesting that the
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Figure 25. Densitometry quantification of transcript expression was performed for each
gene at the end of the differentiation stages. Transcripts were normalized to the GAPDH
loading control (shown as mean ± S.E.M).
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Figure 26. (A) FH-HLC were stained with Oil-Red-O to visualize lipid accumulation
with phase and bright field (BF) microscopy. (B) FH-HLC cellular uptake (white arrows)
of Indocyanine Green (ICG) was imaged with BF microscopy after 1 hour of treatment.
The same site was also assessed for ICG clearance 24 hours later. (Scale bar = 200 µm).
(C) FH-HLC demonstrate survival and engraftment in vivo in Rag1-/- x LDLR-/- doubleKO mice when implanted with adipose-derived stromal and vascular support cells (white
arrows indicate network formation). FH-HLC without stromal support failed to survive
or express Albumin after the two-week implant period. (Scale bar = 50 µm).
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differentiation protocol yielded a predominantly immature hepatic population (Figure
26B). Still, these results indicate that FH-iPSC can differentiate down a hepatic lineage
into FH-HLC. We then asked if FH-HLC could engraft in vivo (Figure 26C). We
previously demonstrated the utility of adipose-derived stromal vascular fraction cells
(SVF) in providing vital stromal and vascular support437 to implanted parenchymal
hepatocytes within a liver-tissue mimic438. Consequently, we combined human SVF with
FH-HLC in collagen-I constructs and implanted them subcutaneously in Rag1-/- x LDLR/-

double-knockout mice for 2 weeks. We labeled the explanted constructs with Albumin-

488 and UEA-1-Cy5 (binds to human endothelium). Fluorescence confocal microscopy
showed that FH-HLC had engrafted and expressed Albumin in the presence of SVF,
whereas FH-HLC did not survive in the absence of SVF. Together, these findings suggest
that FH-iPSC can differentiate down a hepatic lineage and, given the proper stromal and
vascular support, survive and engraft in vivo.

Verification of pEHZ-LDLR-LDLR functionality. To verify the functionality of
pEHZ-LDLR-LDLR, we utilized CHO-a7, an Ldlr-deficient cell line424,439 (CHO-a7LDLR) (Figure 27). Transfected CHO-a7 were selected with Hygromycin-B then
compared against wild-type CHO (CHO-WT) and non-transfected CHO-a7 on the basis
of their ability to bind and internalize fluorescent DiI-LDL cholesterol. Each CHO-a7
was treated overnight with Lovastatin, excess free sterols, or ethanol (a vehicle control)
in lipoprotein-deficient serum. Lovastatin is an HMG-CoA reductase inhibitor that blocks
the rate-limiting step in cholesterol synthesis424,440. By impeding the cells’ endogenous
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Figure 27. Transfected CHO-a7-LDLR exhibited LDL internalization sensitive to
Lovastatin, excess sterols, or ethanol (vehicle control). This behavior paralleled that of
CHO-WT under the same media conditions, and both were in stark contrast to the lack of
LDL-C uptake seen in Ldlr-dysfunctional CHO-a7.
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production of LDL-C, Lovastatin facilitates exogenous cholesterol internalization via
surface up-regulation of the LDLR, allowing the cell to still meet its metabolic
requirements while having an overall therapeutic effect on serum cholesterol levels.
Excess free sterols are membrane permeable. Consequently, they can be internalized by
receptor-independent mechanisms that secondarily result in LDLR down-regulation441.
Under such conditions, CHO-WT showed an expected pattern of maximum DiI-LDL
internalization with Lovastatin treatment over the ethanol control, and almost complete
abrogation of DiI-LDL uptake when pre-treated with excess free sterols. In contrast,
CHO-a7 expectedly demonstrated virtually no DiI-LDL internalization regardless of the
treatment condition. The transfected CHO-a7-LDLR exhibited DiI-LDL internalization
that was appropriately sensitive to exogenous Lovastatin and demonstrated functional
restoration of LDL receptor-mediated endocytosis. Exposure to excess sterols yielded a
decrease in LDL-C internalization, while ethanol vehicle treatment yielded a slight
increase. This behavior parallels that seen in Ldlr-competent CHO-WT under the same
experimental conditions, validating the LDLR functionality and physiologic sensitivity of
the episomal plasmid.

FH-iPSC transfection with pEHZ-LDLR-LDLR. FH-iPSC retain the same
genetic dysfunction as their source patient fibroblasts and therefore offer limited
therapeutic value with regards to restoring LDLR-mediated endocytosis. Since
constitutive LDLR transgene expression for treating FH has not yet achieved a cure442,443
and may even be cytotoxic444,445 we elected to use the plasmid pEHZ-LDLR-LDLR to
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impart physiological responsiveness by 10kb of up-stream genomic control
sequences424,446,447.
We initially confirmed pEHZ-LDLR-LDLR physiological restoration of receptormediated endocytosis in the Ldlr-deficient cell line CHO-a7 (Figure 27)424,439. Because
of the plasmid’s large 31kb size, we utilized electroporation transfection448 and tested a
wide range of parameters using both decaying exponential and square-wave
electroporators (Table 4).
Using a BTX 630ECM decaying exponential electroporator with a 4mm
cuvette448, we found that settings achieving time constants (τ) between 16 and 18ms were
optimal for achieving iPSC survival and transfection. Smaller τ were associated with
increased iPSC survival but inadequate plasmid delivery, while τ greater than 18ms
resulted in cell death. We also tested the effects of temperature and buffer on
electroporation success. For the conditions tested, pre-chilling all components was
critical. Moreover, we found no difference with using either phosphate-buffered saline
(PBS) or a commercially available electroporation buffer.
We then tested the NEPA21 square-wave electroporator using a range of parameters
for plasmid delivery to human pluripotent stem cells. From the range of settings tested, a
voltage of 300V and pulse length time of 0.5ms facilitated iPSC survival and successful
delivery of the 31kb plasmid. We then conducted all square-wave electroporations at
room temperature in Opti-MEM media. 48 hours after electroporation, Hygromycin-B
selection was initiated at 10µg/ml for at least 5 days, followed by 0.5-1µg/ml thereafter as
a maintenance dose.
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pEHZ-LDLR-LDLR retention and functional restoration. pEHZ-LDLR-LDLR is
stably maintained as an episome and does not integrate into the host genome424. After
culturing FH-iPSC-LDLR under continuous Hygromycin-B selection429 for over 6
months, we subjected the cells to alkaline lysis and recovered the plasmid via ethanol
precipitation. The isolated plasmid was purified and digested with the restriction enzyme
AgeI, yielding two appropriately sized fragments measuring 18.6kb and 12.1kb (Figure
28Ai). We then validated the functionality of the recovered plasmid by transfecting it into
Ldlr-deficient CHO-a7 (CHO-a7-LDLR; Figure 28Aii). The recovered plasmid restored
the physiological feedback control of LDLR-mediated endocytosis in the CHO-a7LDLR. These findings collectively demonstrate that (a) pEHZ-LDLR-LDLR is retained as
an episome in human iPSC and (b) its function is independent of genomic integration.
We next wanted to determine if pEHZ-LDLR-LDLR had an effect on the inherent
pluripotence of our FH-iPSC. Therefore, we assessed expression of TRA-1-60 on
transfected cells cultured for over a year under Hygromycin-B antibiotic selection
pressure. Like their non-transfected FH-iPSC counterparts (Figure 22C), FH-iPSCLDLR retained a robust expression of TRA-1-60 (Figure 28Bi). Expression of NANOG
in FH-iPSC±LDLR was also confirmed by PCR (Figure 28Bii). These results suggest
that transfection with the episomal plasmid pEHZ-LDLR-LDLR does not diminish iPSC
pluripotence.
To determine if FH-iPSC-LDLR derivatives also retained the plasmid and displayed
functional restoration of LDLR-mediated endocytosis, we differentiated FH-iPSC±LDLR
into FH-HLC±LDLR. The derived HLC were cultured with Lovastatin, excess free
sterols, or ethanol vehicle control overnight in lipoprotein-deficient media prior to
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Figure 28. (A.i) pEHZ-LDLR-LDLR episome was recovered from FH-iPSC-LDLR and
cleaves into expected fragment sizes after digestion by AgeI-HF restriction enzyme. (A.ii)
Recovered plasmid transfected into Ldlr-deficient CHO-a7 demonstrates restored
physiologic receptor-mediated endocytosis via DiI-LDL internalization. (B.i) FH-iPSCLDLR colonies cultured for over 12 months still exhibit iPSC-characteristic well-defined
borders and express TRA-1-60-488 via live-labeling (Scale bar = 100 µm). (B.ii)
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Pluripotence of long-term cultured FH-iPSC±LDLR was verified by PCR, which
demonstrated NANOG expression. β-actin was used as a loading control. (C) FH-HLCLDLR displayed differential physiologic sensitivity, with highest DiI-LDL internalization
with exposure to Lovastatin and almost complete internalization abrogation with
exposure to excess sterols. Little internalization of DiI-LDL was detected in FH-HLC.
Ethanol was used as a vehicle control (Scale bar = 200 µm).
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incubation with DiI-LDL (Figure 28C). The FH-HLC demonstrated little internalization
of DiI-LDL, indicating that without any transgene intervention, LDLR-mediated
endocytosis of LDL remained dysfunctional. However, FH-HLC-LDLR exhibited
markedly elevated LDL endocytosis that demonstrated the same physiological sensitivity
to peripherally applied statin, sterols, or vehicle control as seen with the CHO-a7-LDLR
(Figure 27). These findings indicate that pEHZ-LDLR-LDLR effectively restores
physiological feedback control of LDLR activity in FH-iPSC derivatives.

Restored receptor-mediated LDL endocytosis quantification. To facilitate the
quantification

of

pEHZ-LDLR-LDLR-driven

specific

LDL

internalization,

we

differentiated FH-iPSC±LDLR into mesenchymal cells (FH-MC±LDLR; Figure 29A)
utilizing an established protocol from our lab425. These cells grow in a monolayer and are
contact-inhibited, allowing quantification of specific LDL receptor-mediated endocytosis.
FH-MC and FH-MC-LDLR were cultured in lipoprotein-deficient serum media
supplemented with Lovastatin, excess sterols or ethanol control before exposure to DiILDL (Figure 29B). The ethanol control yielded appreciable, though not significant (p =
0.27), differences in internalization between the two groups (FH-MC: 188.57 ± 74.33 vs.
FH-MC-LDLR: 438.82 ± 180.57 fluorescence units/mg protein (FU/mg); mean ± SEM)
reflecting the cellular lipid requirement due to the lipoprotein-deficient media
environment. This difference was amplified when the cells were exposed to the additional
stimulus of Lovastatin. Transgene-expressing cells displayed a statistically significant
increase (p = 0.035) in specific internalization versus their non-transfected counterparts
(FH-MC: 321 ± 61.7 FU/mg vs. FH-MC-LDLR: 526.15 ± 21.18 FU/mg). As expected,
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Figure 29. (A) Phase microscopy image of transfected FH-iPSC-derived mesenchymal
cells (FH-MC±LDLR) (Scale bar = 500 µm) depicts a fibroblastic monolayer suitable for
quantification studies. (B) Quantification of specific DiI-LDL internalization by FH-MC
displayed impaired LDL internalization. Transfected FH-MC-LDLR demonstrated
significantly greater ability to internalize DiI-LDL. Bars are depicted as means ± S.E.M.,
and these graphs characterize experiments conducted in triplicate (*,v = p < 0.05 and

vvv = p < 0.001; * = significance between cell types and similar treatments, while v
= significance within a cell type).
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free sterols suppressed DiI-LDL internalization to a statistically equivalent level
regardless of transgene presence (FH-MC: 56.90 ± 25.93 vs. FH-MC-LDLR: 99.15 ±
5.80 FU/mg, p = 0.19) since free sterol internalization is receptor independent449. Within
the transfected FH-MC-LDLR population, the suppression elicited by free sterols was
extremely significant when compared to Lovastatin (p = 0.00004) and significant with
regards to the ethanol control (p = 0.02). Presenting these differences another way,
transfected FH-MC-LDLR demonstrated 1.63- and 2.33-fold increases in specific DiILDL internalization over FH-MC in the presence of Lovastatin and ethanol, respectively.
These findings suggest that the pEHZ-LDLR-LDLR plasmid functionally restores LDL
receptor-mediated endocytosis without direct genetic manipulation in FH-iPSC-derived
progeny.

DISCUSSION
Familial Hypercholesterolemia (FH) is a heritable disease of LDL receptor (LDLR)
dysfunction. While the only known cure for FH is liver transplant, unfortunately, the
availability of donor livers pales in comparison to a high demand. Furthermore, there are
long-term issues to consider with transplant, such as compatibility, cost, quality-of-life,
and possibly death. Because the availability of quality hepatocytes is a key issue, induced
pluripotent stem cells (iPSC) presented us with a means of generating a sufficient
quantity of cells that we could then differentiate into hepatocyte-like cells (HLC). In
addition to developing a large quantity of cells, iPSC have the added benefit of being
obtained in an autologous manner, potentially mitigating issues with rejection and
obviating the need for immunosuppressive agents. However, a key hurdle with this
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approach is that if we were to use FH patient-derived iPSC (FH-iPSC), these cells and
their derivatives would contain the same LDLR dysfunction as their parent cells, and
would therefore provide little to no therapeutic benefit.
Thus, we developed a proof-of-concept strategy that carries broad implications for
generating and functionally restoring genetically deficient iPSC. To do so, we utilized a
transient reprogramming vector as well as non-viral, episomal vectors that confer
genomic LDLR transgene control. Based on these methods, we made the following
significant findings:
(a) An episomal, transgene plasmid can be maintained extra-chromosomally within
iPSC.
(b) This plasmid does not impair the pluripotency of iPSC.
(c) Genomic control of plasmid LDLR transgene expression restores physiologic
functionality to genetically deficient cells.
We used synthetic transient RNA (i.e., modRNA) to reprogram FH-fibroblasts into
FH-iPSC. Our relatively low reprogramming efficiency with modRNA was considerably
lower than published figures (approaching 2%234). This efficiency could result from the
LDLR genetic deficiency of our cells, though several other reports describing FH-iPSC
generation with viral vectors fail to mention reprogramming efficiencies89,270,450.
Therefore, our efficiency of 0.016% could potentially be attributed to experimental
variation. Furthermore, as iPSC are highly proliferative, overall efficiency is not a
significant concern since, theoretically, only one iPS cell is required to generate a whole
colony of cells.
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Approaches to genetically correct the LDLR deficiency in FH via gene therapies
have traditionally utilized viral vectors127,451-453. As an example, some have used the
portal vein to dispense infectious viral particles directly to the liver. In animals, two
distinct outcomes were observed:
(1) Circulating LDL cholesterol levels were significantly, but transiently, reduced451.
(2) LDL cholesterol levels did not reach targeted goals due to potential plasmid
loss454, immune detection of transduced cells453, inactivation of the LDLR
transgene455, or a suboptimal transduction of host hepatocytes451,452.
Viral vectors such as adenoviruses or retroviruses have insert capacities typically
less than 10kb. Because of this relatively small size, the options for controlling transgene
expression are limited456. For instance, the use of Cytomegalovirus (CMV) or Rous
Sarcoma Virus (RSV) promoters to control LDLR transgene expression led to excessive
lipid internalization, causing cell death130,131. Lipid accumulation was observed in the
livers of Watanabe heritable hyperlipidemia (WHHL) rabbits given a CMV-driven LDLR
in E1-deleted adenovirus457. To contrast, recent reports have described the use of
hepatocyte-specific promoters, such as thyroid-binding globiulin or alpha-1 anti-trypsin
(A1AT), to constitutively drive LDLR transgene expression. In these instances, cytotoxic
lipid accumulations were not seen127,451. Therefore, hepatocyte-specific promoters may
ultimately protect against lipid accumulation, though their mechanism of action has not
been specified458. However, given that functional LDL receptors are physiologically
regulated via a feedback loop, the constitutive expression of LDLR may have long-term,
detrimental consequences.
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Alternatively, episomal plasmids containing genomic DNA expression control
sequences can be used to address the LDLR deficiency in FH. These genomic sequences
can confer precise physiological control of the LDLR transgene while enhancing longterm LDLR expression459. We utilized the episomal plasmid pEHZ-LDLR-LDLR, which
contains the EBV retention and replication sequences EBNA1 and oriP. These sequences
allow pEHZ-LDLR-LDLR to be maintained as an episome6. The EBNA1 trans regulatory
protein, in particular, is unique for two reasons. First, it is the only EBV protein required
for retained episomal function460. Second, unlike the other EBV proteins, EBNA1 is not
immunogenic461. Thus, host immune response to the plasmid is mitigated.
The expression of the LDLR is tightly controlled by an endogenous feedback
loop462. Cells regulate surface LDLR expression based on circulating LDL levels and
membrane cholesterol content462. Prior studies demonstrate that pEHZ-LDLR-LDLR
reestablished receptor-mediated endocytosis in FH fibroblasts and persisted long-term in
non-dividing hepatocytes in vivo6, although the transfection efficiency was unclear. In
our application, pEHZ-LDLR-LDLR restored physiologically sensitive receptor-mediated
endocytosis in FH-iPSC. Additionally, this function was retained in various FH-iPSCderived progeny.
To our knowledge, this is the first report demonstrating the delivery and stable
transfection of a relatively large (38kb) episomal plasmid into human iPSC using
electroporation. Though we could have transfected the source FH fibroblasts prior to
reprogramming, the effect of a large 31-kb plasmid on reprogramming is unknown, as is
the viability of the plasmid in the long term. Transfection of FH-iPSC-derived cells was
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also an option. However, these cells would still require long-term antibiotic selection,
which is problematic with hepatocytes considering that they culture poorly423.
Electroporation provided us with another alternative transfection modality. Because
others successfully delivered plasmids to hPSC using electroporation463,464, we sought to
do the same with FH-iPSC. Electroporation generally presents several challenges. There
are several parameters reported in the literature, many of which depend on buffers
utilized, temperature, cuvette size, and even the type of machine used. For instance,
decayed-exponential electroporation has been shown to be effective for prokaryote
transfection, while square-wave electroporation is typically used for transfection of
mammalian cells465. We used both decayed-exponential and square-wave electroporation,
and produced viable, transfected FH-iPSC (FH-iPSC-LDLR) that were resistant to
Hygromycin B selection. Though we observed relatively low transfection efficiencies,
this phenomenon may be attributable to the sensitivity of pluripotent stem cells, which
are difficult to transfect465, the large size of the plasmid, and the physical and chemical
stresses of electroporation459. Further, it has been shown that the EBV plasmid
transfection event partly destabilizes mechanisms of replication in the days following
transfection taking about two weeks to achieve stability466. Though we were unable to
precisely quantify transfection efficiency, an advantage of utilizing pluripotent stem cells
is that even with low efficiency, a potentially unlimited number of transfected cells can
be generated. Furthermore, if a sufficient quantity of cells carrying the genomic DNAcontrolled transgene could be delivered, then host homeostatic control of LDL
metabolism could be restored without the need for constitutive LDLR expression.
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Another issue to address with our approach is plasmid retention, a common problem
seen with using episomal viral vectors for direct gene therapy to the liver467. EBV-based
plasmids replicate once per cell cycle460 and, without antibiotic selection, are lost at a rate
of 2 to 5% per cell division446. Therefore, using iPSC as a therapeutic cell source may
require continuous selection until a stable phenotype (such as hepatocytes) can be
derived. To that end, two approaches could be used to achieve this goal: (a) differentiate
FH-iPSC-LDLR in vitro with antibiotic selection until a minimally proliferative state is
reached prior to implantation, or (b) generate a liver-tissue mimic with stromal and
vascular support that facilitates selection and phenotype stabilization prior to
implantation.
Secondly, it is important to recognize that our strategy represents a functional, and
not a genetic, correction and does not impede expression of the endogenous defective
LDLR. There is potential for dysfunctional endogenous LDLR to interfere with the
function of the corrected exogenous gene product. As most FH patients do not know
exactly what their genetic dysfunction is and since there are over 1200 reported LDLR
mutations affecting function57, it will be necessary to determine if specific mutations or
classes of mutations prevent phenotype recovery by pEHZ-LDLR-LDLR. Though
clinically classified as “homozygote” (GM01355; the source patient exhibited a
maximum LDL of 700mg/dl and presented with xanthomas), the FH cells used here
demonstrated some LDLR activity and responsiveness to Lovastatin, suggesting that the
patient may actually be a compound heterozygote468,469. Transfected cells showed an
approximate 2-fold increase in DiI-LDL internalization and no inhibitory effect from the
defective endogenous LDLR was detected468. This 2-fold increase in internalization is
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potentially significant for three reasons: first, it demonstrates that internalization is being
effected by the exogenous gene product and not just stimulation of the endogenous
LDLR468. Second, it coincides with the observation that LDL-C internalization is LDLR
allelic in a gene-dose dependent manner462 and third, it demonstrates physiological
control as having an upper limit130. The internalization data normalized to the ethanol
control suggests a pattern of normal feedback regulation462. Put another way, though the
non-transfected cells have a reduced capacity for LDL-C internalization, they display an
expected physiological responsiveness paralleled by the transfected cells. The long-term
viability of a cell-based therapy for FH may hinge on preventing excessive LDL-C
uptake by any one cell.
Though our approach specifically targets the LDLR dysfunction in FH, a strategy
using episomes with genomic control of transgenes can be tailored to other biological
conditions or clinical deficiency with potential for amelioration by iPSC intervention,
further enhancing its clinical potential in tissue engineering applications.
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CHAPTER VI
SUMMARY AND CONCLUSIONS

Each hepatocyte is capable of carrying out over 500 metabolic processes, making
the liver one of the key metabolic regulatory organs in the body
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. Therefore, it is not

surprising that liver dysfunction can be detrimental to various systemic processes,
inducing cardiovascular disease to neurological diseases, to even multi-organ failure and
death. In several pathologies, liver transplant remains the only curative option, though the
availability of high-quality, compatible organs for transplant is impeded by a severely
restricted supply. Recent research emphases now include tissue-engineered solutions that
aim to assist or replace ailing liver organs.
In this project, we used the heritable disease Familial Hypercholesterolemia (FH)
as a model for which we could develop a functional liver-tissue mimic device. Over the
span of this dissertation project, we accomplished three goals. First, we were the first to
develop a proof-of-concept liver tissue mimic device by combining HepG2 model
hepatocyte cells with parenchymal support provided by adipose-derived stromal vascular
fraction (SVF) cells. This liver-tissue mimic was able to engraft with the host vasculature
and clear peripherally injected, circulating LDL cholesterol9.
Second, one of the chief problems with liver transplantation (in addition to the
inadequate supply of quality hepatocytes), and transplantation in general, is donor-host
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compatibility. To this end, we tailored our liver-tissue mimic device to FH patients by (a)
using patient cells to develop induced pluripotent stem cells (iPSC), potentially
mitigating issues with parenchymal supply; (b) functionally correcting the LDL receptor
(LDL-R) deficiency in patient-derived iPSC, allowing patient-derived cells to be restored
in their LDL-R functionality; (c) differentiating corrected iPSC into hepatocyte-like cells
(HLC), as hepatocytes traditionally express the highest levels of LDL-R in the body; and
(d) promoting the engraftment of HLC in vivo by using SVF, since hepatocytes require
vascular support for survival and function. Most importantly, functionalized HLC were
able to internalize peripheral LDL, unlike their genetically deficient counterparts, which
retain the LDL-R dysfunction. Here, we were the first to use entirely non-viral, nonintegrating modalities for generating and functionally correcting these cells, potentially
mitigating adverse future outcomes associated with viral-vector usage1. Moreover, with
further development, functionalized HLC could serve as a bridge-to-transplantation or
mitigate transplantation entirely, since FH patients exhibit otherwise entirely normal liver
function.
Third, the vasculature is essential to liver-tissue mimic functionality. In our proofof-concept liver-tissue mimic, we observed that 3D constructs with HepG2 model
hepatocytes lacking SVF were unable to internalize circulating LDL cholesterol. In our
FH-specific iPSC-derived liver-tissue mimic, 3D HLC constructs lacking SVF support
expressed significantly less albumin, suggesting that the HLC were either less functional
(i.e., albumin output was reduced) or did not survive. Thus, both of these findings
suggest that SVF is essential for parenchymal cell functionality, phenotype maintenance,
and likely even survival. Thus, we wished to examine the means by which SVF

165

spontaneously assembled into a functional vasculature, allowing it to critically support
metabolically active cells such as hepatocytes. Here, we were the first to show that the
Wnt signaling pathway is broadly implicated in hSVF endothelial cell (EC) vascular
networking, and that the Wnt5a isoform in particular acts to modulate the assembly, not
complexity, of hSVF vascular networks.
These efforts have resulted in a methodology that can be used to create organtissue autologous, iPSC-derived parenchyma supported by adipose-derived SVF. We also
have the means to correct inherent genetic deficiency to restore functionality to these
cells, such that these organ-tissue mimics impart a therapeutic value. Because SVF is
critical to the ultimate functionality of these constructs (i.e., to produce a lasting,
functional tissue-engineered device), our discovery of one regulatory mechanism in SVF
vascular assembly provides us with a means of modulating the vasculature to meet
different needs. Obviously, other mechanistic components are of interest, and will be
discussed in greater detail later on.
With respect to future efforts, it is academically reassuring to see that our findings
raise more questions than they have answered. Several issues to examine revolve around
our generation of a liver-tissue mimic. One topic of interest is the intricate, intimate
relationship between normal liver hepatocytes and the sinusoidal vasculature within the
liver. The liver vasculature not only promotes hepatocyte survival, but also plays a
critical role in the exchange between systemic circulation and hepatocytes. Normal
hepatocytes modulate their microenvironment to promote liver sinusoidal endothelial cell
network formation, facilitating vital bulk transport. Our findings suggest that implanted
hepatocytes also influence their microenvironment as demonstrated by their intimate
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interaction with adipose-derived SVF – an interaction that was seen in 3D constructs
using either HepG2 or iPSC-derived HLC. Thus, one logical question is how do
hepatocytes recruit an adipose SVF-derived vasculature? To this end, we could
investigate the patterns in vascular assembly of SVF in isolation compared to SVF in
direct or indirect contact with hepatocytes. Several assays (such as PCR, western blot,
ELISA, as well as proteomics to name a few) would allow us to identify the proteins that
mediate this interaction.
From this, a second topic to investigate would be the adaptation of the vasculature
towards a hepatic phenotype. As mentioned in the background, embryologic development
of the liver is actually made possible through intimate interactions with the cardiac
mesoderm as well as the septum transversum mesenchyme. In this process, angioblasts
(precursors to the liver sinusoids) are interspersed amongst cords of hepatoblasts (the
precursors to hepatocytes and cholangiocytes). Thus, these two precursors are in close
interaction throughout the liver’s development. Since HLC are regarded to be immature
(they express a significant proportion of AFP even by the end of directed differentiation),
their combination with SVF may ultimately form a vasculature that represents a
sinusoidal, fenestrated system as opposed to a vascular system comprised of tight
junctions and a continuous basement membrane. Here, we could look for liver sinusoidal
endothelial cell (LSEC) markers (such as LYVE-1 or SE-1, for example) as well as use
various microscopy techniques to identify a sinusoidal ultrastructure.
A third issue lies with the development of the HLC themselves. In this regard, we
have just stated that the HLC are, to a degree, immature. The presence of AFP and
Albumin (in terms of gene and protein expression) suggests that our directed
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differentiation protocols do not yield a population of cells that are uniform in their
maturity. Thus, one question that stems from this is: do HLC need to be mature to impart
a functional, therapeutic effect? Related to this, in the context of FH, it would be
interesting to see if immature and mature HLC express LDL-R to varying degrees, or
experience differences in LDL-R-mediated uptake and metabolism of LDL cholesterol.
To this end, we have shown that HLC can perform this task, but have yet to demonstrate
differences with respect to functional primary hepatocytes. Furthermore, if mature cells
were desired over immature cells, would having HLC interspersed with SVF cells in 2D
or 3D environments accelerate their maturity?
With regards to the vasculature, an issue requiring further examination is Wnt5a’s
role in SVF vascular assembly. For instance, with Wnt5a, we are still unaware of
precisely which cells endogenously produce this ligand. Our data indicates that Wnt5a is
common in hSVF cultures. As previously discussed, hSVF represents a heterogeneous
cell population that includes endothelial cells, smooth muscle cells, fibroblasts,
macrophages, pericytes, and various types of stem cells. Others have suggested that
Wnt5a from macrophages, pericytes, or endothelial cells plays a role in modulating
angiogenesis, but many of these efforts combine pure endothelial populations with
transformed or immortalized stromal support cells. Our findings provide a basis for
further investigation in heterogeneous populations such as SVF, but to date, the
mechanisms by which SVF self-assembles still remains to be fully elucidated. Though
our initial experiments with SVF show varying proportions of endothelial, perivascular,
and stem cell populations between fresh and cultured SVF isolates, we could isolate EC
alone using flow cytometry or MACS and see if these cells form networks of similar
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complexity as those seen in full, heterogeneous populations. In a reductionist approach,
we could then supplement FACS- or MACS-isolated SVF subpopulations to attempt to
restore the extent of vascular self-assembly seen with the complete isolation. In all of
these experiments, Wnt5a expression at the gene and protein level could be assessed to
determine (a) which cells express the genes for Wnt5a production and/or (b) if Wnt5a
production requires two or more cells to communicate with one another. From (b), the
modality of communication (juxtacrine or paracrine) could also be determined.
Our work also suggests a potential signaling axis via the prominent expression of
the Wnt5a receptor Frizzled-4 (Fzd4). However, we do not yet know if the binding of
Wnt5a to Fzd4 is precisely what drives changes in SVF vascular complexity. One simple
experiment to establish the role of Fzd4 in this phenomenon would be to use a Fzd4
blocking peptide or to knockdown Fzd4 expression via RNA interference. We could then
determine if the resulting vascular phenotype is comparable to that seen when Wnt5a
neutralizing antibody was utilized. If the resulting vasculature were the same phenotype
as untreated cultures, this would indicate that Fzd4 signaling may not play a role in
vascular patterning. If a completely different vascular assembly outcome were seen,
different from the outcomes seen with untreated and Anti-Wnt5a-treated cultures, this
finding would provide us with yet another mechanistic axis to pursue later on. Further, in
this scenario, it is possible that this axis may involve other Wnt isoforms, as Fzd4 can
also bind Wnt4470 as well as Norrin (a protein associated with retinal vascular
development)471. Since our experimental data showed that FZD4 was expressed in hSVF
cultures, one hypothesis could be that Wnt5a binding of Fzd4 initiates a signaling cascade
that leads to the modulation of hSVF vascular self-assembly. To this end, we could

169

examine the expression of downstream markers from Wnt5a-Fzd4 binding. For example,
Umbhauer and colleagues demonstrated that Wnt5a-Fzd4 signaling activates ß-catenin472.
Another downstream product of Fzd4 signaling (not yet shown with Wnt5a as the ligand)
is Protein Kinase C473. These downstream markers could be used to verify upstream
activity, such as the addition or removal of the Wnt5a ligand or receptor.
Lastly, our results indicate that adding rhWnt5a to cultures devoid of other Wnt
isoforms, stimulates an increase in EC sheeting. This level of sheeting was absent in
cultures not treated with the Wnt release inhibitor IWP2. One possibility here is that other
Wnt isoforms work with Wnt5a to promote hierarchy, branching, and overall
organization and complexity. Wnt5a is but one mediator. Furthermore, the blockage of
Wnt5a via a neutralizing antibody does not completely abrogate network formation,
though this antibody may not completely block the activity of Wnt5a. Blockade of all
Wnt isoforms via IWP2 produced a greater decrease in vascular network formation as
opposed to blockade of just Wnt5a, though Wnt5a does play a significant role in this
process. These observations further suggest that Wnt5a modulates vascular networking
(Figure 30) along with other Wnt isoforms, or that Wnt5a affects the vascular complexity
but other (non-Wnt) factors (such as VEGF, PDGF-B, etc.) mediate vascular selfassembly. Future research efforts will likely uncover a constellation of Wnt isoforms and
related molecules (such as Norrin, as an example) that participate in SVF self-assembly.
Broadly speaking, we have established the methods for a complex solution. In
addition to demonstrating that SVF-derived vasculatures support the engraftment and
functionality of implanted hepatocytes, we provide a platform for the engraftment of
other parenchymal cell types. In addition to showing that Wnt5a mediates SVF vascular
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Figure 30. We have demonstrated that Wnt5a modulates hSVF EC self-assembly into
vascular networks. However, there are several unknowns: (1) Which cells release
Wnt5a? (2) Which receptor(s) is required? (3) Where is this receptor located? (We
hypothesize that the Wnt5a receptor that has a role in mediating self-assembly is found
on endothelial cells, as shown above). (4) Does Wnt5a modulate extravascular activity,
such as connective tissue phenotype? These are just a few examples of future research
avenues to consider.

171

self-assembly, we also suggest that Wnt5a can be a target for manipulating derived
vasculatures. And with respect to our final aim, in addition to generating and functionally
restoring the LDL-R activity of autologous FH-iPSC, we provide a general platform for
the use of non-viral, non-integrating modalities. Our efforts also provide a platform to
generate tissue mimics for a variety of therapies. SVF cells could be utilized for vascular
support, while iPSC-derived parenchyma could be generated and genetically
manipulated. Lastly, we provide a strategy for gene therapy for any derived cell type,
since iPSC can theoretically generate all cell types and can be obtained autologously. In
sum, the data presented in this dissertation provides us with the necessary components for
the generation and testing of a functional, therapeutic, autologous liver-tissue mimic.
In several of these cases, we would be afforded the opportunity not only to study
the functionalization of various components of a liver-tissue mimic, but also the
mechanisms behind how these components interact with one another. Such a mimic
would potentially allow us to better understand how native liver processes take place
without having to rely on primary cell isolation. This would also facilitate the
development and screening of various therapeutic agents. Not only would these
investigations provide us with further insight into how a tissue-engineered liver-tissue
mimic might function in a therapeutic, translational capacity, but it would lay the
groundwork for the rapid development and modulation of other organ-tissue mimics as
well. This could have a profound impact on traditionally challenged medical fields such
as transplantation.

172

REFERENCES

1

Ramakrishnan, V. M. et al. Restoration of Physiologically Responsive LowDensity Lipoprotein Receptor-Mediated Endocytosis in Genetically Deficient
Induced Pluripotent Stem Cells. Sci Rep 5, 13231, doi:10.1038/srep13231 (2015).

2

Al-Allaf, F. A. et al. LDLR-Gene therapy for familial hypercholesterolaemia:
problems, progress, and perspectives. Int Arch Med 3, 36, doi:10.1186/17557682-3-36 (2010).

3

Grossman, M. R., SE; Kozarsky, K; Stein, EA; Engelhardt, JF; Muller, D; Lupien,
PJ; Wilson, JM. Successful ex vivo gene therapy directed to liver in a patient with
familial hypercholesterolemia. Nature genetics 6, 335-341 (1994).

4

Yamanaka,

S.

A

fresh

look

at

iPS

cells.

Cell

137,

13-17,

doi:10.1016/j.cell.2009.03.034 (2009).
5

SoRelle, R. Human Gene Therapy: Science Under Fire. Circulation 101, e90239024 (2000).

6

Hibbitt, O. C. et al. Long-term physiologically regulated expression of the lowdensity lipoprotein receptor in vivo using genomic DNA mini-gene constructs.
Mol Ther 18, 317-326, doi:10.1038/mt.2009.249 (2010).

173

7

Tabas, I. Consequences of cellular cholesterol accumulation: basic concepts and
physiological implications. Journal of Clinical Investigation 110, 905-911,
doi:10.1172/jci200216452 (2002).

8

Chen, A. A. et al. Humanized mice with ectopic artificial liver tissues. Proc Natl
Acad

Sci

USA

108,

11842-11847,

doi:10.1073/pnas.1101791108/-

/DCSupplemental (2011).
9

Nunes, S. S. et al. Generation of a functional liver tissue mimic using adipose
stromal vascular fraction cell-derived vasculatures. Sci Rep 3, 2141,
doi:10.1038/srep02141 (2013).

10

Berg, J. M., Tymoczko, J. L., Gatto Jr., G. J. & Stryer, L. Biochemistry 8th
Edition. (Freeman & Company, W. H., 2015).

11

Trapani, L., Segatto, M. & Pallottini, V. Regulation and deregulation of
cholesterol homeostasis: The liver as a metabolic "power station". World J
Hepatol 4, 184-190, doi:10.4254/wjh.v4.i6.184 (2012).

12

Lehninger, A. L., Nelson, D. L. & Cox, M. M. Lipid Biosynthesis. (Freeman, W.
H., 2010).

13

Liscum, L. in Biochemistry of Lipids, Lipoproteins, and Membranes, 5th Ed.
(eds D. E. Vance & J. E. Vance) Ch. 14, 399-421 (Elsevier, 2002).

14

Gropper, S. S. & Smith, J. L. Advanced nutrition and human metabolism, 6th ed.,
(Wadsworth/Cengage Learning, 2013).

15

Lee, T. H. By the way, doctor. I just got my cholesterol checked, and I'm
confused. LDL is bad and HDL is good, so how can they be combined into an
overall number that makes any sense? Isn't that like an accountant mixing debits

174

with credits? Wouldn't it make more sense to have a net cholesterol number (HDL
minus LDL), or perhaps a ratio? Harv Health Lett 28, 8 (2003).
16

Goldstein, J. L. & Brown, M. S. A century of cholesterol and coronaries: from
plaques to genes to statins. Cell 161, 161-172, doi:10.1016/j.cell.2015.01.036
(2015).

17

El Harchaoui, K. E. et al. High-Density Lipoprotein Particle Size and
Concentration and Coronary Risk. Ann Intern Med 150, 84-93 (2009).

18

Rifai, N., Warnick, G. R. & Dominiczak, M. H. Handbook of Lipoprotein Testing.
(Amer. Assoc. for Clinical Chemistry, 2000).

19

Asztalos, B. F., Tani, M. & Ishida, B. in The HDL Handbook: Biological
Functions and Clinical Implications

(ed T. Komoda) Ch. 3, 37-64 (Elsevier,

2014).
20

Takata, K., Horiuchi, S., Rahim, A. T. M. A. & Morino, Y. Receptor-mediated
internalization of high-density lipoprotein by rat sinusoidal liver cells:
identification of a nonlysosomal endocytic pathways by fluorescence-labeled
ligand. J Lipid Res 29, 1117-1126 (1988).

21

Anderson, R. G. W., Brown, M. S. & Goldstein, J. L. Role of the Coated
Endocytic Vesicle in the Uptake of Receptor-Bound Low Density Lipoprotein in
Human Fibroblasts. Cell 10, 351-364 (1977).

22

Schoenheimer, R. & Breusch, F. Synthesis and destruction of cholesterol in the
organism. J Biol Chem 103, 439-448 (1933).

23

Brown, M. S. & Goldstein, J. L. Regulation of the Activity of the Low Density
Lipoprotein Receptor in Human Fibroblasts. Cell 6, 307-316 (1975).

175

24

Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol
homeostasis. Science 232, 34-47 (1986).

25

Yokoyama, C. et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein
that controls transcription of the low density lipoprotein receptor gene. Cell 75,
187-197 (1993).

26

Hua, X., Nohturfft, A., Goldstein, J. L. & Brown, M. S. Sterol resistance in CHO
cells traced to point mutation in SREBP cleavage-activating protein. Cell 87, 415426 (1996).

27

Sakai, J., Nohturfft, A., Goldstein, J. L. & Brown, M. S. Cleavage of sterol
regulatory element-binding proteins (SREBPs) at site-1 requires interaction with
SREBP cleavage-activating protein. Evidence from in vivo competition studies. J
Biol Chem 273, 5785-5793 (1998).

28

Sakai, J. et al. Molecular identification of the sterol-regulated luminal protease
that cleaves SREBPs and controls lipid composition of animal cells. Molecular
Cell 2, 505-514, doi:Doi 10.1016/S1097-2765(00)80150-1 (1998).

29

Radhakrishnan, A., Sun, L. P., Kwon, H. J., Brown, M. S. & Goldstein, J. L.
Direct binding of cholesterol to the purified membrane region of SCAP:
mechanism for a sterol-sensing domain. Mol Cell 15, 259-268 (2004).

30

Motamed, M. et al. Identification of luminal Loop 1 of Scap protein as the sterol
sensor that maintains cholesterol homeostasis. J Biol Chem 286, 18002-18012,
doi:10.1074/jbc.M111.238311 (2011).

31

Sun, L. P., Seemann, J., Goldstein, J. L. & Brown, M. S. Sterol-regulated
transport of SREBPs from endoplasmic reticulum to Golgi: Insig renders sorting

176

signal in Scap inaccessible to COPII proteins. Proc Natl Acad Sci U S A 104,
6519-6526 (2007).
32

Rawson, R. B. et al. Complementation cloning of S2P, a gene encoding a putative
metalloprotease required for intramembrane cleavage of SREBPs. Mol Cell 1, 4757 (1997).

33

Shimano, H. et al. Overproduction of cholesterol and fatty acids causes massive
liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin
Invest 98, 1575-1584 (1996).

34

Horton, J. D. et al. Combined analysis of oligonucleotide microarray data from
transgenic and knockout mice identifies direct SREBP target genes. Proc Natl
Acad Sci U S A 100, 12027-12032 (2003).

35

Brown, A. J., Sun, L. P., Feramisco, J. D., Brown, M. S. & Goldstein, J. L.
Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP
escort protein that regulates cholesterol metabolism. Mol Cell 10, 237-245 (2002).

36

Yang, T. et al. Crucial step in cholesterol homeostasis: sterols promote binding of
SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in
ER. Cell 110, 489-500 (2002).

37

Ignatowski, A. I. Ueber die Wirkung der tierschen Einweisse auf der Aorta.
Virchow's Arch Pathol Anat 198, 248 (1909).

38

Anitschkow, N. & Chalatow, S. Ueber experimentelle Cholester-insteatose und
ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse. Zentrbl Allg
Pathol Pathol Anat 24, 1-9 (1913).

177

39

Keys, A. Seven Countries. A Multivariate Analysis of Death and Coronary Heart
Disease. (Harvard Univ. Press., 1980).

40

Gofman, J. W. et al. Blood Lipids and Human Atherosclerosis. Circulation 2,
161-178 (1950).

41

Dobbin, V., Gofman, J. W. & Nichols, A. V. Influence of dietary factors upon
human serum lipoprotein concentrations. . Geriatrics 12, 7-17 (1957).

42

Study,

F.

H.

Research

Milestones,

<https://www.framinghamheartstudy.org/about-fhs/research-milestones.php>
(2015).
43

Mackness, M. I., Arrol, S. & Durrington, P. N. Paraoxonase prevents
accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286, 152154 (1991).

44

Hessler, J. R., Robertson, A. L., Jr. & Chisolm, G. M., 3rd. LDL-induced
cytotoxicity and its inhibition by HDL in human vascular smooth muscle and
endothelial cells in culture. Atherosclerosis 32, 213-229 (1979).

45

Parthasarathy, S., Barnett, J. & Fong, L. G. High-density lipoprotein inhibits the
oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044,
275-283 (1990).

46

Barter, P. et al. HDL cholesterol, very low levels of LDL cholesterol, and
cardiovascular events. New England Journal of Medicine 357, 1301-1310,
doi:DOI 10.1056/NEJMoa064278 (2007).

178

47

Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a
mendelian randomisation study. The Lancet 380, 572-580, doi:10.1016/s01406736(12)60312-2 (2012).

48

Gotto, A. M., Jr. & Brinton, E. A. Assessing low levels of high-density
lipoprotein cholesterol as a risk factor in coronary heart disease: a working group
report and update. J Am Coll Cardiol 43, 717-724, doi:10.1016/j.jacc.2003.08.061
(2004).

49

Berliner, J. A. et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation,
and genetics. Circulation 91, 2488-2496 (1995).

50

Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating
the biology of atherosclerosis. Nature 473, 317-325, doi:10.1038/nature10146
(2011).

51

Tabas, I., Williams, K. J. & Boren, J. Subendothelial lipoprotein retention as the
initiating process in atherosclerosis: update and therapeutic implications.
Circulation

116,

1832-1844,

doi:10.1161/CIRCULATIONAHA.106.676890

(2007).
52

Goldstein, J. B., MS. Binding and Degradation of Low Density Lipoproteins by
Cultured Human Fibroblasts. JBC 249, 5153-5162 (1974).

53

Brown, M. S., Dana, S. E. & Goldstein, J. L. Receptor-dependent hydrolysis of
cholesteryl esters contained in plasma low density lipoprotein. Proc Natl Acad Sci
U S A 72, 2925-2929 (1975).

179

54

Goldstein, J. L., Basu, S. K., Brunschede, G. Y. & Brown, M. S. Release of low
density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans.
Cell 7, 85-95 (1976).

55

Müller, C. Xanthomata, hypercholestero-lemia, angina pectoris. Acta Med Scand
89, 75-84 (1938).

56

Khachadurian, A. K. THE INHERITANCE OF ESSENTIAL FAMILIAL
HYPERCHOLESTEROLEMIA. Am J Med 37, 402-407 (1964).

57

Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and
undertreated in the general population: guidance for clinicians to prevent coronary
heart disease: consensus statement of the European Atherosclerosis Society. Eur
Heart J 34, 3478-3490a, doi:10.1093/eurheartj/eht273 (2013).

58

Goldstein, J. L., Hobbs, H. H. & Brown, M. S. in The Metabolic and Molecular
Bases of Inherited Disease, 8th Ed. (eds C. R. Scriver, A. L. Beaudet, W. S. Sly,
& D. Valle) 2863-2914 (McGraw-Hill, Inc., 2001).

59

Nabel, E. G. Cardiovascular disease. New Engl J Med 349, 60-72 (2003).

60

Usifo,

E.

et

al.

Low-density

lipoprotein

receptor

gene

familial

hypercholesterolemia variant database: update and pathological assessment. Ann
Hum Genet 76, 387-401, doi:10.1111/j.1469-1809.2012.00724.x (2012).
61

Defesche, J. C. Low-Density Lipoprotein Receptor - Its Structure, Function, and
Mutations. Seminars in Vascular Medicine 4, 5-11 (2004).

62

Austin, M. A., Hutter, C. M., Zimmern, R. L. & Humphries, S. E. Familial
hypercholesterolemia and coronary heart disease: a HuGE association review. Am
J Epidemiol 160, 421-429 (2004).

180

63

Horton, J. D., Cohen, J. C. & Hobbs, H. H. PCSK9: a convertase that coordinates
LDL catabolism. J Lipid Res Suppl, S172-177 (2009).

64

Cohen, J. C., Boerwinkle, E., Mosley, T. H. & Hobbs, H. H. Sequence variations
in PCSK9, low LDL, and protection against coronary heart disease. New Engl J
Med 354, 1264-1272 (2006).

65

Brown, M. S., Faust, J. R., Goldstein, J. L., Kaneko, I. & Endo, A. Induction of 3hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts
incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J
Biol Chem 253, 1121-1128 (1978).

66

Informatics, I. I. f. H.

(2011).

67

Kovanen, P. T., Bilheimer, D. W., Goldstein, J. L., Jaramillo, J. J. & Brown, M.
S. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.
Proc Natl Acad Sci U S A 78, 1194-1198 (1981).

68

Vega, G. L. & Grundy, S. M. Influence of lovastatin therapy on metabolism of
low density lipoproteins in mixed hyperlipidaemia. J Intern Med 230, 341-350
(1991).

69

Mabuchi, H. et al. Reduction of serum cholesterol in heterozygous patients with
familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
New Engl J Med 308, 609-613 (1983).

70

Uauy, R., Vega, G. L., Grundy, S. M. & Bilheimer, D. M. Lovastatin therapy in
receptor-negative homozygous familial hypercholesterolemia: lack of effect on
low-density lipoprotein concentrations or turnover. J Pediatr 113, 387-392
(1988).

181

71

Stein, E. A. Management of dyslipidemia in the high-risk patient. Am Heart J
144, S43-50 (2002).

72

Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and
cardiovascular

events.

N

Engl

J

Med

372,

1489-1499,

doi:10.1056/NEJMoa1501031 (2015).
73

Marenah, C. in Clinical biochemistry: metabolic and clinical aspects Vol. 35
(eds W. Marshall & S. Bangert) 621-640 (1995).

74

Burneis, K. et al. Ezetimibe alone or in combination with simvastatin increases
small dense low-density lipoproteins in healthy men: a randomized trial. Eur
Heart J 31, 1633-1639 (2010).

75

Schuff-Werner, P., Fenger, S. & Kohlschein, P. Role of lipid apheresis in
changing times. Clin Res Cardiol Suppl 7, 7-14, doi:10.1007/s11789-012-0049-3
(2012).

76

Goldstein, J. L. & Brown, M. S. Regulation of low-density lipoprotein receptors:
implications for pathogenesis and therapy of hypercholesterolemia and
atherosclerosis. Circulation 76, 504-507 (1987).

77

Revell,

S.

P.

et

al.

Liver

transplantation

for

homozygous

familial

hypercholesterolaemia. Arch Dis Child 73, 456-458 (1995).
78

Wierzbicki, A. S. The role of lipid lowering in transplantation. Int J Clin Pract
53, 54-59 (1999).

79

Youngblom, E. & Knowles, J. W. Familial Hypercholesterolemia. Gene Reviews
(2014).

182

80

Mansoorian, M. et al. Liver transplantation as a definitive treatment for familial
hypercholesterolemia: A series of 36 cases. Pediatr Transplant 19, 605-611,
doi:10.1111/petr.12562 (2015).

81

Starzl, T. E. et al. Heart-liver transplantation in a patient with familial
hypercholesterolaemia. Lancet 1, 1382-1383 (1984).

82

Bilheimer, D. W., Goldstein, J. L., Grundy, S. M., Starzl, T. E. & Brown, M. S.
Liver transplantation to provide low-density-lipoprotein receptors and lower
plasma cholesterol in a child with homozygous familial hypercholesterolemia. N
Engl J Med. 311, 1658-1664, doi:10.1056/NEJM198412273112603 (1984).

83

Figuera, D. et al. Combined transplantation of heart and liver from two different
donors in a patient with familial type IIa hypercholesterolemia. J Heart
Transplant 5, 327-329 (1986).

84

Hibbitt, O. C. et al. Delivery and long-term expression of a 135 kb LDLR
genomic DNA locus in vivo by hydrodynamic tail vein injection. J Gene Med 9,
488-497, doi:10.1002/jgm.1041 (2007).

85

Oka, K. et al. Long-term stable correction of low-density lipoprotein receptordeficient mice with a helper-dependent adenoviral vector expressing the very lowdensity lipoprotein receptor. Circulation 103, 1274-1281 (2001).

86

Takahashi, S., Ohsugi, K., Yamamoto, T., Shiomi, M. & Sakuragawa, N. A novel
approach to ex vivo gene therapy for familial hypercholesterolemia using human
amniotic epithelial cells as a transgene carrier. Tohoku J Exp Med 193, 279-292
(2001).

183

87

Chowdhury, J. R. et al. Long-term improvement of hypercholesterolemia after ex
vivo gene therapy in LDLR-deficient rabbits. Science 254, 1802-1805 (1991).

88

Okura, H. et al. Transplantation of human adipose tissue-derived multilineage
progenitor cells reduces serum cholesterol in hyperlipidemic Watanabe rabbits.
Tissue Eng Part C Methods 17, 145-154, doi:10.1089/ten.TEC.2010.0139 (2011).

89

Fattahi, F. et al. Disease-corrected hepatocyte-like cells from familial
hypercholesterolemia-induced pluripotent stem cells. Mol Biotechnol 54, 863-873,
doi:10.1007/s12033-012-9635-3 (2013).

90

Heyde, M. et al. Gene therapy used for tissue engineering applications. J Pharm
Pharmacol 59, 329-350, doi:10.1211/jpp.59.3.0002 (2007).

91

Zhang, X. & Godbey, W. T. Viral vectors for gene delivery in tissue engineering.
Adv Drug Deliv Rev 58, 515-534, doi:10.1016/j.addr.2006.03.006 (2006).

92

Savulescu, J. Harm, ethics committees and the gene therapy death. J Med Ethics
27, 148-150 (2001).

93

Buchschacher, G. L. Introduction to retroviruses and retroviral vectors. Somat
Cell Mol Genet 26, 1-11 (2001).

94

Yu, S. S. et al. Transient gene expression mediated by integrase-defective
retroviral

vectors.

Biochem

Biophys

Res

Commun

368,

942-947,

doi:10.1016/j.bbrc.2008.02.012 (2008).
95

Hacein-Bey-Abina, S. et al. A serious adverse event after successful gene therapy
for X-linked severe combined immunodeficiency. N Engl J Med 348, 255-256
(2003).

184

96

Katz, R. A., Greger, J. G. & Skalka, A. M. Effects of cell cycle status on early
events in retroviral replication. J Cell Biochem 94, 880-889 (2005).

97

Caron, M. C. & Caruso, M. A nuclear localization signal in the matrix of spleen
necrosis virus (SNV) does not allow efficient gene transfer into quiescent cells
with SNV-derived vectors. Virology 338, 292-296 (2005).

98

Roe, T., Reynolds, T. C., Yu, G. & Brown, P. O. Integration of murine leukemia
virus DNA depends on mitosis. EMBO J 12, 2099-2108. (1993).

99

Lewis, P., Hensel, M. & Emerman, M. Human immunodeficiency virus infection
of cells arrested in the cell cycle. EMBO J 11, 3053-3058 (1992).

100

Yamashita, M. & Emerman, M. Retroviral infection of non-dividing cells: old and
new perspectives. Virology 344, 88-93 (2006).

101

Grossman, M. et al. A pilot study of ex vivo gene therapy for homozygous
familial hypercholesterolaemia. Nat Med 1, 1148-1154 (1995).

102

Khoo, B. Genetic therapies to lower cholesterol. Vasc Pharmacol 64, 11-15
(2015).

103

Snoeys, J. et al. Species differences in transgene DNA uptake in hepatocytes after
adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther 14,
604-612, doi:10.1038/sj.gt.3302899 (2007).

104

Wisse, E. An electron microscopic study of the fenestrated endothelial lining of
rat liver sinusoids. J Ultrastruct Res 31, 125-150 (1970).

105

Wisse, E. An ultrastructural characterization of the endothelial cell in the rat liver
sinusoid under normal and various experimental conditions, as a contribution to

185

the distinction between endothelial and Kupffer cells. J Ultrastruct Res 38, 528562 (1972).
106

Kuzmin, A. I., Finegold, M. & Eisensmith, R. C. Macrophage depletion increases
the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo.
Gene Ther 4, 309-316 (1997).

107

Wolff, G. et al. Enhancement of in vivo adenovirus-mediated gene transfer and
expression by prior depletion of tissue macrophages in the target organ. J Virol
71, 624-629 (1997).

108

Snoeys, J. et al. Lipid emulsions potently increase transgene expression in
hepatocytes after adenoviral transfer. Mol Ther 13, 98-107 (2006).

109

Verma, I. M. & Somia, N. Gene therapy -- promises, problems and prospects.
Nature 389, 239-242 (1997).

110

Smith, A. E. Viral vectors in gene therapy. Annu Rev Microbiol. 49, 807-838
(1995).

111

Khan, T. A., Sellke, F. W. & Laham, R. J. Gene therapy progress and prospects:
therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 10, 285291 (2003).

112

Qian, H. S. et al. Improved adenoviral vector for vascular gene therapy :
beneficial effects on vascular function and inflammation. Circ Res 88, 911-917
(2001).

113

Wen, S., Graf, S., Massey, P. G. & Dichek, D. A. Improved vascular gene transfer
with a helper-dependent adenoviral vector. Circulation 110, 1484-1491 (2004).

186

114

Fleury, S. et al. Helper-dependent adenovirus vectors devoid of all viral genes
cause less myocardial inflammation compared with first-generation adenovirus
vectors. Basic Res Cardiol 99, 247-256 (2004).

115

Pastore, L. et al. Helper-dependent adenoviral vector-mediated long-term
expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient
mice. Gene 327, 153-160 (2004).

116

Hollinger, K. & Chamberlain, J. S. Viral vector-mediated gene therapies. Curr
Opin Neurol. 28, 522-527 (2015).

117

Chen, H. Comparative observation of the recombinant adeno-associated virus 2
using transmission electron microscopy and atomic force microscopy. Microsc
Microanal 13, 384-389 (2007).

118

Odom, G. L., Gregorevic, P., Allen, J. M. & Chamberlain, J. S. Gene therapy of
mdx mice with large truncated dystrophins generated by recombination using
rAAV6. Mol Ther 19, 36-45, doi:10.1038/mt.2010.205 (2011).

119

Lostal, W., Kodippili, K., Yue, Y. & Duan, D. Full-length dystrophin
reconstitution with adeno-associated viral vectors. Hum Gene Ther 25, 552-562,
doi:10.1089/hum.2013.210 (2014).

120

Koo, T., Popplewell, L., Athanasopoulos, T. & Dickson, G. Triple trans-splicing
adeno-associated virus vectors capable of transferring the coding sequence for
full-length dystrophin protein into dystrophic mice. Hum Gene Ther 25, 98-108,
doi:10.1089/hum.2013.164 (2014).

187

121

Chicoine, L. G. et al. Plasmapheresis eliminates the negative impact of AAV
antibodies on microdystrophin gene expression following vascular delivery. Mol
Ther 22, 338-347, doi:10.1038/mt.2013.244 (2014).

122

Hareendran, S. et al. Adeno-associated virus (AAV) vectors in gene therapy:
immune challenges and strategies to circumvent them. Rev Med Virol 23, 399413, doi:10.1002/rmv.1762 (2013).

123

Yla-Herttuala, S. Endgame: glybera finally recommended for approval as the first
gene therapy drug in the European union. Mol Ther 20, 1831-1832,
doi:10.1038/mt.2012.194 (2012).

124

Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-Factor
IX and limitations imposed by the host immune response. Nat Med 12, 342-347,
doi:10.1038/nm1358 (2006).

125

Mingozzi, F. et al. CD8(+) T-cell responses to adeno-associated virus capsid in
humans. Nat Med 13, 419-422, doi:10.1038/nm1549 (2007).

126

Rogers, G. L. et al. Innate Immune Responses to AAV Vectors. Front Microbiol
2, 194, doi:10.3389/fmicb.2011.00194 (2011).

127

Kassim, S. H. et al. Adeno-associated virus serotype 8 gene therapy leads to
significant lowering of plasma cholesterol levels in humanized mouse models of
homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther
24, 19-26, doi:10.1089/hum.2012.108 (2013).

128

Narsinh, K. H. & Wu, J. C. Gene correction in human embryonic and induced
pluripotent stem cells: promises and challenges ahead. Mol Ther 18, 1061-1063,
doi:10.1038/mt.2010.92 (2010).

188

129

Kozarsky, K. F., Jooss, K., Donahee, M., Strauss III, J. F. & Wilson, J. M.
Effective treatment of familial hypercholesterolemia in the mouse model using
adenovirus-mediated transfer of the VLDL receptor gene. Nature genetics 13, 5462 (1996).

130

Heeren, J., Weber, W. & Beisiegel, U. Intracellular processing of endocytosed
triglyceride-rich lipoproteins comprises both recycling and degradation. Journal
of Cell Science 112, 349-359 (1999).

131

Cichon, G. et al. Non-physiological overexpression of the low density lipoprotein
receptor (LDLr) gene in the liver induces pathological intracellular lipid and
cholesterol storage. J Gene Med 6, 166-175, doi:10.1002/jgm.473 (2004).

132

Krieger, M., Brown, M. S. & Goldstein, J. L. Isolation of Chinese Hamster Cell
Mutants Defective in the Receptor-mediated Endocytosis of Low Density
Lipoprotein. J Mol Biol 150, 167-184 (1981).

133

Le Douarin, G., Le Douarin, N. & Cuminge, D. Ultrastructural study of the
autodifferentiation capabilities of the mesoderm of the cardiac area in the chick
embryo. C R Acad Sci Hebd Seances Acad Sci D 260, 6998-7001 (1965).

134

Le Douarin, N. An experimental analysis of liver development. Med Biol. 53,
427-455 (1975).

135

Stark, K. L., McMahon, J. A. & McMahon, A. P. FGFR-4, a new member of the
fibroblast growth factor receptor family, expressed in the definitive endoderm and
skeletal muscle lineages of the mouse. Development 113, 641-651 (1991).

189

136

Sugi, Y., Sasse, J., Barron, M. & Lough, J. Developmental expression of
fibroblast growth factor receptor-1 (cek-1; flg) during heart development. Dev
Dyn 202, 115-125 (1995).

137

Ciruna, B. G., Schwartz, L., Harpal, K., Yamaguchi, T. P. & Rossant, J. Chimeric
analysis of fibroblast growth factor receptor-1 (Fgfr1) function: a role for FGFR1
in morphogenetic movement through the primitive streak. Development 124,
2829-2841 (1997).

138

Jung, J., Zheng, M., Goldfarb, M. & Zaret, K. S. Initiation of mammalian liver
development from endoderm by fibroblast growth factors. Science 284, 19982003 (1999).

139

Crossley, P. H. & Martin, G. R. The mouse Fgf8 gene encodes a family of
polypeptides and is expressed in regions that direct outgrowth and patterning in
the developing embryo. Development 121, 439-451 (1995).

140

Duncan, S. A. Mechanisms controlling early development of the liver. Mech Dev.
120, 19-33 (2003).

141

Deutsch, G., Jung, J., Zheng, M., Lóra, J. & Zaret, K. S. A bipotential precursor
population for pancreas and liver within the embryonic endoderm. Development
128, 871-881 (2001).

142

Rossi, J. M., Dunn, N. R., Hogan, B. L. & Zaret, K. S. Distinct mesodermal
signals, including BMPs from the septum transversum mesenchyme, are required
in combination for hepatogenesis from the endoderm. Genes Dev 15, 1998-2009
(2001).

190

143

Singh, V. Textbook of Clinical Embryology. 140-168 (Reed Elsevier India Private
Limited, 2012).

144

Carlson, B. M. Human Embryology & Developmental Biology, 5th Ed.,
(Saunders, 2013).

145

Kuntz, E. & Kuntz, H.-D. Hepatology, Principles and Practice: History,
Morphology, Diagnostics, Clinic, Therapy, 3rd Ed. 3 edn, (Springer, 2005).

146

Lalor, P. F., Lai, W. K., Curbishley, S. M., Shetty, S. & Adams, D. H. Human
hepatic sinusoidal endothelial cells can be distinguished by expression of
phenotypic markers related to their specialised functions in vivo. World J
Gastroenterol 12, 5429-5439 (2006).

147

Jenne, C. N. & Kubes, P. Immune surveillance by the liver. Nat Immunol 14, 9961006, doi:10.1038/ni.2691 (2013).

148

Straub, A. C. et al. Arsenic-stimulated liver sinusoidal capillarization in mice
requires NADPH oxidase-generated superoxide. J Clin Invest 118, 3980-3989,
doi:10.1172/JCI35092 (2008).

149

Huet, P.-M., Goresky, C. A., Villenueve, J.-P., Marleau, D. & Lough, J. O.
Assessment of Liver Microcirculation in Human Cirrhosis. J Clin Invest 70, 12341244 (1982).

150

Kordes, C. et al. CD133+ hepatic stellate cells are progenitor cells. Biochem
Biophys Res Commun 352, 410-417, doi:10.1016/j.bbrc.2006.11.029 (2007).

151

Hindley, C. J., Mastrogiovanni, G. & Huch, M. The plastic liver: differentiated
cells, stem cells, every cell? J Clin Invest 124, 5099-5102 (2014).

191

152

Yang, L. et al. Fate-mapping evidence that hepatic stellate cells are epithelial
progenitors

in

adult

mouse

livers.

Stem

Cells

26,

2104-2113,

doi:10.1634/stemcells.2008-0115 (2008).
153

CDC.

Chronic

Liver

Disease

and

Cirrhosis,

<http://www.cdc.gov/nchs/fastats/liver-disease.htm> (2015).
154

ALF.

Liver

Transplant,

<http://www.liverfoundation.org/abouttheliver/info/transplant/> (2015).
155

Allen, J. W., Hassanein, T. & Bhatia, S. N. Advances in bioartificial liver devices.
Hepatology 34, 447-455 (2001).

156

Mitaka, T. The current status of primary hepatocyte culture. Int J Exp Pathol 79,
393-409 (1998).

157

Shulman, M. & Nahmias, Y. Long-term culture and coculture of primary rat and
human hepatocytes. Methods Mol Biol 945, 287-302, doi:10.1007/978-1-62703125-7_17 (2013).

158

Kubota, H. & Reid, L. M. Clonogenic hepatoblasts, common precursors for
hepatocytic and biliary lineages, are lacking classical major histocompatibility
complex class I antigen. Proc Natl Acad Sci U S A 97, 12132-12137 (2000).

159

Isom, H. C., Secott, T., Georgoff, I., Woodworth, C. & Mummaw, J. Maintenance
of differentiated rat hepatocytes in primary culture. Proc Natl Acad Sci U S A 82,
3252-3256 (1985).

160

Dich, J., Vind, C. & Grunnet, N. Long-term culture of hepatocytes: effect of
hormones on enzyme activities and metabolic capacity. Hepatology 8, 39-45
(1988).

192

161

Kelly, J. H. & Darlington, G. J. Modulation of the liver specific phenotype in the
human hepatoblastoma line Hep G2. In Vitro Cell Dev Biol 25, 217-222 (1989).

162

Nyberg, S. L. & Misra, S. P. Hepatocyte liver-assist systems--a clinical update.
Mayo Clin Proc 73, 765-771 (1998).

163

Werner, A. et al. Cultivation of immortalized human hepatocytes HepZ on
macroporous CultiSpher G microcarriers. Biotechnol Bioeng 68, 59-70 (2000).

164

Kono, Y., Yang, S., Letarte, M. & Roberts, E. A. Establishment of a human
hepatocyte line derived from primary culture in a collagen gel sandwich culture
system. Exp Cell Res 221, 478-485 (1995).

165

Gripon, P. et al. Infection of a human hepatoma cell line by hepatitis B virus.
Proc Natl Acad Sci U S A 99, 15655-15660 (2002).

166

Parent, R., Marion, M. J., Furio, L., Trepo, C. & Petit, M. A. Origin and
characterization of a human bipotent liver progenitor cell line. Gastroenterology
126, 1147-1156 (2004).

167

Chen, S. C. et al. Clinical experience with a porcine hepatocyte-based liver
support system. Int J Artif Organs 19, 664-669 (1996).

168

Morsiani, E. et al. Early experiences with a porcine hepatocyte-based bioartificial
liver in acute hepatic failure patients. Int J Artif Organs 25, 192-202 (2002).

169

van de Kirkhove, M. P., Hoekstra, R., Chamuleau, R. A. & van Gulik, T. M.
Clinical application of bioartificial liver support systems. Ann Surg 240, 216-230
(2004).

193

170

Demetriou, A. A. et al. Prospective, Randomized, Multicenter, Controlled Trial of
a Bioartificial Liver in Treating Acute Liver Failure. Annals of Surgery 239, 660670, doi:10.1097/01.sla.0000124298.74199.e5 (2004).

171

Vannier, P. & Carriolet, R. Xenografts and the probability of viral zoonotic risk:
reflections based on the sanitary control of a pig population free from specific
pathogenic organisms and risk analysis. Pathol Biol 48, 389-394 (2000).

172

Boneva, R. S., Folks, T. M. & Chapman, L. E. Infectious disease issues in
xenotransplantation. Clin Microbiol Rev 14, 1-14, doi:10.1128/CMR.14.1.114.2001 (2001).

173

Schrem, H., Kleine, M., Borlak, J. & Klempnauer, J. Physiological
incompatibilities of porcine hepatocytes for clinical liver support. Liver Transpl
12, 1832-1840, doi:10.1002/lt.20918 (2006).

174

Kelly, S. J. Studies of the developmental potential of four- and eight-cell stage
mouse blastomeres. J Exp Zool 200, 365-376 (1977).

175

Stadtfeld, M. & Hochedlinger, K. Induced pluripotency: history, mechanisms, and
applications. Genes Dev 24, 2239-2263, doi:10.1101/gad.1963910 (2010).

176

Briggs, R. & King, T. J. Transplantation of living nuclei from blastula cells into
enucleated frogs' eggs. Proc Natl Acad Sci U S A 38, 455-463 (1952).

177

King, T. J. & Briggs, R. Changes in the nuclei of differentiating gastrula cells, as
demonstrated by nuclear transplantation. Proc Natl Acad Sci U S A 41 (1955).

178

Gurdon, J. B., Byrne, J. A. & Simonsson, S. Nuclear reprogramming and stem
cell creation. Proc Natl Acad Sci U S A 100, 11819-11822 (2003).

194

179

Wakayama, T. & Yanagimachi, R. Cloning of male mice from adult tail-tip cells.
Nat Genet 22, 127-128 (1999).

180

Tamashiro, K. L. et al. Cloned mice have an obese phenotype not transmitted to
their offspring. Nat Med 8, 262-267 (2002).

181

Stevens, L. C. & Little, C. C. Spontaneous testicular teratomas in an inbred strain
of mice. Proc Natl Acad Sci U S A 40, 1080-1087 (1954).

182

Kleinsmith, L. J. & Pierce, G. B. Multipotentiality of single embryonal carcinoma
cells. Cancer Res 24, 1544-1551 (1964).

183

Kahan, B. W. & Ephrussi, B. Developmental potentialities of clonal in vitro
cultures of mouse testicular teratoma. J Natl Cancer Inst 44 (1970).

184

Miller, R. A. & Ruddle, F. H. Pluripotent teratocarcinoma-thymus somatic cell
hybrids. Cell 9, 45-55 (1976).

185

Miller, R. A. & Ruddle, F. H. Properties of teratocarcinoma-thymus somatic cell
hybrids. Somat Cell Genet 3, 247-261 (1977).

186

Solter, D., Skreb, N. & Damjanov, I. Extrauterine growth of mouse egg-cylinders
results in malignant teratoma. Nature 227, 503-504 (1970).

187

Evans, M. J. & Kaufman, M. H. Establishment in culture of pluripotential cells
from mouse embryos. Nature 292, 154-156 (1981).

188

Martin, G. R. Isolation of a pluripotent cell line from early mouse embryos
cultured in medium conditioned by terato-carcinoma stem cells. Proc Natl Acad
Sci U S A 78, 7634-7638 (1981).

195

189

Andrews, P. W. et al. Pluripotent embryonal carcinoma clones derived from the
human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Lab
Invest 50, 147-162 (1984).

190

Andrews, P. W. Retinoic acid induces neuronal differentiation of a cloned human
embryonal carcinoma cell line in vitro. Dev Biol 103, 285-293 (1984).

191

Pera, M. F., Cooper, S., Mills, J. & Parrington, J. M. Isolation and
characterization of a multipotent clone of human embryonal carcinoma cells.
Differentiation 42, 10-23 (1989).

192

Bongso, T. A., Fong, C. Y., Ng, C. Y. & Ratnam, S. S. Blastocyst transfer in
human in vitro fertilization: the use of embryo co-culture. Cell Biol Int 18, 11811189 (1994).

193

Thomson, J. A. et al. Isolation of a primate embryonic stem cell line. Proc Natl
Acad Sci U S A 92, 7844-7848 (1995).

194

Thomson, J. A. et al. Pluripotent cell lines derived from common marmoset
(Callithrix jacchus) blastocysts. Biol Reprod 55, 254-259 (1996).

195

Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts.
Science 282, 1145-1147 (1998).

196

Stice, S. L. et al. Human embryonic stem cells: challenges and opportunities.
Repro Fert Dev 18, 839-846 (2006).

197

EuroStemCell.

Embryonic

stem

cell

research:

an

ethical

dilemma,

<http://www.eurostemcell.org/factsheet/embyronic-stem-cell-research-ethicaldilemma> (2011).

196

198

Davis, R. L., Weintraub, H. & Lassar, A. B. Expression of a single transfected
cDNA converts fibroblasts to myoblasts. Cell 51, 987-1000 (1987).

199

Xie, H., Ye, M., Feng, R. & Graf, T. Stepwise reprogramming of B cells into
macrophages. Cell 117, 663-676 (2004).

200

Laiosa, C. V., Stadtfeld, M., Xie, H., de Andres-Aguayo, L. & Graf, T.
Reprogramming of committed T cell progenitors to macrophages and dendritic
cells by C/EBP alpha and PU.1 transcription factors. Immunity 25, 731-744
(2006).

201

Tada, M., Tada, T., Lefebvre, L., Barton, S. C. & Surani, M. A. Embryonic germ
cells induce epigenetic reprogramming of somatic nucleus in hybrid cells. EMBO
J 16, 6510-6520 (1997).

202

Tada, M., Takahama, Y., Abe, K., Nakatsuji, N. & Tada, T. Nuclear
reprogramming of somatic cells by in vitro hybridization with ES cells. Curr Biol.
11, 1553-1558 (2001).

203

Tokuzawa, Y. et al. Fbx15 is a novel target of Oct3/4 but is dispensable for
embryonic stem cell self-renewal and mouse development. Mol Cell Biol 23,
2699-2708 (2003).

204

Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676,
doi:10.1016/j.cell.2006.07.024 (2006).

205

Takahashi, K. et al. Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861-872, doi:10.1016/j.cell.2007.11.019
(2007).

197

206

Giorgetti, A. et al. Generation of induced pluripotent stem cells from human cord
blood

using

OCT4

and

SOX2.

Cell

Stem

Cell

5,

353-357,

doi:10.1016/j.stem.2009.09.008 (2009).
207

Kim, J. B. et al. Pluripotent stem cells induced from adult neural stem cells by
reprogramming with two factors. Nature 454, 646-650, doi:10.1038/nature07061
(2008).

208

Tsai, S. Y. et al. Oct4 and klf4 reprogram dermal papilla cells into induced
pluripotent stem cells. Stem Cells 28, 221-228, doi:10.1002/stem.281 (2010).

209

Utikal, J., Maherali, N., Kulalert, W. & Hochedlinger, K. Sox2 is dispensable for
the reprogramming of melanocytes and melanoma cells into induced pluripotent
stem cells. J Cell Sci 122, 3502-3510 (2009).

210

Yu, J. et al. Induced Pluripotent Stem Cell Lines Derived from Human Somatic
Cells. Sciencexpress, 1-4 (2007).

211

Lei, H. et al. De novo DNA cytosine methyltransferase activities in mouse
embryonic stem cells. Development 122, 3195-3205 (1996).

212

Matsui, T. et al. Proviral silencing in embryonic stem cells requires the histone
methyltransferase ESET. Nature 464, 927-931 (2010).

213

Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competnet
induced pluripotent stem cells. Nature 448, 313-317 (2007).

214

Brambrink, T. et al. Sequential expression of pluripotency markers during direct
reprogramming of mouse somatic cells. Cell Stem Cell 2, 151-159 (2008).

198

215

Sommer, C. A. et al. Excision of reprogramming transgenes improves the
differentiation potential of iPS cells generated with a single excisable vector. .
Stem Cells 28, 64-74 (2010).

216

Stadtfeld, M., Maherali, N., Breault, D. T. & Hochedlinger, K. Defining
molecular cornerstones during fibroblast to iPS cell reprogramming in mouse.
Cell Stem Cell 2, 230-240 (2008).

217

Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human
ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27, 851-857,
doi:10.1038/nbt.1562 (2009).

218

Maherali, N. et al. A high-efficiency system for the generation and study of
human induced pluripotent stem cells. Cell Stem Cell 3, 340-345 (2008).

219

Wernig, M. et al. A drug- inducible transgenic system for direct reprogramming
of mul- tiple somatic cell types. Nat Biotechnol 26, 916-924 (2008).

220

Woltjen, K. et al. piggyBac transposition reprograms fibroblasts to induced
pluripotent stem cells. . Nature 458, 766-770 (2009).

221

Zhou, W. & Freed, C. R. Adenoviral gene delivery can repro- gram human
fibroblasts to induced pluripotent stem cells. Stem Cells 27, 2667-2674 (2009).

222

Fusaki, N., Ban, H., Nishiyama, A., Saeki, K. & Hasegawa, M. Efficient
induction of transgene-free human pluripotent stem cells using a vector based on
Sendai virus, an RNA virus that does not integrate into the host genome. . Proc
Jpn Acad 85, 348-362 (2009).

223

Jia, F. et al. A nonviral minicircle vector for deriving human iPS cells. Nat
Methods 7, 197-199, doi:10.1038/nmeth.1426 (2010).

199

224

Yu, J. et al. Human induced pluripotent stem cells free of vector and transgene
sequences. . Science 324, 797-801 (2009).

225

Soldner, F. et al. Parkinson's disease patient-derived induced pluripotent stem
cells

free

of

viral

reprogramming

factors.

Cell

136,

964-977,

doi:10.1016/j.cell.2009.02.013 (2009).
226

Chang, C. W. et al. Polycistronic lentiviral vector for ‘hit and run’ reprogramming
of adult skin fibroblasts to induced pluripotent stem cells. . Stem Cells 27, 10421049 (2009).

227

Wilson, M. H., Coates, C. J. & George, A. L. PiggyBac Transposon-mediated
Gene Transfer in Human Cells. Mol Ther 15, 139-145 (2007).

228

Kaji, K. et al. Virus-free induction of pluripotency and subsequent excision of
reprogramming factors. Nature 458, 771-775 (2009).

229

Cho, H. J. et al. Induction of pluripotent stem cells from adult somatic cells by
protein-based repro- gramming without genetic manipulation. Blood 116, 386-395
(2010).

230

Warren, L. et al. Highly efficient reprogramming to pluripotency and directed
differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7,
618-630, doi:10.1016/j.stem.2010.08.012 (2010).

231

Yakubov, E., Rechavi, G., Rozenblatt, S. & Givol, D. Reprogramming of human
fibroblasts to pluripotent stem cells using mRNA of four transcription factors.
Biochem Biophys Res Commun 394, 189-193, doi:10.1016/j.bbrc.2010.02.150
(2010).

200

232

Bernal, J. A. RNA-based tools for nuclear reprogramming and lineageconversion: towards clinical applications. J Cardiovasc Transl Res 6, 956-968,
doi:10.1007/s12265-013-9494-8 (2013).

233

Hussein, S. M. & Nagy, A. A. Progress made in the reprogramming field: new
factors, new strategies and a new outlook. Curr Opin Genet Dev 22, 435-443,
doi:10.1016/j.gde.2012.08.007 (2012).

234

Gonzalez, F., Boue, S. & Izpisua Belmonte, J. C. Methods for making induced
pluripotent stem cells: reprogramming a la carte. Nat Rev Genet 12, 231-242,
doi:10.1038/nrg2937 (2011).

235

Sullivan, G. J., Bai, Y., Fletcher, J. & Wilmut, I. Induced pluripotent stem cells:
epigenetic memories and practical implications. Mol Hum Reprod 16, 880-885,
doi:10.1093/molehr/gaq091 (2010).

236

Bilic, J. & Izpisua Belmonte, J. C. Concise review: Induced pluripotent stem cells
versus embryonic stem cells: close enough or yet too far apart? Stem Cells 30, 3341 (2012).

237

Maherali, N. et al. Directly reprogrammed fibroblasts show global epigenetic
remodeling and widespread tissue contribution. Cell Stem Cell 1, 55-70 (2007).

238

Wernig, M. et al. In vitro reprogramming of fibroblasts into a pluripotent ES-celllike state. Nature 448, 318-324 (2007).

239

Mikkelsen, T. S. et al. Dissecting direct reprogramming through integrative
genomic analysis. Nature 454, 49-55, doi:10.1038/nature07056 (2008).

201

240

Feng, Q. et al. Hemangioblastic derivatives from human induced pluripotent stem
cells exhibit limited expansion and early senescence. Stem Cells 28, 704-712,
doi:10.1002/stem.321 (2010).

241

Chin, M. H. et al. Induced pluripotent stem cells and embryonic stem cells are
distinguished by gene expression signatures. Cell Stem Cell 5, 111-123,
doi:10.1016/j.stem.2009.06.008 (2009).

242

Wilson, K. D. et al. MicroRNA profiling of human-induced pluripotent stem
cells. Stem Cells Dev 18, 749-758, doi:10.1089/scd.2008.0247 (2009).

243

Hu, B. Y. et al. Neural differentiation of human induced pluripotent stem cells
follows developmental principles but with variable potency. Proc Natl Acad Sci U
S A 107, 4335-4340, doi:10.1073/pnas.0910012107 (2010).

244

Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467,
285-290, doi:10.1038/nature09342 (2010).

245

Ji, H. et al. Comprehensive methylome map of lineage commitment from
haematopoietic progenitors. Nature 467, 338-342, doi:10.1038/nature09367
(2010).

246

Polo, J. M. et al. Cell type of origin influences the molecular and functional
properties of mouse induced pluripotent stem cells. Nat Biotechnol 28, 848-855,
doi:10.1038/nbt.1667 (2010).

247

Newman, A. M. & Cooper, J. B. Lab-specific gene expression signatures in
pluripotent stem cells. Cell Stem Cell 7, 258-262, doi:10.1016/j.stem.2010.06.016
(2010).

202

248

Osafune, K. et al. Marked differences in differentiation propensity among human
embryonic stem cell lines. Nat Biotechnol 26, 313-315, doi:10.1038/nbt1383
(2008).

249

Tavakoli, T. et al. Self-renewal and differentiation capabilities are variable
between human embryonic stem cell lines I3, I6 and BG01V. BMC Cell Biol 10,
44, doi:10.1186/1471-2121-10-44 (2009).

250

Gutierrez-Aranda, I. et al. Human induced pluripotent stem cells develop
teratoma more efficiently and faster than human embryonic stem cells regardless
the site of injection. Stem Cells 28, 1568-1570, doi:10.1002/stem.471 (2010).

251

Lowry, W. E. & Quan, W. L. Roadblocks en route to the clinical application of
induced pluripotent stem cells. J Cell Sci 123, 643-651, doi:10.1242/jcs.054304
(2010).

252

Ben-David, U. & Benvenisty, N. Chemical ablation of tumor-initiating human
pluripotent stem cells. Nat Protoc 9, 729-740, doi:10.1038/nprot.2014.050 (2014).

253

Ben-David, U. et al. Selective elimination of human pluripotent stem cells by an
oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell
12, 167-179, doi:10.1016/j.stem.2012.11.015 (2013).

254

Wu, C. et al. Development of an inducible caspase-9 safety switch for pluripotent
stem

cell-based

therapies.

Mol

Ther

Methods

Clin

Dev

1,

14053,

doi:10.1038/mtm.2014.53 (2014).
255

Nakagawa, M. et al. Generation of induced pluripotent stem cells without Myc
from

mouse

and

human

fibroblasts.

doi:10.1038/nbt1374 (2008).

203

Nat

Biotechnol

26,

101-106,

256

Judson, R. L., Babiarz, J. E., Venere, M. & Blelloch, R. Embryonic stem cellspecific microRNAs promote induced pluripotency. Nat Biotechnol 27, 459-461,
doi:10.1038/nbt.1535 (2009).

257

Uren, A. G., Kool, J., Berns, A. & van Lohuizen, M. Retroviral insertional
mutagenesis: past, present and future. Oncogene 24, 7656-7672 (2005).

258

Okita, K. et al. A more efficient method to generate integration-free human iPS
cells. Nat Methods 8, 409-412 (2011).

259

Okita, K., Hong, H., Takahashi, K. & Yamanaka, S. Generation of mouse-induced
pluripotent stem cells with plasmid vectors. Nat Protoc 5, 418-428,
doi:10.1038/nprot.2009.231 (2010).

260

Huang, B. et al. A virus-free poly-promoter vector induces pluripotency in
quiescent bovine cells under chemically defined conditions of dual kinase
inhibition. PLoS One 6 (2011).

261

Yu, J., Chau, K. F., Vodyanik, M. A., Jiang, J. & Jiang, Y. Efficient feeder-free
episomal reprogramming with small molecules. PLoS One 6, e17557,
doi:10.1371/journal.pone.0017557 (2011).

262

Puppi, J. et al. Improving the techniques for human hepatocyte transplantation:
report from a consensus meeting in London. Cell Transplant 21, 1-10,
doi:10.3727/096368911X566208 (2012).

263

Liu, L. et al. The microenvironment in hepatocyte regeneration and function in
rats with advanced cirrhosis. Hepatology 55, 1529-1539, doi:10.1002/hep.24815
(2012).

204

264

Hoppo, T., Komori, J., Manohar, R., Stolz, D. B. & Lagasse, E. Rescue of lethal
hepatic failure by hepatized lymph nodes in mice. Gastroenterology 140, 656-666
e652, doi:10.1053/j.gastro.2010.11.006 (2011).

265

Song, Z. et al. Efficient generation of hepatocyte-like cells from human induced
pluripotent stem cells. Cell Res 19, 1233-1242, doi:10.1038/cr.2009.107 (2009).

266

Si-Tayeb, K. et al. Highly efficient generation of human hepatocyte-like cells
from

induced

pluripotent

stem

cells.

Hepatology

51,

297-305,

doi:10.1002/hep.23354 (2010).
267

Ishikawa, T. et al. Human induced hepatic lineage-oriented stem cells:
autonomous specification of human iPS cells toward hepatocyte-like cells without
any

exogenous

differentiation

factors.

PLoS

One

10,

e0123193,

doi:10.1371/journal.pone.0123193 (2015).
268

Takebe, T. et al. Vascularized and functional human liver from an iPSC-derived
organ bud transplant. Nature 499, 481-484, doi:10.1038/nature12271 (2013).

269

Zaret, K. S. & Grompe, M. Generation and regeneration of cells of the liver and
pancreas. Science 322, 1490-1494, doi:10.1126/science.1161431 (2008).

270

Cayo, M. A. et al. JD induced pluripotent stem cell-derived hepatocytes faithfully
recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology
56, 2163-2171, doi:10.1002/hep.25871 (2012).

271

Basma, H. et al. Differentiation and transplantation of human embryonic stem
cell-derived

hepatocytes.

Gastroenterology

doi:10.1053/j.gastro.2008.10.047 (2009).

205

136,

990-999,

272

Schwartz, R. E., Fleming, H. E., Khetani, S. R. & Bhatia, S. N. Pluripotent stem
cell-derived

hepatocyte-like

cells.

Biotechnol

Adv

32,

504-513,

doi:10.1016/j.biotechadv.2014.01.003 (2014).
273

Purves, W. K., Orians, G. H. & Heller, H. C. Life: The Science of Biology, 4th
Ed., (Sinauer Associates, 1994).

274

Schmidt-Lademann, S., Stoeter, P. & Voigt, K. Embryonal and fetal development
of capillaries: microangiographic investigations. Diagn Imaging 49, 177-187
(1980).

275

Stoeter, P., Schmidt-Lademann, S. & Voigt, K. Embryonal and fetal development
of capillaries: microangiographic investigations. Diagn Imaging 49, 131-140
(1980).

276

Penn, J. Retinal and Choroidal Angiogenesis. 1 edn, 119 (Springer, 2008).

277

Pavelka, M. & Roth, J. Functional Ultrastructure. 1 edn, 232 (Springer-Verlag,
2005).

278

Aschner, J. L., Lum, H., Fletcher, P. W. & Malik, P. B. Bradykinin- and
thrombin-induced increases in endothelial permeability occur independently of
phospholipase C but require protein kinase C activation. J Cell Physiol 173, 387396 (1997).

279

Corson, M. A. et al. Phosphorylation of endothelial nitric oxide synthase in
response to fluid shear stress. Circ Res 79, 984-991 (1996).

280

Govers, R. & Rabelink, T. J. Cellular regulation of endothelial nitric oxide
synthase. Am J Physiol Renal Physiol 280, F193-206 (2001).

206

281

Moncada, S. & Erusalimsky, J. D. Does nitric oxide modulate mitochondrial
energy generation and apoptosis? Nat Rev Mol Cell Biol 3, 214-220 (2002).

282

Gimbrone, M. A. Vascular endothelium, hemodynamic forces, and atherogenesis.
Am J Pathol 155, 1-5 (1999).

283

Deanfield, J. E., Halcox, J. P. & Rabelink, T. J. Endothelial function and
dysfunction: testing and clinical relevance. Circulation 115, 1285-1295 (2007).

284

Ghosh, S. & Karin, M. Missing pieces in the NF-kappaB puzzle. Cell 109, S81-96
(2002).

285

Kinlay, S. et al. Role of endothelin-1 in the active constriction of human
atherosclerotic coronary arteries. Circulation 104, 1114-1118 (2001).

286

Moncada, S., Higgs, E. A. & Vane, J. R. Human arterial and venous tissues
generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.
Lancet 1, 18-20 (1977).

287

Alberts, B. et al. Molecular Biology of the Cell. 6 edn, 1464 (Garland Science,
2014).

288

Folkman, J. & Haudenschild, C. Angiogenesis in vitro. Nature 288, 551-556
(1980).

289

Madri, J. A. & Williams, S. K. Capillary Endothelial Cell Cultures: Phenotypic
Modulation by Matrix Components. J Cell Biol 97, 153-165 (1983).

290

Montesano, R., Orci, L. & Vassalli, P. In vitro rapid organization of endothelial
cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97,
1648-1652 (1983).

207

291

Vogt, M. T. & Farber, E. On the molecular pathology of ischemic renal cell death.
Reversible and irreversible cellular and mitochondrial metabolic alterations. Am J
Pathol 53, 1-26 (1968).

292

Cammermeyer, J. "Ischemic neuronal disease" of Spielmeyer. A reevaluation.
Arch Neurol 29, 391-393 (1973).

293

Jennings, R. B. & Ganote, C. E. Structural changes in myocardium during acute
ischemia. Circ Res 35, 156-172 (1974).

294

Jones, R. T. & Trump, B. F. Cellular and subcellular effects of ischemia on the
pancreatic acinar cell: in vitro studies of rat tissue. Virchow's Arch B Cell Pathol
19, 325-336 (1975).

295

Delva, E. et al. Vascular occlusions for liver resections. Operative management
and tolerance to hepatic ischemia: 142 cases. Ann Surg 209, 211-218 (1989).

296

Griffith, L. G. & Naughton, G. Tissue engineering--current challenges and
expanding opportunities. Science 295, 1009-1014 (2002).

297

Cardinal, K. O., Bonnema, G. T., Hofer, H., Kehlet Barton, J. & Williams, S. K.
Tissue-Engineered Vascular Grafts as In Vitro Blood Vessel Mimics for the
Evaluations of Endothelialization of Intravascular Devices. Tissue Eng Part A 12,
3431-3438 (2006).

298

Traktuev, D. O. et al. A population of multipotent CD34-positive adipose stromal
cells share pericyte and mesenchymal surface markers, reside in a periendothelial
location,

and

stabilize

endothelial

networks.

doi:10.1161/CIRCRESAHA.107.159475 (2008).

208

Circ

Res

102,

77-85,

299

Koh, Y. J. et al. Stromal vascular fraction from adipose tissue forms profound
vascular network through the dynamic reassembly of blood endothelial cells.
Arterioscler

Thromb

Vasc

Biol

31,

1141-1150,

doi:10.1161/ATVBAHA.110.218206 (2011).
300

Merfeld-Clauss, S. et al. Adipose stromal cells differentiate along a smooth
muscle lineage pathway upon endothelial cell contact via induction of activin A.
Circ Res 115, 800-809, doi:10.1161/CIRCRESAHA.115.304026 (2014).

301

Leblanc, A. J., Touroo, J. S., Hoying, J. B. & Williams, S. K. Adipose stromal
vascular fraction cell construct sustains coronary microvascular function after
acute myocardial infarction. Am J Physiol Heart Circ Physiol 302, H973-982,
doi:10.1152/ajpheart.00735.2011 (2012).

302

Premaratne, G. U. et al. Stromal vascular fraction transplantation as an alternative
therapy for ischemic heart failure: anti-inflammatory role. J Cardiothorac Surg 6,
43, doi:10.1186/1749-8090-6-43 (2011).

303

Rehman, J. et al. Secretion of angiogenic and antiapoptotic factors by human
adipose stromal cells. Circulation 109, 1292-1298 (2004).

304

Cervelli, V. et al. Application of enhanced stromal vascular fraction and fat
grafting mixed with PRP in post-traumatic lower extremity ulcers. Stem Cell Res
6, 103-111, doi:10.1016/j.scr.2010.11.003 (2011).

305

Rodbell, M. Metabolism of Isolated Fat Cells. J Biol Chem 239, 375-380 (1964).

306

Rodbell, M. & Jones, A. B. Metabolism of Isolated Fat Cells. J Biol Chem 241,
140-142 (1966).

209

307

Rodbell, M. The Metabolism of Isolated Fat Cells. J Biol Chem 241, 3909-3917
(1966).

308

Wagner, R. C. & Matthews, M. A. The isolation and culture of capillary
endothelium from epididymal fat. Microvasc Res 10, 286-297 (1975).

309

Van, R. L., Bayliss, C. E. & Roncari, D. A. Cytological and enzymological
characterization of adult human adipocyte precursors in culture. J Clin Invest 58,
699-704 (1976).

310

Takahashi, K., Goto, T., Mukai, K., Sawasaki, Y. & Hata, J. Cobblestone
monolayer cells from human omental adipose tissue are possibly mesothelial, not
endothelial. In Vitro Cell Dev Biol 25, 109-111 (1989).

311

Williams, S. K., Wang, T. F., Castrillo, R. & Jarrell, B. E. Liposuction-derived
human fat used for vascular graft sodding contains endothelial cells and not
mesothelial cells as the major cell type. J Vasc Surg. 19, 916-923 (1994).

312

Riordan, N. H. et al. Non-expanded adipose stromal vascular fraction cell therapy
for multiple sclerosis. J Transl Med 7, 29, doi:10.1186/1479-5876-7-29 (2009).

313

Zimmerlin, L. et al. Stromal vascular progenitors in adult human adipose tissue.
Cytometry A 77, 22-30, doi:10.1002/cyto.a.20813 (2010).

314

Gimble, J. M., Bunnell, B. A., Chiu, E. S. & Guilak, F. Concise review: Adiposederived stromal vascular fraction cells and stem cells: let's not get lost in
translation. Stem Cells 29, 749-754, doi:10.1002/stem.629 (2011).

315

Goodwin, A. M. & D'Amore, P. A. in Tumor Angiogenesis (eds D. Marmé & N.
Fusenig) Ch. 15, (Springer-Verlag, 2008).

210

316

Boyd, N. L. et al. Dissecting the role of human embryonic stem cell-derived
mesenchymal cells in human umbilical vein endothelial cell network stabilization
in three-dimensional environments. Tissue Eng Part A 19, 211-223,
doi:10.1089/ten.tea.2011.0408 (2013).

317

Koike, N. et al. Tissue engineering: creation of long-lasting blood vessels. Nature
428, 138-139 (2004).

318

Stratman, A. N., Malotte, K. M., Mahan, R. D., Davis, M. J. & Davis, G. E.
Pericyte recruitment during vasculogenic tube assembly stimulates endothelial
basement membrane matrix formation. Blood 114, 5091-5101, doi:10.1182/blood2009-05- (2009).

319

Yoshimura, K. et al. Characterization of freshly isolated and cultured cells
derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol
208, 64-76, doi:10.1002/jcp.20636 (2006).

320

Eto, H. et al. Characterization of human adipose tissue-resident hematopoietic cell
populations reveals a novel macrophage subpopulation with CD34 expression and
mesenchymal

multipotency.

Stem

Cells

Dev

22,

985-997,

doi:10.1089/scd.2012.0442 (2013).
321

Rupnick, M. A. et al. Adipose tissue mass can be regulated through the
vasculature. Proc Natl Acad Sci U S A 99, 10730-10735 (2002).

322

Prunet-Marcassus, B. et al. From heterogeneity to plasticity in adipose tissues:
site-specific differences. Exp Cell Res 312, 727-736 (2006).

323

Ong, W. K. & Sugii, S. Adipose-derived stem cells: fatty potentials for therapy.
Int J Biochem Cell Biol 45, 1083-1086, doi:10.1016/j.biocel.2013.02.013 (2013).

211

324

Rajashekhar, G. et al. Regenerative therapeutic potential of adipose stromal cells
in

early

stage

diabetic

retinopathy.

PLoS

One

9,

e84671,

doi:10.1371/journal.pone.0084671 (2014).
325

Kono, T. M. et al. Human adipose-derived stromal/stem cells protect against
STZ-induced hyperglycemia: analysis of hASC-derived paracrine effectors. Stem
Cells 32, 1831-1842, doi:10.1002/stem.1676 (2014).

326

Cai, L. et al. Suppression of hepatocyte growth factor production impairs the
ability of adipose-derived stem cells to promote ischemic tissue revascularization.
Stem Cells 25, 3234-3243, doi:10.1634/stemcells.2007-0388 (2007).

327

Crisan, M. et al. A perivascular origin for mesenchymal stem cells in multiple
human organs. Cell Stem Cell 3, 301-313, doi:10.1016/j.stem.2008.07.003 (2008).

328

Amos, P. J. et al. IFATS collection: The role of human adipose-derived stromal
cells in inflammatory microvascular remodeling and evidence of a perivascular
phenotype. Stem Cells 26, 2682-2690, doi:10.1634/stemcells.2008-0030 (2008).

329

Zannettino, A. C. et al. Multipotential human adipose-derived stromal stem cells
exhibit a perivascular phenotype in vitro and in vivo. J Cell Physiol 214, 413-421
(2008).

330

Smas, C. M. & Sul, H. S. Pref-1, a protein containing EGF-like repeats, inhibits
adipocyte differentiation. Cell 73, 725-734 (1993).

331

Merfeld-Clauss, S., Gollahalli, N., March, K. L. & Traktuev, D. O. Adipose tissue
progenitor cells directly interact with endothelial cells to induce vascular network
formation. Tissue Eng Part A 16, 2953-2966, doi:10.1089/ten.TEA.2009.0635
(2010).

212

332

Merfeld-Clauss, S., Lupov, I. P., Lu, H., March, K. L. & Traktuev, D. O. Adipose
Stromal Cell Contact with Endothelial Cells Results in Loss of Complementary
Vasculogenic Activity Mediated by Induction of Activin A. Stem Cells 33, 30393051 (2015).

333

Williams, S. K. et al. Adipose Stromal Vascular Fraction Cells Isolated Using an
Automated Point of Care System Improve the Patency of Expanded
Polytetrafluoroethylene Vascular Grafts. Tissue Eng Part A 19, 1295-1302
(2013).

334

Katz, A. J., Hedrick, M. H., Llull, R. & Futrell, J. W. A novel device for the
simple and efficient refinement of liposuctioned tissue. Plast Reconstr Surg 107,
595-597 (2001).

335

Brey, E. M. Vascularization: Regenerative Medicine and Tissue Engineering.
(2014).

336

Fox, I. J. & Roy-Chowdhury, J. Hepatocyte Transplantation. J Hepatol 40, 878886 (2004).

337

Strom, S. C. et al. Transplantation of human hepatocytes. Transplant Proc 29,
2103-2106 (1997).

338

Nagata, H. et al. Prolonged survival of porcine hepatocytes in cynomolgus
monkeys. Gastroenterology 132, 321-329, doi:10.1053/j.gastro.2006.10.013
(2007).

339

Habibullah, C. M., Syed, I. H., Qamar, A. & Taher-Uz, Z. Human fetal
hepatocyte

transplantation

in

patients

Transplantation 58, 951-952 (1994).

213

with

fulminant

hepatic

failure.

340

Kaully, T., Kaufman-Francis, K., Lesman, A. & Levenberg, S. Vascularization The Conduit to Viable Engineered Tissues. Tissue Eng Part B 15, 159-169
(2009).

341

Chiu, L. L., Iyer, R. K., Reis, L. A., Nunes, S. S. & Radisic, M. Cardiac tissue
engineering: current state and perspectives. Front Biosci 17, 1533-1550 (2012).

342

Jain, R. K. Molecular regulation of vessel maturations. Nat Med 9, 685-693
(2003).

343

Markkanen, J. E., Rissanen, T. T., Kivela, A. & Yla-Herttuala, S. Growth
factorinduced therapeutic angiogenesis and arteriogenesis in the heart--gene
therapy. Cardiovasc Res 65, 656-664 (2005).

344

Han, J. et al. Adipose tissue is an extramedullary reservoir of functional
hematopoetic stem and progenitor cells. Blood 115, 957-964, doi:10.1182/blood2009- (2010).

345

Hoying, J. B. & Williams, S. K. Effects of basic fibroblast growth factor on
human microvessel endothelial cell migration on collagen I correlates inversely
with adhesion and is cell density dependent. J Cell Physiol 168, 294-304 (1996).

346

Chang, C. C. et al. Angiogenesis in a microvascular construct for transplantation
depends on the method of chamber circulation. Tissue Eng Part A 16, 795-805
(2010).

347

Nunes, S. S., Rekapally, H., Chang, C. C. & Hoying, J. B. Vessel arterial-venous
plasticity in adult neovascularization phenotypes. Microvasc Res 79, 10-20
(2009).

214

348

Boyd, N. L. et al. Microvascular mural cell functionality of human embryonic
stem cell-derived mesenchymal cells. Tissue Eng Part A 17, 1537-1548,
doi:10.1089/ten.TEA.2010.0397 (2011).

349

Carmona, R. et al. Immunolocalization of the transcription factor Slug in the
developing avian heart. Anat Embryol (Berl) 201, 103-109 (2000).

350

Gao, Y., Hu, H. Z., Chen, K. & Yang, J. Z. Primary porcine hepatocytes with
portal vein serum cultured on microcarriers or in spheroidal aggregates. World J
Gastroenterol 6 (2000).

351

Nunes, S. S. et al. Angiogenic potential of microvessel fragments is independent
of the tissue of origin and can be influenced by the cellular composition of the
implants. Microcirculation 17, 557-567 (2010).

352

Nunes, S. S. et al. Implanted microvessels progress through distinct
neovascularization

phenotypes.

Microvasc

Res

79,

10-20,

doi:10.1016/j.mvr.2009.10.001 (2010).
353

Langer, R. Tissue engineering: perspectives, challenges, and future directions.
Tissue Eng Part A 13, 1-2 (2007).

354

Johnson, P. C., Mikos, A. G., Fisher, J. P. & Jansen, J. A. Strategic directions in
tissue engineering. Tissue Eng Part A 13, 2827-2837 (2007).

355

Au, P. et al. Paradoxical effects of PDGF-BB overexpression in endothelial cells
on engineered blood vessels in vivo. Am J Pathol 175, 294-302 (2009).

356

Folkman, J. & Hochberg, M. Self-regulation of growth in three dimensions. J Exp
Med 138, 745-753 (1973).

215

357

Davis, G. E., Koh, W. & Stratman, A. N. Mechanisms controlling human
endothelial lumen formation and tube assembly in three-dimensional extracellular
matrices. Birth Defects Res C Embryo Today 81, 270-285 (2007).

358

Gersh, I. & Still, M. A. Blood vessels in fat tissue. Relation to problems of gas
exchange. J Exp Med 81, 219-232 (1945).

359

Pinheiro, C. H. et al. Local injections of adipose-derived mesenchymal stem cells
modulate inflammation and increase angiogenesis ameliorating the dystrophic
phenotype in dystrophin-deficient skeletal muscle. Stem Cell Rev 8, 363-374,
doi:10.1007/s12015-011-9304-0 (2012).

360

Cai, J. et al. Directed differentiation of human embryonic stem cells into
functional hepatic cells. Hepatology 45, 1229-1239, doi:10.1002/hep.21582
(2007).

361

Kedem, A. et al. Vascular endothelial growth factor-releasing scaffolds enhance
vascularization and engraftment of hepatocytes transplanted on liver lobes. Tissue
Eng Part A 11, 715-722 (2005).

362

Mizuno, H., Tobita, M. & Uysal, A. C. Concise review: Adipose-derived stem
cells as a novel tool for future regenerative medicine. Stem Cells 30, 804-810
(2012).

363

Broudy, V. C. et al. Human umbilical vein endothelial cells display high-affinity
c-kit receptors and produce a soluble form of the c-kit receptor. Blood 83, 21452152 (1994).

364

Lammie, A. et al. Expression of c-kit and kit ligand proteins in normal human
tissues. J Histochem Cytochem 42, 1417-1425 (1994).

216

365

Majumder, S., Brown, K., Qiu, F. H. & Besmer, P. c-kit protein, a transmembrane
kinase: identification in tissues and characterization. Mol Cell Biol 8, 4896-4903
(1988).

366

Abramsson, A., Lindblom, P. & Betsholtz, C. Endothelial and nonendothelial
sources of PDGF-B regulate pericyte recruitment and influence vascular pattern
formation in tumors. J Clin Invest 112, 1142-1151 (2003).

367

Bjarnegard, M. et al. Endothelium-specific ablation of PDGFB leads to pericyte
loss and glomerular, cardiac and placental abnormalities. Development 131, 18471857 (2004).

368

Zhao, Y., Waldman, S. D. & Flynn, L. E. Multilineage co-culture of adiposederived stem cells for tissue engineering. J Tissue Eng Regen Med 9, 826-837
(2012).

369

Williams, S. K., Wang, T. F., Castrillo, R. & Jarrell, B. E. Liposuction-derived
human fat used for vascular graft sodding contains endothelial cells and not
mesothelial cells as the major cell type. J Vasc Surg 19, 916-923 (1994).

370

Maijub, J. G. et al. Concentration Dependent Vascularization of Adipose Stromal
Vascular Fraction Cells. Cell Transplant, doi:10.3727/096368914X685401
(2014).

371

Madri, J. A. & Williams, S. K. Capillary endothelial cell cultures: phenotypic
modulation by matrix components. Journal of Cell Biology 97, 153-165 (1983).

372

Madri, J. A., Pratt, B. M. & Tucker, A. M. Phenotypic modulation of endothelial
cells by transforming growth factor-beta depends upon the composition and
organization of the extracellular matrix. J.Cell Biol. 106, 1375-1384 (1988).

217

373

Wiley, D. M. et al. Distinct signalling pathways regulate sprouting angiogenesis
from the dorsal aorta and the axial vein. Nat Cell Biol 13, 686-692,
doi:10.1038/ncb2232 (2011).

374

Ladwein, M. & Rottner, K. On the Rho'd: the regulation of membrane protrusions
by Rho-GTPases. FEBS Lett 582, 2066-2074, doi:10.1016/j.febslet.2008.04.033
(2008).

375

Hasan, S. S. & Siekmann, A. F. The same but different: signaling pathways in
control of endothelial cell migration. Curr Opin Cell Biol 36, 86-92,
doi:10.1016/j.ceb.2015.07.009 (2015).

376

Chen, B. et al. Small molecule-mediated disruption of Wnt-dependent signaling
in

tissue

regeneration

and

cancer.

Nat

Chem

Biol

5,

100-107,

doi:10.1038/nchembio.137 (2009).
377

Murdoch, B. et al. Wnt-5A augments repopulating capacity and primitive
hematopoietic development of human blood stem cells in vivo. Proc Natl Acad
Sci U S A 100, 3422-3427, doi:10.1073/pnas.0130233100 (2003).

378

Blumenthal, A. et al. The Wingless homolog WNT5A and its receptor Frizzled-5
regulate inflammatory responses of human mononuclear cells induced by
microbial stimulation. Blood 108, 965-973, doi:10.1182/blood-2005-12-5046
(2006).

379

Cheng, C. W., Yeh, J. C., Fan, T. P., Smith, S. K. & Charnock-Jones, D. S.
Wnt5a-mediated non-canonical Wnt signalling regulates human endothelial cell
proliferation and migration. Biochem Biophys Res Commun 365, 285-290,
doi:10.1016/j.bbrc.2007.10.166 (2008).

218

380

Lin, L. & Sherman, P. D. Cleansing Data the Chauvinet Way. SESUG
Proceedings, 1-11 (2007).

381

Montesano, R., Orci, L. & Vassalli, P. In vitro rapid organization of endothelial
cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97,
1648-1652 (1983).

382

Willert, K. et al. Wnt proteins are lipid-modified and can act as stem cell growth
factors. Nature 423, 448-452 (2003).

383

Reis, M. et al. Endothelial Wnt/beta-catenin signaling inhibits glioma
angiogenesis and normalizes tumor blood vessels by inducing PDGF-B
expression. J Exp Med 209, 1611-1627, doi:10.1084/jem.20111580 (2012).

384

Gherghe, C. M. et al. Wnt1 is a proangiogenic molecule, enhances human
endothelial progenitor function, and increases blood flow to ischemic limbs in a
HGF-dependent manner. FASEB J 25, 1836-1843, doi:10.1096/fj.10-172981
(2011).

385

Klein, D. et al. Wnt2 acts as an angiogenic growth factor for non-sinusoidal
endothelial cells and inhibits expression of stanniocalcin-1. Angiogenesis 12, 251265, doi:10.1007/s10456-009-9145-5 (2009).

386

Daneman, R. et al. Wnt/ß-catenin signaling is required for CNS, but not nonCNS, angiogenesis. Proceedings of the National Academy of Sciences 106, 641646, doi:10.1073/pnas.0901563106 (2009).

387

Jover, B., Girardot, D., de Courtois Roy de Vacquieres, F., Casellas, D. & Moles,
J. P. Wnt-4 potently inhibits capillary outgrowth from rat aorta in 3D culture.

219

Fundam Clin Pharmacol 27, 465-470, doi:10.1111/j.1472-8206.2012.01044.x
(2013).
388

Arderiu, G., Espinosa, S., Peña, E., Aledo, R. & Badimon, L. Monocyte-secreted
Wnt5a interacts with FZD5 in microvascular endothelial cells and induces
angiogenesis through tissue factor signaling. J Mol Cell Biol 6, 380-393,
doi:10.1093/jmcb/mju036 (2014).

389

Murdoch, C. E., Bachschmid, M. M. & Matsui, R. Regulation of
neovascularization by S-glutathionylation via the Wnt5a/sFlt-1 pathway. Biochem
Soc Trans 42, 1665-1670, doi:10.1042/BST20140213 (2014).

390

Melgar-Lesmes, P. & Edelman, E. R. Monocyte-endothelial cell interactions in
the regulation of vascular sprouting and liver regeneration in mouse. J Hepatol,
doi:10.1016/j.jhep.2015.05.011 (2015).

391

Ekström, E. J. et al. WNT5A induces release of exosomes containing proangiogenic and immunosuppressive factors from malignant melanoma cells.
Molecular Cancer 13, 1-15 (2014).

392

Korn, C. et al. Endothelial cell-derived non-canonical Wnt ligands control
vascular

pruning

in

angiogenesis.

Development

141,

1757-1766,

doi:10.1242/dev.104422 (2014).
393

Bian, W. J. et al. A novel Wnt5a-Frizzled4 signaling pathway mediates activityindependent dendrite morphogenesis via the distal PDZ motif of Frizzled 4. Dev
Neurobiol 75, 805-822, doi:10.1002/dneu.22250 (2015).

220

394

Sen, M., Chamorro, M., Reifert, J., Corr, M. & Carson, D. A. Blockade of Wnt5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis
Rheum 44, 772-781 (2001).

395

Oishi, I. et al. The receptor tyrosine kinase Ror2 is involved in non-canonical
Wnt5a/JNK signalling pathway. Genes to Cells 8, 645-654 (2003).

396

Liu, Y., Rubin, B., Bodine, P. V. & Billiard, J. Wnt5a induces homodimerization
and activation of Ror2 receptor tyrosine kinase. J Cell Biochem 105, 497-502,
doi:10.1002/jcb.21848 (2008).

397

Angers, S. & Moon, R. T. Proximal events in Wnt signal transduction. Nat Rev
Mol Cell Biol 10, 468-477, doi:10.1038/nrm2717 (2009).

398

Catalan, V. et al. Activation of noncanonical Wnt signaling through WNT5A in
visceral adipose tissue of obese subjects is related to inflammation. J Clin
Endocrinol Metab 99, E1407-1417, doi:10.1210/jc.2014-1191 (2014).

399

Maschauchán, T. N. H. et al. Wnt5a signaling induces proliferation and survival
of endothelial cells in vitro and expression of MMP-1 and Tie-2. Molecular
Biology of the Cell 17, 5163-5172, doi:10.1091/mbc.E06 (2006).

400

Morris, M. E. et al. Systemically delivered adipose stromal vascular fraction cells
disseminate to peripheral artery walls and reduce vasomotor tone through a
CD11b+ cell-dependent mechanism. Stem Cells Transl Med 4, 369-380,
doi:10.5966/sctm.2014-0252 (2015).

401

Zuk, P. A. et al. Multilineage cells from human adipose tissue: implications for
cell-based therapies. Tissue Eng 7, 211-228 (2001).

221

402

Lin, G. et al. Defining stem and progenitor cells within adipose tissue. Stem Cells
Dev 17, 1053-1063, doi:10.1089/scd.2008.0117 (2008).

403

Butler, M. J. & Sefton, M. V. Cotransplantation of adipose-derived mesenchymal
stromal cells and endothelial cells in a modular construct drives vascularization in
SCID/bg

mice.

Tissue

Eng

Part

A

18,

1628-1641,

doi:10.1089/ten.TEA.2011.0467 (2012).
404

Frerich, B., Zuckmantel, K. & Hemprich, A. Microvascular engineering in
perfusion culture: immunohistochemistry and CLSM findings. Head Face Med 2,
26, doi:10.1186/1746-160X-2-26 (2006).

405

Olson, L. E. & Soriano, P. PDGFRbeta signaling regulates mural cell plasticity
and

inhibits

fat

development.

Dev

Cell

20,

815-826,

doi:10.1016/j.devcel.2011.04.019 (2011).
406

Tallquist, M. D., Soriano, P. & Klinghoffer, R. A. Growth factor signaling
pathways in vascular development. Oncogene 18, 7917-7932 (1999).

407

Lindahl, P., Johansson, B. R., Levéen, P. & Betsholtz, C. Pericyte Loss and
Microaneurysm Formation in PDGF-B-Deficient Mice. Science 277, 242-245
(1997).

408

Lindblom, P. et al. Endothelial PDGF-B retention is required for proper
investment of pericytes in the microvessel wall. Genes & Dev 17, 1835-1840,
doi:10.1101/ (2003).

409

Hirschi, K. K., Robovsky, S. A. & D'Amore, P. A. PDGF, TGF-beta, and
Heterotypic Cell-Cell Interactions Mediate Endothelial Cell-induced Recruitment

222

of 10T1/2 Cells and Their Differentiation to a Smooth Muscle Fate. J Cell Biol
141, 805-814 (1998).
410

Goumans, M. J. et al. Balancing the activation state of the endothelium via two
distinct TGF-beta type I receptors. The EMBO Journal 21, 1743-1753 (2002).

411

Lebrin, F. et al. Endoglin promotes endothelial cell proliferation and TGFbeta/ALK1 signal transduction. The EMBO Journal 23, 4018-4028, doi:10.1038/
(2004).

412

Dejana, E. The role of wnt signaling in physiological and pathological
angiogenesis. Circ Res 107, 943-952, doi:10.1161/CIRCRESAHA.110.223750
(2010).

413

Goodwin, A. M., Sullivan, K. M. & D'Amore, P. A. Cultured endothelial cells
display endogenous activation of the canonical Wnt signaling pathway and
express multiple ligands, receptors, and secreted modulators of Wnt signaling.
Dev Dyn 235, 3110-3120, doi:10.1002/dvdy.20939 (2006).

414

Newman, A. C. & Hughes, C. C. W. Macrophages and angiogenesis: a role for
Wnt signaling. Vascular Cell 4, 1-7 (2012).

415

Parish, C. L. et al. Wnt5a-treated midbrain neural stem cells improve dopamine
cell replacement therapy in parkinsonian mice. J Clin Invest 118, 149-160,
doi:10.1172/JCI32273 (2008).

416

Potok, M. A. et al. WNT signaling affects gene expression in the ventral
diencephalon and pituitary gland growth. Dev Dyn 237, 1006-1020,
doi:10.1002/dvdy.21511 (2008).

223

417

Himmelreich, N., Kaufmann, L. T., Steinbeisser, H., Korner, C. & Thiel, C. Lack
of phosphomannomutase 2 affects Xenopus laevis morphogenesis and the noncanonical Wnt5a/Ror2 signalling. J Inherit Metab Dis 38, 1137-1146,
doi:10.1007/s10545-015-9874-0 (2015).

418

Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell. 126, 663-676,
doi:10.1016/j.cell.2006.07.024 (2006).

419

Rader, D. J., Cohen, J. & Hobbs, H. H. Monogenic hypercholesterolemia: new
insights in pathogenesis and treatment. J Clin Invest. 111, 1795-1803,
doi:10.1172/jci200318925 (2003).

420

Benn, M., Watts, G. F., Tybjaerg-Hansen, A. & Nordestgaard, B. G. Familial
hypercholesterolemia in the danish general population: prevalence, coronary
artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 97,
3956-3964, doi:10.1210/jc.2012-1563 (2012).

421

Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and
undertreated in the general population: guidance for clinicians to prevent coronary
heart disease: consensus statement of the European Atherosclerosis Society. Eur
Heart J. 34, 3478-3490a, doi:10.1093/eurheartj/eht273 (2013).

422

Kim, W. R. et al. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant.
14, 69-96, doi:10.1111/ajt.12581 (2014).

423

Treyer, A. & Müsch, A. Hepatocyte polarity. Compr Physiol. 3, 243-287,
doi:10.1002/cphy.c120009. (2013).

224

424

Hibbitt, O. C. et al. Long-term physiologically regulated expression of the lowdensity lipoprotein receptor in vivo using genomic DNA mini-gene constructs.
Mol Ther. 18, 317-326, doi:10.1038/mt.2009.249 (2010).

425

Boyd, N. L., Robbins, K. R., Dhara, S. K., West, F. D. & Stice, S. L. Human
Embryonic Stem Cell-Derived Mesoderm-Like Epithelium Transitions to
Mesenchymal

Progenitor

Cells.

Tissue

Eng

Part

A.

15,

1897-1907,

doi:10.1089/ten.tea.2008.0351 (2009).
426

Mitalipova, M. M. et al. Preserving the genetic integrity of human embryonic
stem cells. Nat Biotechnol. 23, 19-20, doi:10.1038/nbt0105-19 (2005).

427

Hentze, H. et al. Teratoma formation by human embryonic stem cells: evaluation
of essential parameters for future safety studies. Stem Cell Res. 2, 198-210,
doi:10.1016/j.scr.2009.02.002 (2009).

428

Song, Z. et al. Efficient generation of hepatocyte-like cells from human induced
pluripotent stem cells. Cell Res. 19, 1233-1242, doi:10.1038/cr.2009.107 (2009).

429

Lufino, M. M., Manservigi, R. & Wade-Martins, R. An S/MAR-based infectious
episomal genomic DNA expression vector provides long-term regulated
functional complementation of LDLR deficiency. Nucleic Acids Res. 35, e98,
doi:10.1093/nar/gkm570 (2007).

430

Goldstein, J. L. & Brown, M. S. Binding and Degradation of Low Density
Lipoproteins by Cultured Human Fibroblasts. J Biol Chem. 249, 5153-5162
(1974).

225

431

Warren, L. et al. Highly efficient reprogramming to pluripotency and directed
differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 7,
618-630, doi:10.1016/j.stem.2010.08.012 (2010).

432

Takahashi, K. et al. Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell. 131, 861-872, doi:10.1016/j.cell.2007.11.019
(2007).

433

Boyer, L. A. et al. Core transcriptional regulatory circuitry in human embryonic
stem cells. Cell. 122, 947-956, doi:10.1016/j.cell.2005.08.020 (2005).

434

Fattahi, F. et al. Disease-corrected hepatocyte-like cells from familial
hypercholesterolemia-induced pluripotent stem cells. Mol Biotechnol. 54, 863873, doi:10.1007/s12033-012-9635-3 (2013).

435

Kakaei,

F.

et

al.

Liver

transplantation

for

homozygous

familial

hypercholesterolemia: two case reports. Transplant Proc. 41, 2939-2941,
doi:10.1016/j.transproceed.2009.07.028 (2009).
436

Wiegand, B. D., Ketterer, S. G. & Rapaport, E. The use of indocyanine green for
the evaluation of hepatic function and blood flow in man. Am J Dig Dis. 5, 427436 (1960).

437

Maijub, J. G. et al. Concentration Dependent Vascularization of Adipose Stromal
Vascular

Fraction

Cells.

Cell

Transplant.

In

press,

doi:10.3727/096368914X685401 (2014).
438

Nunes, S. S. et al. Generation of a functional liver tissue mimic using adipose
stromal vascular fraction cell-derived vasculatures. Sci Rep. 3, 2141,
doi:10.1038/srep02141 (2013).

226

439

Krieger, M., Brown, M. S. & Goldstein, J. L. Isolation of Chinese Hamster Cell
Mutants Defective in the Receptor-mediated Endocytosis of Low Density
Lipoprotein. J Mol Biol. 150, 167-184 (1981).

440

Ma, P. T. S. et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA
for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl
Acad Sci USA. 83, 8370-8374 (1986).

441

Ho, Y. K., Brown, M. S., Bilheimer, D. W. & Goldstein, J. L. Regulation of Low
Density Lipoprotein Receptor Activity in Freshly Isolated Human Lymphocytes. J
Clin Invest. 58, 1465-1474 (1976).

442

Grossman, M. et al. A pilot study of ex vivo gene therapy for homozygous
familial hypecholesterolemia. Nat Med. 1, 1148-1154, doi:10.1038/nm1195-1148
(1995).

443

Grossman, M. et al. Successful ex vivo gene therapy directed to liver in a patient
with familial hypercholesterolemia. Nat Genet. 6, 335-341, doi:10.1038/ng0494335 (1994).

444

Cichon, G. et al. Non-physiological overexpression of the low density lipoprotein
receptor (LDLr) gene in the liver induces pathological intracellular lipid and
cholesterol storage. J Gene Med. 6, 166-175, doi:10.1002/jgm.473 (2004).

445

Heeren, J., Weber, W. & Beisiegel, U. Intracellular processing of endocytosed
triglyceride-rich lipoproteins comprises both recycling and degradation. J Cell
Sci. 112, 349-359 (1999).

227

446

Leight, E. R. & Sugden, B. The cis-acting family of repeats can inhibit as well as
stimulate establishment of an oriP replicon. J Virol. 75, 10709-10720,
doi:10.1128/JVI.75.22.10709-10720.2001 (2001).

447

Leight, E. R. & Sugden, B. Establishment of an oriP replicon is dependent upon
an

infrequent,

epigenetic

event.

Mol

Cell

Biol.

21,

4149-4161,

doi:10.1128/MCB.21.13.4149-4161.2001 (2001).
448

Costa, M. et al. A method for genetic modification of human embryonic stem
cells using electroporation. Nat Protoc. 2, 792-796, doi:10.1038/nprot.2007.105
(2007).

449

Maxfield, F. R. & Menon, A. K. Intracellular sterol transport and distribution.
Curr Opin Cell Biol. 18, 379-385, doi:10.1016/j.ceb.2006.06.012 (2006).

450

Rachid, S. C., S; Hannan, N; Marcinak, SJ; Miranda, E; Alexander, G; HuangDoran, I; Griffin, J; Ahrlund-Richter, L; Skepper, J; Semple, R; Weber, A;
Lomas, DA; Valler, L. Modeling inherited metabolic disorders of the liver using
human

induced

pluripotent

stem

cells.

JCI

120,

3127-3136,

doi:10.1172/jci43122ds1 (2010).
451

Jacobs, F., Van Craeyveld, E., Feng, Y., Snoeys, J. & De Geest, B. Adenoviral
low density lipoprotein receptor attenuates progression of atherosclerosis and
decreases

tissue

cholesterol

levels

in

a

murine

model

of

familial

hypercholesterolemia. Atherosclerosis 201, 289-297 (2008).
452

Kassim, S. H. et al. Gene therapy in a humanized mouse model of familial
hypercholesterolemia leads to marked regression of atherosclerosis. PLoS One 5
(2010).

228

453

Stein, C. S., Martins, I. & Davidson, B. L. Long-term reversal of
hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice
by adenovirus-mediated LDLR gene transfer combined with CD154 blockade. J
Gene Med 2, 41-51 (2000).

454

Li, C. Y. et al. Micropatterned cell-cell interactions enable functional
encapsulation of primary hepatocytes in hydrogel microtissues. Tissue Eng Part A
20, 2200-2212 (2014).

455

Löser, P., Jennings, G. S., Strauss, M. & Sandig, V. Reactivation of the
Previously Silenced Cytomegalovirus Major Immediate-Early Promoter in the
Mouse Live: Involvement of NFkB. J Virol 72, 180-190 (1998).

456

Thomas, C. E., Ehrhardt, A. & Kay, M. A. Progress and problems with the use of
viral vectors for gene therapy. Nat Rev Genet 4, 346-358 (2003).

457

Kozarsky, K. F. et al. In vivo correction of low density lipoprotein receptor
deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant
adenoviruses. J Biol Chem 269, 13695-13702 (1994).

458

Van Craeyveld, E., Jacobs, F., Gordts, S. C. & De Geest, B. Gene therapy for
Familial Hypercholesterolemia. Curr Pharm Des 17, 2575-2591 (2011).

459

Costa, M. et al. A method for genetic modification of human embryonic stem
cells using electroporation. Nat Protoc 2, 792-796, doi:10.1038/nprot.2007.105
(2007).

460

Yates, J. L. & Guan, N. Epstein-Barr virus-derived plasmids replicate only once
per cell cycle and are not amplified after entry into cells. J Virol. 65, 483-488
(1991).

229

461

Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. & Masucci, M. G.
Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala
repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S
A 94, 12616-12621 (1997).

462

Goldstein, J. L. & Brown, M. S. The LDL receptor. Arterioscler Thromb Vasc
Biol 29, 431-438, doi:10.1161/ATVBAHA.108.179564 (2009).

463

Song, H., Chung, S. K. & Xu, Y. Modeling disease in human ESCs using an
efficient BAC-based homologous recombination system. Cell Stem Cell 6, 80-89,
doi:10.1016/j.stem.2009.11.016 (2010).

464

Irion, S. et al. Identification and targeting of the ROSA26 locus in human
embryonic stem cells. Nat Biotechnol 25, 1477-1482, doi:10.1038/nbt1362
(2007).

465

Mohr, J. C., de Pablo, J. J. & Palacek, S. P. Electroporation of Human Embryonic
Stem Cells: Small and Macromolecule Loading and DNA Transfection.
Biotechnol Prog 22, 825-834 (2006).

466

Leight, E. R. & Sugden, B. Establishment of an oriP replicon is dependent upon
an

infrequent,

epigenetic

event.

Mol

Cell

Biol

21,

4149-4161,

doi:10.1128/MCB.21.13.4149-4161.2001 (2001).
467

Li, J. et al. In vivo gene therapy for hyperlipidemia: phenotypic correction in
Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin
Invest. 95, 768-773, doi:10.1172/JCI117725 (1995).

468

Brown, M. S., Goldstein, J. L., Havel, R. J. & Steinberg, D. Gene therapy for
cholesterol. Nature genetics 7, 349-350 (1994).

230

469

Hobbs, H. H., Brown, M. S. & Goldstein, J. L. Molecular Genetics of the LDL
Receptor Gene in Familial Hypercholesterolemia. Human Mutation 1, 445-466
(1992).

470

Hunter, D. D., Zhang, M., Ferguson, J. W., Koch, M. & Brunken, W. J. The
extracellular matrix component WIF-1 is expressed during, and can modulate,
retinal development. Mol Cell Neurosci 27, 477-488 (2004).

471

Shen, G. et al. Structural basis of the Norrin-Frizzled 4 interaction. Cell Res 25
(2015).

472

Umbhauer, M. et al. The C-terminal cytoplasmic Lys-thr-X-X-X-Trp motif in
frizzled receptors mediates Wnt/beta-catenin signalling. EMBO J 19, 4944-4954
(2000).

473

Sheldahl, L. C., Park, M., Malbon, C. C. & Moon, R. T. Protein kinase C is
differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent
manner. Curr Biol. 9, 695-698 (1999).

231

CURRICULUM VITA
NAME:

Venkat Madhav Ramakrishnan

ADDRESS:

Cardiovascular Innovation Institute
University of Louisville School of Medicine
302 E. Muhammad Ali Boulevard
Suite 512/513
Louisville, KY 40202

DOB:

Lexington, Kentucky - February 17, 1988

EDUCATION
& TRAINING:

M.D.
University of Louisville School of Medicine
2011-present
Ph.D., Physiology & Biophysics
University of Louisville School of Medicine
2013-2015
M.S., Physiology & Biophysics
University of Louisville School of Medicine
2013-2014
Fulbright Scholar, Urologic Tissue Engineering
University Hospital Zürich
2010-2011
B.S., Biology – Cellular / Physiology
University of Louisville
2006-2010

AWARDS
& HONORS:

Michael Tanner Memorial Award for Excellence in Graduate
Student Sciences
2014

232

Norton Healthcare Medical Student Research Award, 2nd Place
2013
Magna cum Laude
2010
University Honors Scholar
2010
Certificate of Honors, Department of Biology
2010
Cardinal Award of Excellence – Scholar/Leader
2010
Honors Thesis Presentation: “Identification of Single Nucleotide
Polymorphisms Associated with Metastatic Prostate Cancer”
2010
Arts & Sciences Alumni Council Overall Achievement Award
2009
Dean’s List and Dean’s Scholar
2007-2010
Guaranteed Entrance to Medical School (GEMS)
2006-2010
Kentucky Governor’s Scholar
2005
SCHOLARSHIPS
& FELLOWSHIPS: Integrated Programs in the Biomedical Sciences (IPIBS) Graduate
Fellowship
2013-2015
Summer Research Scholars Program (SRSP)
2012, 2013
Physician-Scientist Training Program (M.D. / Ph.D.) Scholarship
2011-present
Summer Urological Research Experience (SURE) Program at the
Johns Hopkins Brady Urological Institute
2011

233

J. William Fulbright Research Fellowship, Switzerland
2010-2011
Alvin J. Siteman Cancer Center Summer Opportunities Program at
Washington University School of Medicine in St. Louis
2010
National Merit Finalist Scholarship
2006-2010
Grawemeyer Scholarship
2006-2010
PROFESSIONAL
SOCIETIES:

International Society for Stem Cell Research
2014-2015
American Heart Association
2013-2015
American Physician Scientists Association
2013-present
Tissue Engineering & Regenerative Medicine International Society
2013-present
Greater Louisville Medical Society
2011-present

PUBLICATIONS:
1.

Kiehl N, Kinsey S, Ramakrishnan V, DaJusta DG. “Pediatric Prostatic
Abscess.” Urology (Gold Journal). 2012 Dec; 80(6): pp. 1364-5.

2.

Boyd NL, Nunes SS, Krishnan L, Jokinen JD, Ramakrishnan VM, Bugg
AR, Hoying JB. “Dissecting the role of human embryonic stem cellderived mesenchymal cells in human umbilical vein endothelial cell
network stabilization in three-dimensional environments.” Tissue
Engineering Part A. 2013 Jan; 19(1-2): pp. 211-23.

3.

Nunes SS, Maijub JG, Krishnan L, Ramakrishnan VM, Clayton LR,
Williams SK, Hoying JB*, Boyd NL*. “Generation of a functional liver
tissue mimic using adipose stromal vascular fraction cell-derived
vasculatures”. Scientific Reports. 2013 Jul; (3): pp. 1-7.

234

4.

Largo RA*, Ramakrishnan VM*, Marschall JS*, Ziogas A, Eberli D**,
Ehrbar M**. “Long-term Biostability and Bioactivity of Engineered
VEGF121 in vitro and in vivo”. Biomaterials Science. 2014 Apr; (2): pp.
581-590.

5.

Ramakrishnan VM*, Yang JY*, Tien KT, McKinley TR, Bocard BR,
Maijub JG, Burchell PO, Williams SK, Morris, ME, Hoying, JB, WadeMartins R, West FD, Boyd NL. “Restoration of Physiologically
Responsive Low-Density Lipoprotein Receptor-Mediated Endocytosis in
Genetically Deficient Induced Pluripotent Stem Cells”. Scientific Reports.
2015 Aug (in press).

6.

Ramakrishnan VM, Tien KT, McKinley TR, Bocard BR, McCurry TM,
Williams SK, Hoying JB, Boyd NL. “Wnt5a Modulates the Assembly of
Human Stromal Vascular Fraction-Derived Microvasculatures”
(submitted).

BOOK CHAPTER:
1.

R.A. Largo*, V.M. Ramakrishnan*, M. Ehrbar, A. Ziogas, J. Plock, and
D. Eberli. “Angiogenesis and Vascularity for Tissue Engineering
Applications.” Regenerative Medicine and Tissue Engineering: From
Cells to Organs (Book 1). ISBN: 978-953-307-337-8. InTech Publishing
Group.

EDITORIAL:
1.

“Modern Technology and the Changing Medical Landscape” V.M.
Ramakrishnan. Louisville Medicine (Greater Louisville Medical
Society). Volume 63, Issue 5, October 2015.

ABSTRACT ORAL & POSTER PRESENTATIONS:
1.

“Effect of Carbon Nano Tubes on the Compression and Flexural
Properties of Calcium Sulfate,” V.M. Ramakrishnan, R. Andrews, and
D.A. Puleo, Annual Meeting and Exhibition of the American and
Canadian Associations for Dental Research (AADR), Orlando, FL.
(03/2006)

2.

“Effects of Hydrogel Nanoparticles and Protein-Adsorbed Calcium Sulfate
Particles on Mechanical Properties of Calcium Sulfate,” V.M.
Ramakrishnan, B. Orellana, M.V. Thomas, J.Z. Hilt, and D.A. Puleo,
Society for Biomaterials’ 2009 Annual Meeting, San Antonio, TX.
(04/2009)

3.

“Fibrin TG-VEGF is a Supporter of Early Angiogenesis in Urinary
Sphincter Engineering,” R.A. Largo*, V.M. Ramakrishnan*, A. Ziogas,
235

M. Ehrbar, J. Plock, and D. Eberli, Schweizerischen Gesellschaft für
Urologie (SGU; Swiss Congress of Urology) 67th Annual Meeting, Basel,
Switzerland. (09/2011).
4.

“Fibrin TG-VEGF is a Supporter of Early Angiogenesis in Urinary
Sphincter Engineering,” R.A. Largo*, V.M. Ramakrishnan*, A. Ziogas,
M. Ehrbar, J. Plock, and D. Eberli, European Association of Urology
(EAU) 2012 Annual Meeting, Paris, France. (02/2012).

5.

“Rare Germline Variants Associate with Aggressive Forms of Prostate
Cancer,” L.A. Tessler, V.M. Ramakrishnan, B. Wu, R. Goldfeder, R.D.
Mitra, and A.S. Kibel, American Urological Association (AUA) 2012
Annual Meeting, Atlanta, GA (05/2012). ORAL PRESENTATION

6.

“Fibrin TG-VEGF is a Supporter of Early Angiogenesis in Urinary Tissue
Engineering,” R.A. Largo*, V.M. Ramakrishnan*, A. Ziogas, M. Ehrbar,
J. Plock, and D. Eberli, AUA 2012 Annual Meeting, Atlanta, GA
(5/2012). ORAL PRESENTATION

7.

“Long-term Cell Demanded Release of TG-VEGF121 for the Development
of Mature Vascular Networks In Vivo,” R.A. Largo*, J.S. Marschall*, A.
Banfi, V.M. Ramakrishnan, A. Ziogas, T. Sulser, K. Lorentz, J. Hubbell,
M. Ehrbar, and D. Eberli, Tissue Engineering and Regenerative Medicine
World Congress (TERMIS) 2012 Annual Meeting, Vienna, Austria
(09/2012). ORAL PRESENTATION

8.

“Pre-establishment of a Vascular Network for Urinary Sphincter
Engineering,” R.A. Largo, V.M. Ramakrishnan*, J.S. Marschall*, A.
Ziogas, J. Plock, M. Ehrbar, and D. Eberli, TERMIS 2012 World
Congress Meeting, Vienna, Austria (09/2012).

9.

“Development of an engineered implantable vascularized cell-based LDL
apheresis device,” V.M. Ramakrishnan, J.G. Maijub, S.K. Williams,
N.L. Boyd, 1st Annual South-Central MD-PhD Conference, University of
Louisville, Louisville, KY (09/2012).

10.

“Development of an engineered implantable vascularized cell-based LDL
apheresis device,” V.M. Ramakrishnan, J.G. Maijub, M.E. Morris, J.B.
Hoying, S.K. Williams, N.L. Boyd, Research!Louisville 2012 Annual
Meeting, University of Louisville, Louisville, KY (09/2012).

11.

“Development of an engineered implantable vascularized cell-based LDL
apheresis device,” J.G. Maijub, V.M. Ramakrishnan, S.S. Nunes, J.
Dale, A.R. Bugg, M.E. Morris, J.B. Hoying, S.K. Williams, N.L. Boyd,
Biomedical Engineering Society (BMES) 2012 Annual Meeting, Atlanta,
GA (10/2012).

236

12.

“Vascularizing the Engineered Tissue,” N.L. Boyd, S.S. Nunes, J.G.
Maijub, V.M. Ramakrishnan, J.B. Hoying, and S.K. Williams, Materials
Research Society (MRS) 2013 Annual Meeting, San Francisco, CA
(04/2013).

13.

“Adipose Stromal Vascular Fraction-Derived Vasculature Supports
Implantation of Parenchymal Hepatocytes,” V.M. Ramakrishnan*, P.O.
Burchell*, J.I. Beier, J.R. Dale, G.E. Arteel, J.B. Hoying, S.K. Williams,
and N.L. Boyd. Research!Louisville 2013 Annual Meeting, University of
Louisville, Louisville, KY (09/2013).

14.

“Adipose Stromal Vascular Fraction-Derived Vasculature Supports
Implantation of Parenchymal Hepatocytes,” V.M. Ramakrishnan*, P.O.
Burchell*, J.I. Beier, J.R. Dale, G.E. Arteel, J.B. Hoying, S.K. Williams,
and N.L. Boyd. American Physician Scientists Association (APSA) 2013
Midwestern Meeting, The Ohio State University, Columbus, OH
(11/2013).

15.

“Characterization of Familial Hypercholesterolemia Patient-Derived
Hepatocyte-Like Cells,” K.T. Tien, V.M. Ramakrishnan, and N.L. Boyd.
DuPont Manual Regional Science and Engineering Fair, University of
Louisville, Louisville, KY (03/2014)

16.

“Characterization of Familial Hypercholesterolemia Patient-Derived
Hepatocyte-Like Cells,” K.T. Tien, V.M. Ramakrishnan, and N.L. Boyd.
Kentucky Junior Academy of Science, University of Kentucky, Lexington,
KY (06/2014)

17.

“Episomal Plasmid Functionally Corrects Monogenic-Deficient Induced
Pluripotent Stem Cells,” V.M. Ramakrishnan, J.Y. Yang, P.O. Burchell,
K.T. Tien, B.R. Bocard, J.G. Maijub, S.K. Williams, J.B. Hoying, F.D.
West, and N.L. Boyd. Research!Louisville 2014 Annual Meeting,
University of Louisville, Louisville, KY (09/2014)

18.

“Generation and LDLR Functional Correction of Familial
Hypercholesterolemia iPSC with Physiologically Responsive NonIntegrating BAC Vector,” V.M. Ramakrishnan, J.Y. Yang, P.O.
Burchell, K.T. Tien, B.R. Bocard, J.G. Maijub, S.K. Williams, R. WadeMartins, F.D. West, and N.L. Boyd. American Heart Association (AHA)
Scientific Sessions 2014 Annual Meeting, Chicago, IL (11/2014);
published in the supplement to Circulation, Volume 130, 2014, Abstract
A15669.

19.

“Characterization of the Spontaneous Capillary-Like Network Formation
of Human Stromal Vascular Fraction Cells,” B.R. Bocard, K.T. Tien,

237

V.M. Ramakrishnan, and N.L. Boyd. Kentucky Academy of Sciences
Centennial Meeting, Lexington, KY (11/2014).
20.

“Characterization of Familial Hypercholesterolemia Patient-Derived
Hepatocyte-Like Cells,” K.T. Tien, V.M. Ramakrishnan, and N.L. Boyd.
American Junior Academy of Science: AAS Conference, San José, CA
(02/2015)

21.

“Characterization of the Spontaneous Capillary-Like Network Formation
of Human Stromal Vascular Fraction Cells,” K.T. Tien, B.R. Bocard,
V.M. Ramakrishnan, and N.L. Boyd. Kentucky Junior Science and
Humanities Symposium, University of Louisville, Louisville, KY
(02/2015)

22.

“Characterization of the Spontaneous Capillary-Like Network Formation
of Human Stromal Vascular Fraction Cells,” K.T. Tien, B.R. Bocard,
V.M. Ramakrishnan, and N.L. Boyd. DuPont Manual Regional Science
and Engineering Fair, University of Louisville, Louisville, KY (03/2015)

23.

“Characterization of the Spontaneous Capillary-Like Network Formation
of Human Stromal Vascular Fraction Cells,” K.T. Tien, B.R. Bocard,
V.M. Ramakrishnan, and N.L. Boyd. Kentucky Science and Engineering
Fair, Eastern Kentucky University, Richmond, KY (03/2015)

24.

“Wnt5a Modulates In Vitro Spontaneous Endothelial Networking in
Human Adipose-Derived Stromal Vascular Fraction Cells,” V.M.
Ramakrishnan, K.T. Tien, B.R. Bocard, S.K. Williams, J.B. Hoying, and
N.L. Boyd. 1st Annual UofL Vascular Research Symposium, University of
Louisville, Louisville, KY (04/2015)

25.

“Wnt5a Modulates Early Angiogenesis of Human Stromal Vascular
Fraction Cells In Vitro,” V.M. Ramakrishnan. 30th Annual MD/PhD
National Student Conference, Keystone, CO (07/2015)

26.

“Generation of an Engineered, Vascularized, iPSC-Derived Hepatic
Module,” V.M. Ramakrishnan, J.Y. Yang, K.T. Tien, J.G. Maijub, P.O.
Burchell, B.R. Bocard, S.K. Williams, M.E. Morris, J.B. Hoying, R.
Wade-Martins, F.D. West, and N.L. Boyd. TERMIS 2015 4th World
Congress Meeting, Boston, MA (09/2015); published in Tissue
Engineering: Part A, Volume 21, Supplement 1, 2015, p. S-242.

27.

“Stimulation of Human Intra-islet Endothelial Cells Yields Peri-islet
Capillaries,” G. Loganathan, V.M. Ramakrishnan, N.L. Boyd, J.E.
Beare, B. Tweed, L. Kleinert, M.J. Hughes, J.B. Hoying, S.K. Williams,
and B.N. Appakalai. International Pancreas and Islet Transplant
Association (IPITA)-International Xenotransplantation Association (IXA)-

238

Cell Transplant Society (CTS) Joint Congress, Melbourne, Australia
(11/2015) ORAL PRESENTATION
28.

“Wnt5a Regulates Adipose Stromal Vascular Fraction Self-Assembly,”
V.M. Ramakrishnan, K.T. Tien, T.R. McKinley, B.R. Bocard, T.M.
McCurry, S.K. Williams, J.B. Hoying, and N.L. Boyd.
Research!Louisville 2015 Annual Meeting, University of Louisville,
Louisville, KY (10/2015)

29.

“Quantification of Wnt5a-Mediated Endothelial Network Self-Assembly,”
T.R. McKinley, V.M. Ramakrishnan, T.M. McCurry, S.K. Williams,
J.B. Hoying, and N.L. Boyd. Research!Louisville 2015 Annual Meeting,
University of Louisville, Louisville, KY (10/2015)

30.

“Stimulation of Intra-islet Endothelial Cells to Form Peri-islet Capillaries
(PICs) in Human Islets: Role of Adipose-Derived Stromal Vascular
Fraction (SVF) and ECGS solution,” G. Loganathan, V.M.
Ramakrishnan, N.L. Boyd, J.E. Beare, B. Tweed, L. Kleinert, M.J.
Hughes, J.B. Hoying, S.K. Williams, and B.N. Appakalai.
Research!Louisville 2015 Annual Meeting, University of Louisville,
Louisville, KY (10/2015)

PATENTS:

“Cell Systems and Methods for Delivering Disease-Specific Therapies,”
N.L. Boyd, S.K. Williams, J.B. Hoying, and V.M. Ramakrishnan.
Publication # WO2014039854 A1
Application # PCT/US2013/058555
2012
“Device for Circumcision,” V.M. Ramakrishnan, R.A. Largo, and
J. Vörös.
Filing # E.P. 11182397.7
2011

INVITED PRESENTATIONS:
1.

“Development of an Engineered Implantable Autologous Hepatovascular
Unit”, UofL Liver Group Seminar, University of Louisville School of
Medicine, (02/2015).

2.

“Episomal Plasmid Functionally Corrects Monogenic-Deficient Induced
Pluripotent Stem Cells,” for members of the Institute for Cellular
Therapeutics, University of Louisville School of Medicine, (03/2015).

3.

“Career Exploration in Medicine and Research”, for Georgetown
College’s Howard Hughes Medical Institutions GC-PALS Program
Participants (10/2015).

239

